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Abstract 
 
Cervical cancer is a major cause of death in women and is strongly associated with infection 
by human papillomavirus (HPV).  Integration of HPV is thought to form a key step in the 
formation of cancer, and is thought to involve the upregulation of HPV E6 and E7 due to the 
loss of E2 transcriptional control.  Leptomycin B (LMB), a nuclear export inhibitor, has 
previously been shown to induce apoptosis in HPV-containing cancer cell lines and HPV 16 
E7 or E6/E7 transduced primary keratinocytes, but not in normal cells.  This thesis shows that 
LMB can induce apoptosis and a reduction in the colony survival of derivatives of the W12 
cell line that contain HPV 16 in either episomal or integrated form.  The HPV genome status, 
including variations in viral integration type, appears to influence the cumulative and 
temporal pattern of LMB-induced apoptosis.  The effects of LMB were also apparent in cells 
grown in organotypic raft culture, with differences in behaviour again apparent between cells 
containing episomal and integrated HPV.  As previously noted, treatment with LMB was 
associated with increased expression of the cell regulators p53 and p21; however, the 
induction of apoptosis was not dependent upon transcriptionally active p53.  It is therefore 
likely that induction and mediation of LMB-induced apoptosis occurs via alternative, 
currently unidentified, pathways.  These findings suggest that LMB can induce apoptosis in 
keratinocytes containing HPV 16 in either episomal or integrated form, with genome status 
and potentially lesion grade likely to influence the response of HPV-associated anogenital 
lesions to LMB treatment.  
 
 
 x 
Table of Contents 
 
Chapter 1: Introduction ................ 1 
1.1. Human Papillomavirus ................................................................................................. 2 
1.1.1. HPV Structure .......................................................................................................................3 
1.1.2. HPV Life cycle ......................................................................................................................4 
1.1.3. HPV Genome .........................................................................................................................7 
1.1.4. A Summary of HPV genes ....................................................................................................7 
1.1.5. HPV 16 E2 ...........................................................................................................................11 
1.1.6. HPV 16 E6 and E7 ..............................................................................................................13 
1.1.7. E6/ E7 Gene Transcription ..................................................................................................13 
1.1.8. The Role of E6 and E7 in Carcinogenesis ...........................................................................15 
1.1.9. Integration of the HPV Genome into Host DNA.................................................................16 
1.2. Low and High Risk HPV ............................................................................................ 19 
1.2.1. Low Risk HPV ....................................................................................................................20 
1.2.2. High Risk HPV ....................................................................................................................22 
1.3. Cellular Regulation by p53 and p21 .......................................................................... 25 
1.3.1. p53 –‘The Guardian of the Genome’ ...................................................................................25 
1.3.2. The p21 Response ................................................................................................................29 
1.4. Apoptosis ...................................................................................................................... 31 
1.4.1. Death Receptor Apoptotic Pathway ....................................................................................34 
1.4.2. Mitochondrial Apoptotic Pathway .......................................................................................35 
1.4.3. The Common Mitochondrial Pathway ................................................................................36 
1.4.4. The Common Final Pathway ...............................................................................................38 
1.4.5. Cellular Consequences of Apoptosis ...................................................................................39 
1.4.6. Apoptosis and p53 ...............................................................................................................40 
1.5. The Influence of the Viral Genes on the Host Cell ................................................... 42 
1.5.1. HPV and the p53 Pathway ...................................................................................................42 
1.5.2. HPV and the Cell Cycle.......................................................................................................43 
1.5.3. HPV and Host Genome Replication ....................................................................................47 
1.5.4. HPV and Cellular Structure .................................................................................................50 
1.5.5. The Influence of HPV on Apoptosis ...................................................................................51 
1.5.5.1. Anti-apoptotic HPV Behaviour ........................................................................................52 
1.5.5.2. The Pro-Apoptotic Functions of HPV ..............................................................................53 
1.6. p53 Activation in HPV Infected Cells: A Strategy for the Treatment of HPV-
Associated Disease .............................................................................................................. 55 
1.6.1. Nuclear Export .....................................................................................................................58 
1.6.2. Leptomycin B ......................................................................................................................61 
1.6.3 The W12 Keratinocytes a Model of Cervical Neoplasia ......................................................65 
1.6.3.1. The Parental W12 Cell Line .............................................................................................65 
1.6.3.2. The W12 Derivatives ........................................................................................................67 
1.6.4. The Predicted Affect of LMB on HPV 16 Infected Cells ...................................................69 
Chapter 2: Materials and Methods ..................................................................... 72 
2.1. Ethics, Health and Safety, and Genetic Modification .............................................. 73 
2.2. Cell lines ....................................................................................................................... 73 
2.2.1. W12 Derivatives ..................................................................................................................73 
2.2.2. J2 3T3 ..................................................................................................................................73 
2.2.3. CaSki ...................................................................................................................................74 
2.2.4. SiHa .....................................................................................................................................74 
2.2.5. Primary Human Keratinocytes ............................................................................................74 
2.2.6. PHKs Transduced with HPV 16 E7 or E6/E7 .....................................................................74 
2.2.7. U2OS ...................................................................................................................................75 
 xi 
2.2.8. U2OS Transfected with HPV 16 E2 ....................................................................................75 
2.2.9. RetroPack PT67 Retroviral Packaging line .........................................................................75 
2.3. LMB .............................................................................................................................. 75 
2.4. Tissue Culture .............................................................................................................. 76 
2.4.1. Normal Cell Culture ............................................................................................................76 
2.4.2. W12 Cell Culture .................................................................................................................77 
2.4.3. PHK+ HPV 16 E7 or E6/7 Cell Culture ..............................................................................78 
2.4.4. Cryogenic Storage of Cell Lines .........................................................................................78 
2.4.5. Rescue of Cryogenically Stored Cell Lines .........................................................................79 
2.5. Morphological Effects of LMB ................................................................................... 79 
2.6. Organotypic Raft Culture ........................................................................................... 80 
2.6.1. Preparation of Collagen Plugs (Day 1) ................................................................................80 
2.6.2. Addition of W12 Cells to Collagen Plug (Day 2-8) ............................................................81 
2.6.3 Transfer of Plugs to Raft Mesh (Day 9) ...............................................................................81 
2.7. Stable Transfection of Cultured Cells ....................................................................... 82 
2.7.1. Dominant Negative p53 Plasmid .........................................................................................82 
2.7.2. Puromycin Dose Response ..................................................................................................82 
2.7.3. Transfection of Packaging Cells ..........................................................................................82 
2.8. Stable Transduction of W12 and PHK Cells ............................................................ 83 
2.8.1. Transduction ........................................................................................................................83 
2.8.2. Selection of Transduced Cells .............................................................................................84 
2.8.3. Stable Transduction of U20S Cells .....................................................................................85 
2.9. Southern Blot ............................................................................................................... 85 
2.9.1. Hirt Extraction of DNA .......................................................................................................86 
2.9.2 DNA Quantification .............................................................................................................86 
2.9.3. BamHI Purification of W12 Plasmid DNA .........................................................................87 
2.9.4. BamHI and HindIII Digestion .............................................................................................88 
2.9.5. Gel Electrophoresis .............................................................................................................88 
2.9.6. Alkaline Transfer .................................................................................................................88 
2.9.7. Probe Preparation ................................................................................................................90 
2.9.8. Southern Blot Hybridisation ................................................................................................90 
2.9.9. Southern Blot Detection ......................................................................................................91 
2.10. Immunocytochemistry............................................................................................... 91 
2.10.1. Immunocytochemistry of Monolayer cells ........................................................................91 
2.10.2. Immunocytochemistry of Raft Cultures ............................................................................94 
2.11. Colony Survival Assay .............................................................................................. 95 
2.12. Analysis of Protein Expression ................................................................................. 96 
2.12.1. Sample Preparation ............................................................................................................96 
2.12.2. Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis ....................................97 
2.12.3. Transfer of Proteins to PDVF membrane ..........................................................................98 
2.12.4. Western Blotting ..............................................................................................................100 
2.12.5. Detection ..........................................................................................................................100 
2.12.6. Stripping and Reprobing of Membranes .........................................................................101 
2.12.7. Experiment-Specific Protocol Variations ........................................................................101 
2.13. Agarose Gel Electrophoresis................................................................................... 105 
2.14. Extraction of DNA and RNA from Cultured Cells .............................................. 106 
2.14.1. DNA Extraction ...............................................................................................................106 
2.14.2. RNA Extraction ...............................................................................................................107 
2.15. Reverse Transcription ............................................................................................. 107 
2.15.1. DNase Digestion of RNA ................................................................................................108 
2.15.2. Reverse Transcription ......................................................................................................108 
2.16. Polymerase Chain Reaction .................................................................................... 109 
2.16.1 E2 PCR and RT-PCR .......................................................................................................109 
 xii 
2.16.2. E6/E7 PCR and RT-PCR .................................................................................................111 
2.16.3. E7 RT-PCR ......................................................................................................................111 
2.16.4 Dnp53R248W PCR ..........................................................................................................112 
2.17. Transformation and Culture of Bacteria .............................................................. 113 
2.17.1. Preparation of LB-Agar Plates ........................................................................................113 
2.17.2. Bacterial Transformation .................................................................................................113 
2.17.3. Bulk Growth of Transformed Bacterial Colonies ............................................................114 
2.17.4. Long Term Storage of Transformed Bacteria ..................................................................114 
2.18. Extraction of Plasmid DNA .................................................................................... 114 
2.19. p53 Reporter Assay of Dnp53R248W .................................................................... 115 
2.19.1. Transfection with pSyn-53 and pRL-CMV .....................................................................115 
2.19.2. Dual-Luciferase Reporter assay for p53 Activity ............................................................116 
Chapter 3:  The Status of HPV 16 in Cells Expressing Episomal and Integrated 
Viral Genomes................................ 118 
3.1. Introduction ............................................................................................................... 119 
3.2. Methods ...................................................................................................................... 119 
3.3. Results ......................................................................................................................... 120 
3.3.1. Analysis of the Physical State of HPV 16 in the W12 Derivatives ...................................120 
3.3.2. The Status of HPV 16 E2 in the W12 Derivatives ............................................................122 
3.3.3. Analysis of the HPV 16 E7 and E6/E7 Status of the Transduced Primary Human 
Keratinocytes ...............................................................................................................................127 
3.3.4. Transcription of HPV 16 E6/E7 in the W12 Derivatives ..................................................128 
3.4. Discussion ................................................................................................................... 129 
Chapter 4: Alterations in Morphology and Colony Survival in Response to 
Leptomycin B ................................. 135 
4.1. Introduction ............................................................................................................... 136 
4.2. Methods ...................................................................................................................... 136 
4.3. Results ......................................................................................................................... 137 
4.3.1. Morphological Effects of LMB on W12 Derivatives in Monolayer .................................137 
4.3.2. Morphological Effects of LMB on W12 Organotypic Raft Culture ..................................137 
4.3.3. LMB Affects the Colony Formation of Cells Containing HPV 16 ...................................139 
4.4. Discussion ................................................................................................................... 142 
Chapter 5: Leptomycin B Induces Apoptosis in Cells Containing the Whole HPV 
16 Genome ...................................... 147 
5.1 Introduction ................................................................................................................ 148 
5.2. Methods ...................................................................................................................... 149 
5.3. Results ......................................................................................................................... 149 
5.3.1. Confirmation of Cytokeratin 18 Expression in the W12 Derivatives ................................149 
5.3.2. The Induction of Apoptosis by LMB in Monolayer Cultures Assessed by 
Immunocytochemistry .................................................................................................................150 
5.3.3. LMB Induces Apoptosis in W12 Derivatives Grown in Raft Culture ...............................152 
5.3.4. Induction of Apoptosis Assessed by Analysis of Protein Expression ...............................154 
5.4. Discussion ................................................................................................................... 161 
Chapter 6: The Expression of p53 and p21 in Response to LMB Treatment169 
6.1. Introduction ............................................................................................................... 170 
6.2. Methods ...................................................................................................................... 170 
6.3. Results ......................................................................................................................... 171 
6.3.1. The Expression of p53 and p21 in W12 Rafts ...................................................................171 
6.3.2. LMB Induces Changes in p53 Expression in the W12 Derivatives Over a 48h Time Course
 .....................................................................................................................................................172 
 xiii 
6.3.3. LMB Induces Increased Expression of p21 in the W12 Derivatives .................................174 
6.3.4. The Expression of p21 as a Doublet in the E63 Derivative.................................................176 
6.4. Discussion ................................................................................................................... 178 
6.4.1. The Expression of p53 and p21 within Rafted W12 Cells ................................................179 
6.4.2. Time Course Expression of p53 and p21 in the W12 Derivatives in Response to LMB ..182 
6.4.3. p21 Doublet Formation in W12E63 ....................................................................................188 
Chapter 7: The Contribution of p53 to LMB-Induced Apoptosis ................. 190 
7.1. Introduction ............................................................................................................... 191 
7.2. Methods ...................................................................................................................... 191 
7.3. Results ......................................................................................................................... 192 
7.3.1. Confirmation of the Presence of the Dnp53R248W Construct .........................................192 
7.3.2. Decrease in p53 Dependent Transcriptional Activity in Cells Transduced with Dominant 
Negative p53 ................................................................................................................................193 
7.3.3. Effect of Dominant Negative p53 on LMB-Induced Apoptosis in HPV 16 Infected Cells
 .....................................................................................................................................................196 
7.4. Discussion ................................................................................................................... 198 
Chapter 8: Conclusions and Further Studies .................................................. 204 
8.1. Conclusions ................................................................................................................ 205 
Chapter 3: The Status of HPV 16 in W12 Cells Containing Episomal and Integrated Viral 
Genomes ......................................................................................................................................206 
Chapter 4: Alterations in Morphology and Colony Survival in Response to Leptomycin B ......206 
Chapter 5: Leptomycin B Induces Apoptosis in Cells Containing the Whole HPV 16 Genome 207 
Chapter 6: The Expression of p53 and p21 in Response to LMB Treatment ..............................208 
Chapter 7: The Contribution of p53 to LMB-Induced Apoptosis ...............................................209 
Clinical Relevance .......................................................................................................................210 
8.2. Further studies ........................................................................................................... 211 
Chapter 3: The Status of HPV 16 in Cells Expressing Episomal and Integrated Viral Genomes
 .....................................................................................................................................................211 
Chapter 4: Alterations in Morphology and Colony Survival in Response to Leptomycin B ......212 
Chapter 5: Leptomycin B Induces Apoptosis in Cells Containing the Whole HPV 16 Genome 212 
Chapter 6: The Expression of p53 and p21 in Response to LMB Treatment ..............................213 
Chapter 7: The Contribution of p53 to LMB-Induced Apoptosis ...............................................213 
References ....................................... 215 
Appendices ..................................... 239 
Appendix A: Suppliers ..................................................................................................... 240 
Appendix B – Protocol Details ......................................................................................... 241 
B1. Solutions and Buffers ............................................................................................................241 
B2. Protein Assay Gels and Buffers ............................................................................................242 
B3. Solutions for Southern Blotting ............................................................................................243 
B4. Antibody Details ...................................................................................................................244 
Appendix C: Additional Information ............................................................................. 246 
C1. Example of Running Mean Calculation for Immunocytochemistry .....................................246 
Appendix D – Publications .............................................................................................. 250 
D.1. Published Meeting Abstracts ...............................................................................................250 
D.2. Review and Research Publications ......................................................................................250 
 xiv 
List of Figures 
  Page 
Chapter 1   
Figure 1.1 Phylogenetic tree of the papillomavirus family  2 
Figure 1.2 Model of the HPV virion structure  3 
Figure 1.3 Organisation of the HPV 16 genome 7 
Figure 1.4 The progression of a normal uninfected epithelium to a HPV 
invasive associated cervical cancer 
23 
Figure 1.5 Ubiquitin associated pathway for protein degradation 27 
Figure 1.6 The apoptotic pathway and its disruption by HPV 16 33 
Figure 1.7 The progression of an apoptotic cell 39 
Figure 1.8 Interaction of HPV with the cell cycle 44 
Figure 1.9 The interaction of E6 and E7 with host genome regulation 47 
Figure 1.10 CRM1-mediated nuclear export 60 
Figure 1.11 Structure of Leptomycin B (LMB) 61 
Figure 1.12 The interaction of LMB with CRM1-mediated nuclear export 62 
Figure 1.13 The predicted affect of LMB on cells infected with HPV 16 70 
   
Chapter 2   
Figure 2.1 Keratinocyte-covered collagen plug on mesh raft  81 
Figure 2.2 Assembly of Southern blot transfer apparatus 89 
Figure 2.3 Lab-Tec chamber slide used for immunocytochemistry 92 
Figure 2.4 Western blot transfer apparatus arrangement 99 
   
Chapter 3   
Figure 3.1 Southern blot analysis of the genome status of W12 derivatives 121 
Figure 3.2 A schematic overview of the distribution of the E2 amplimers 122 
Figure 3.3 PCR and RT-PCR analysis of HPV 16 E2 status in W12 derivatives 123 
Figure 3.4 Variations in HPV 16 E2 amplimer C region 124 
Figure 3.5 Variation in the HPV 16 E2 amplimer B/C region 125 
Figure 3.6 W12 E2 protein expression 126 
Figure 3.7 RT-PCR analysis for HPV 16 E7 and E6/E7 in primary human 
keratinocytes 
127 
 xv 
Figures 3.8 RT-PCR analysis for HPV 16 E6/E7 in W12 derivatives 128 
   
Chapter 4   
Figure 4.1 LMB-induced morphological changes in W12 derivatives in 
monolayer 
137 
Figure 4.2 LMB-induced morphological changes in W12 derivatives in raft 
culture 
138 
Figure 4.3 Colony formation in response to LMB 140 
Figure 4.4 Variation in colony size in response to LMB 142 
   
Chapter 5   
Figure 5.1 Expression of cytokeratin 18 in W12 derivatives 149 
Figure 5.2 Immunocytochemistry for activated caspase-3 and M30 in response 
to LMB in monolayer 
151 
Figure 5.3 Immunocytochemistry for activated caspase-3 and M30 in response 
to LMB in rafted W12 derivatives 
152 
Figure 5.4 Changes in cell morphology and M30 expression in rafted W12 cells 153 
Figure 5.5 Temporal expression of activated caspase-3 in response to LMB 155 
Figure 5.6 Temporal expression of M30 in response to LMB 157 
Figure 5.7 Cumulative expression of activated caspase-3 and M30 in response 
to LMB 
159 
Figure 5.8 Effect of LMB on J2 3T3 fibroblasts 161 
Figure 5.9 Temporal expression pattern of activated caspase-3 and M30 
expression in response to LMB 
166 
   
Chapter 6   
Figure 6.1 Expression of p53 and p21 in raft culture 172 
Figure 6.2 Temporal expression of p53 in response to LMB 173 
Figure 6.3 Temporal expression of p21 in response to LMB 175 
Figure 6.4 Doublet expression of p21 176 
Figure 6.5 Phosphatase digestion of W12 protein lysates 177 
Figure 6.6 Difference in p21 expression by antibodies against internal and C-
terminally located epitopes 
178 
 xvi 
Figure 6.7 Temporal expression pattern of p53 and p21 expression in response 
to LMB 
186 
   
Chapter 7   
Figure 7.1 PCR analysis for Dnp53R248W plasmid in transduced cells 193 
Figure 7.2 Detection of p53 DNA binding in U2OS and E7 transduced PHKs  194 
Figure 7.3 Activated caspase-3 and M30 expression in U2OS in the presence or 
absence of HPV 16 E2 
195 
Figure 7.4 p53 binding activity in wild type, vector only and Dnp53R248W 
transduced U2OS cells  
196 
Figure 7.5 LMB-induced expression of apoptotic markers in Dnp53R248W 
transduced W12 and E6/E7 expressing PHKs 
197 
 
 
List of Tables 
  Page 
Chapter 1   
Table 1.1 The mitochondrial pro- and anti-apoptotic proteins 35 
Table 1.2 Proteins utilising CRM1-mediated nuclear export  63 
Table 1.3 Summary of the W12 derivatives 67 
   
Chapter 2   
Table 2.1 LMB treatment concentrations and times 76 
Table 2.2 Components of agarose electrophoresis gels 105 
Table 2.3 E2 PCR and RT-PCR primer sequences 110 
Table 2.4 Annealing temperatures for E2 primers 110 
Table 2.5 E6/E7 PCR and RT-PCR primer sequences 111 
Table 2.6 E7 RT-PCR primer sequences 112 
Table 2.7 Dnp53R248W primer sequences 112 
Table 2.8 Plasmids used for bacterial transformation 113 
Table 2.9 Protocol details for the luciferase assay 116 
 
 1 
 
 
 
 
 
Chapter 1: Introduction 
 2 
1.1. Human Papillomavirus 
Carcinoma of the cervix is a leading cause of cancer-related deaths in women worldwide 1-3, 
with formation associated with infection by the human papillomavirus (HPV) 4.  
Carcinogenesis is known to require the accumulation of numerous cellular alterations 
involving the increase, decrease or alteration of vital cellular proteins.  The presence and 
integration of high risk HPV appears, in a single step, to provide mechanisms for many of 
these alterations to occur 5.  Many cervical cancer deaths could be prevented by early 
detection of cervical intraepithelial neoplasia (CIN), the progenitors of cervical cancer, by the 
implementation of screening methods such as the UK cervical screening programme.  
Therefore, the study and treatment of HPV infection is of great importance to the prevention 
and treatment of cervical neoplasia.   
 
 
Figure 1.1: A phylogenetic tree displaying some of the papillomavirus family members.  The mucosal 
high (red) and low risk types (blue) are indicated along side cutaneous (blue) and non-human members 
of the papillomaviruses family (black), as classified by Doorbar (2006) 6.  Based on Tachezy et al 
(2002) 7. 
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The human papillomaviruses are members of the papillomaviridae taxonomic family (NCBI 
Taxonomy ID 10581), which contains viruses infecting a number of species such as birds and 
cattle (figure 1.1).  Individual papillomaviruses exhibit strict host species and tissue 
specificity 8.  Approximately 200 different human papillomavirus types have been identified 
using DNA sequencing and phylogenetic tree analysis 9.  A HPV type is defined as varying by 
a minimum of 10% in the E6, E7, and L1 open reading frames (ORF) compared to other 
known HPV types 10-12.  The human specific papillomaviruses have been identified as one of 
the most diverse groups of viruses known to cause disease in humans 13.  One specific subset 
of these viruses infects the human anogenital tract; this group contains approximately 30 
different viral types 2 which cluster within a small area of the HPV phylogenetic tree (figure 
1.1) 10-12.  The human papillomaviruses can be further categorised into groups or genera that 
are phylogenetically related, but biologically different.  Most HPVs are contained within the 
alpha and beta genera; the alpha papillomaviruses are associated with mucosal and cutaneous 
locations and have the potential to cause benign and cancerous lesions (section 1.2), the beta 
papillomaviruses within the general population are associated with cutaneous latent infections 
14.   
1.1.1. HPV Structure  
HPV is a non-enveloped DNA virus whose genome is contained within a 55nm diameter 
icosahedral capsid 8 as shown by figure 1.2.   
                                                
 
Figure 1.2: Model of HPV illustrating the structure of the viral capsid, highlighting the pentamer of the 
major capsid protein (yellow).  Image generated by Stephen C. Harrison and colleagues, Howard 
Hughes Medical Institute.  
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The capsid is formed from pentamers of L1 major capsid protein arranged into 72 capsomeres 
(60 hexavalent and 12 pentavalent) 8 as illustrated in figure 1.2.  The exact location of the 
minor capsid protein L2 within this structure is unclear, although it appears that it is located 
beneath the centre of each capsomere 15,16.  However, evidence from cottontail rabbit 
papillomavirus (CRPV) indicates that a portion is also exposed at the surface of the virion 16.  
The viral capsid structure helps to protect the progeny virions from desiccation after release 
from the epithelial surface 17 and mediates the infectivity of the virion 6.   
1.1.2. HPV Life cycle 
The human papillomavirus is a strictly epitheliotropic virus, infecting cutaneous or mucosal 
epithelial locations 18.  The virus enters where the upper epithelium has undergone trauma, 
allowing viral entry to the actively dividing cells of the basal layer.  A small number of basal 
cells become infected and the virus then spreads to the daughter cells during normal cellular 
division, hence increasing the number of virally infected cells within the suprabasal layers 6,19.  
The cellular receptor utilized by HPV to gain access to host cells is unknown.  There is some 
evidence that the heparin sulphate proteoglycans may be involved in the binding and uptake 
of the virion 20.  However, a secondary receptor in the form of α 6-integrin cell surface 
receptors may also play a role 6,21.  After binding to a cell surface receptor the virion is slowly 
internalised into the cell.  The mechanism of this uptake appears to vary between HPV types; 
in the case of  HPV 16 entry occurs via clathrin-mediated endocytosis 6,22.  However, it has 
been suggested that HPV 31 uses caveolae instead.  Related to lipid rafts, the caveolae are 
formed from collections of glycosphingolipids, cholesterol and various cellular proteins.  
Unlike clathrin coated vesicles, the caveolae do not fuse with lysosomes and therefore the 
contents are protected from enzymatic digestion 23-25.   
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As is commonly seen with other viruses such as SV40 26, the papillomaviruses do not encode 
a complete set of replication machinery (such as a DNA polymerase 27) and therefore must 
hijack the host cell replication machinery in order to replicate their genome 8.  While the virus 
remains within the already dividing layers of the basal epithelium minimal viral interference 
is required for successful maintenance of the viral genome.  However, as the host cells ascend 
towards the surface they exit the cell cycle and begin to differentiate to eventually produce the 
protective keratinised cells indicative of the upper epithelium; as a consequence, these 
differentiating cells no longer provide the machinery required for viral DNA replication.  Due 
to the alterations in behaviour of the host cell within the epithelium, the viral life cycle is 
separated into two distinct phases linked to the differentiation state of the host epithelial cells 
8.  In the suprabasal layers the virus must induce the cells to replicate and inhibit their ability 
to terminally differentiate 28 in order to maintain a replication competent state.  As the host 
epithelial cells migrate toward the surface they provide various cues allowing the virus to co-
ordinate its activity with that of the cell, ensuring that the correct cellular machinery is 
available.  The migration of the virus through the epithelium is therefore associated with a 
spatially regulated expression of the viral genes. 
 
The first phase of the viral life cycle is one of non-productive division, supported by the 
replication of the undifferentiated cells of the basal epithelium 8, where the necessary host 
replication machinery is readily available 27.  During this time the virus establishes its 
episomal genome at a low copy number of approximately 50-100 genomes per cell 18,29.  This 
non-productive phase is achieved using the DNA replication machinery in a bidirectional 
theta mode during S-phase 6 to produce one copy of the viral genome per cell cycle 29.  Within 
the basal layers of the epithelium all the necessary replication machinery is readily available 
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for both cellular and viral replication, therefore viral interference can be minimised and E6 
and E7 can be maintained at very low or non-existent levels 30. 
 
The second ‘productive’ phase of the viral life cycle is supported by the differentiating cells 8 
of the suprabasal epithelium 19.  Here the virus amplifies its DNA to a high copy number 
using a rolling circle mode of replication 29.  As in non-productive replication the virus 
hijacks the cellular machinery.  However, at this point, reactivation of the replication-dormant 
cell by the virus is required.  This process is aided by the presence of viral proteins 
particularly E6 and E7, which interact with the host to reactivate the cell and prevent arrest or 
apoptosis.  
 
As the host cells reach the upper layers of the epithelium, transcription and translation of the 
complete viral genome is initiated.  This includes the late proteins L1 and L2 which are 
required for encapsulation of the amplified viral DNA sequences.  These virions are 
subsequently released at the epithelial surface 8.  For these later phases of the viral life cycle 
to occur, the differentiation-dependent promoter p670 (HPV 16) located within the E7 ORF 31 
must be up regulated, leading to an increase in the transcription of the genes required for 
replication of viral DNA 6.  Prior to encapsulation, the L1 protein forms capsomeres within 
the cytoplasm, and after association with L2, the complex localises to the nuclear 
promyelocytic leukaemia oncogenic domains (POD, section 2.1) 6,32.  Localisation of viral 
DNA to this nuclear region for encapsulation is thought to be aided by the presence of the E2 
protein which binds to viral DNA 6. 
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1.1.3. HPV Genome 
 
 
Figure 1.3: Organisation of the HPV 16 genome showing the early genes (green and red) and the late 
genes (yellow).6  Reproduced with permission. 
 
HPV encodes a circular genome of approximately 8kb (7.904kb in HPV 16 33) with only one 
strand of the double stranded genome transcribed 9 (figure 1.3).  The genome contains the ~ 
4kb early and 3kb late ORFs, with the LCR (long control region) located between the early 
and late ORFs 8,9.  The early genes (E1 to E7) regulate viral gene expression, genomic 
replication and cellular transformation 8.  The late ORFs L1 and L2 encode the major and 
minor capsid proteins, required for late viral functions and formation of the complete 
infectious particle 8.  
1.1.4. A Summary of HPV genes  
The viral genes perform a wide range of functions designed to aid viral replication.  Where 
the virus establishes a productive infection each viral component plays a defined role, 
interacting and interfering with a range of viral or host proteins and pathways.  To be 
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successful, the viral proteins must be produced at specific times during the cells migration 
through the epithelium, and remain under strict viral regulation.  In this section a brief 
overview will be given.  Further details of the individual genes are presented in sections 1.1.5-
9 and 1.5.   
 
The E1 protein is highly conserved within the papillomaviruses and during a natural infection 
is expressed at low levels 6.  E1 has important roles in both viral replication and viral genome 
maintenance 1.   
 
The E2 protein acts as a transcriptional regulator 34 and also aids viral replication by 
interacting with the E1 protein 35.  In order to replicate, the virus requires the E1 and E2 viral 
proteins, with the remaining DNA replication machinery provided by the host cell 36.  The E2 
protein also has the ability to both activate and repress the expression of the HPV oncogenes 
forming an important mechanism for controlling viral activity 37 (see section 1.1.5).  
Inhibition of the HPV 16 p97 viral promoter by E2 allows the virus to reduce the expression 
of the E6 and E7 38,39.    
 
The E4 product is encoded by a spliced E1^E4 sequence, and expressed as a fusion protein 
including the N-terminal region of the E1 protein 40.  The protein is produced late in the early 
phase of the viral life cycle within the mid and upper suprabasal layers of the epithelium 41.  
The exact function of the E4 protein is unknown, although as it is the most abundantly 
expressed viral protein in HPV-infected epithelia, it is likely to play an important role in the 
viral life cycle 1.  It has been shown that E4 has the ability to disrupt the keratin network, 
suggesting a possible role in the later stage of virion production to aid the escape of the virus 
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at the cell surface 6,42.  However, the presence of E4 is not essential for viral transformation or 
capsid assembly 43. 
 
E5 is a short 83-amino-acid hydrophobic membrane protein 44 with a role in HPV-associated 
cellular transformation 45.  The protein is thought to act early in infection, but may also 
contribute to later phases of the viral life cycle 46.  The E5 protein is known to play a role in 
the evasion of immune surveillance by preventing the transfer of the host MHC I complex to 
the cell surface.  By compromising the activation of the cytotoxic T-cell based immune 
response 47.  E5 displays weak oncogenic properties such as the ability to enhance HPV 16-
induced immortalisation of human keratinocytes 48, and an association with anchorage-
independent growth of human keratinocytes in soft agarose 49.  It has been suggested that E5 
may also disrupt endocytic trafficking 50,51 and down regulate gap junction communication in 
the W12 cell line 52.  
  
The E6 gene encodes one of the two crucial HPV transforming proteins 53 that help to provide 
a suitable environment within the host cell for the viral life.  The E6 protein also plays an 
important role in carcinogenesis.  The major role of E6 is to bind to and cause the degradation 
of the cellular regulatory protein p53, allowing the virus to circumvent the cell’s apoptotic 
response.  This is discussed in further detail in section 4.2.1.   
 
The E7 protein acts as the other major HPV oncogene, targeting the cell cycle regulator 
protein pRb (retinoblastoma protein) for degradation.  The transformation potential of HPV is 
significantly increased by the presence of the E7 protein 53, which disrupts the relationship 
between cell differentiation and proliferation in normal keratinocytes, allowing the virus to 
replicate 2.   
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L1 encodes the major viral capsid protein which constitutes 80% 54 of the icosahedral capsid 
55.  The L1 protein is able to self assemble into virus-like particles (VLPs) even in the absence 
of the L2 capsid protein or the viral genome 56.  VLPs have been investigated as a possible 
HPV vaccine source.  They are morphologically and immunologically similar to normal 
virions, and unlike denatured L1 protein VLPs are able to illicit an immunological response 
57.  In vivo the presence of E2 in combination with L1 is thought to increase the efficiency of 
encapsulation and infectivity 58,59.   
 
The L2 protein forms the minor protein component of the viral capsid.  The exact function of 
L2 within the capsid is unclear, but it is likely that it plays a role in the infectivity of the HPV 
virion 8.  It has been suggested that a single L2 unit is located within each capsomere 60, with 
the C-terminal region of L2 interacting with the central pore of the L1 protein 61.  In addition 
to its structural function in the viral capsid, L2 also has the ability to bind DNA, and is 
therefore thought to have other roles during the viral life cycle.  Immediately post-infection 
L2 is thought to be involved in the transfer of uncapsulated viral DNA from the cytoplasm to 
the nucleus 6,22,62, while later in the viral life cycle the protein is thought to have a role in the 
selective encapsulation of the viral DNA 63.  Expression of both the L1 and L2 proteins 
appears to be restricted to the upper epithelium, although mRNA of both genes is present, but 
untranslated in the lower regions of the epithelium 64,65.  
 
The LCR or upstream regulatory region (URR) is a non-coding region of 850bp located 
between the early and late ORF, accounting for approximately 12% of the total viral genome 
1,66.  This region contains glucocorticoid response elements, cis regulatory elements (CREs), 
the origin of replication 8,67, and also a number of other control regions that aid the regulation 
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of viral transcription and replication 66.  The tissue tropism of the papillomaviruses is 
mediated by epithelial specific enhancers located within the LCR 68, which are controlled by 
the binding of transcription factors, such as nuclear factor 1, in an epithelial cell specific 
manner 69.  The promoter p97 (HPV 16) is located upstream of the E6 ORF within the URR, 
and regulates the transcription of both the E6 and E7 genes 37.  p97 possesses a basal activity 
in primary human keratinocytes that can be modulated by the full-length E2 protein 70-72, 
acting as a weak activator of p97 and leading to a two-fold increase in activity, or 
alternatively as a strong repressor of the promoter, causing a hundred-fold decrease in 
activity, with regulation thought to be concentration dependent 37.   
 
The viral E2, E6, and E7 genes play important roles in the behaviour of the episomal virus 
and make a substantial contribution to creating the post-integration environment.  The roles of 
these genes are examined below and in section 1.5.    
1.1.5. HPV 16 E2 
The HPV E2 protein is made up of three functional regions: the N-terminal transactivation 
domain through which it associates with the E1 protein, the hinge region, and the C-terminal 
DNA binding domain 6,73-75.  To operate normally E2 requires functional DNA binding and 
transcriptional activation domains 76.  
 
When acting as a transcriptional regulator in HPV 16, E2 dimerises and associates with four 
highly conserved palindromic sequences (5’ACCN4CGGT 3’77) located within the URR 37.  
Once bound E2 recruits E1 to the origin of replication, and acting as a DNA helicase E1 78 
together with E2 instigates a localised distortion of the DNA structure.  This enables the 
binding of additional E1 proteins, which displace E2 and allow the recruitment of the host 
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replication machinery to the DNA 6.  This machinery includes DNA polymerase α-primase 
79,80 which assists in the initiation and elongation of the DNA in preparation for replication 81.  
The role of E2 in mediating replication may also involve interaction with the cellular protein 
DNA topoisomerase II-beta-binding protein 1 (TopBP1), which is thought to have roles in 
numerous processes such as transcription and replication 82-85.  For transcription and 
translation to occur E2 must bind the most distal E2 binding sites (sites 3 or 4 in HPV 16), 
with other cellular factors interacting with the enhancer elements located within the URR 75,86-
89.  Low levels of the E2 protein are associated with the initiation of E6 and E7 transcription 
via activation of the p97 promoter (HPV 16) in combination with p300 and the CCAAT 
enhancer-binding protein α (C/EBPα) 90.  However, as E2 levels increase, the activity of the 
p97 promoter is inhibited 6, probably due to the rising levels of E2 protein providing 
increasing opportunities for interaction with the more proximal binding sites, displacing the 
cellular transcription factors such as Sp1 and TBP (TATA-box-binding protein) required for 
the activation of p97 6,37,75,88.   
 
The E2 protein has been shown to have a role in ensuring the correct segregation of viral 
genome during host cell division.  It acts as an anchor, tethering the viral DNA to the mitotic 
chromosome 6,16,91-93.  In order to achieve segregation E2 has been proposed to interact with a 
range of proteins including Brd4 (described in BPV) 94, ChlR1 (described in BPV, HPV 11 
and HPV 16) 95,96 and TopBP1 (described in HPV 16) 82.   
 
In the latter stages of the natural infection, as the virus reaches the upper regions the 
epithelium, it no longer requires cells to be maintained in a replication-competent state; this 
change in behaviour is thought to be signalled by increasing levels of E2.  The rise in levels of 
the E2 protein within the cell leads to an increased inhibition of the p97 promoter and a 
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subsequent down regulation of E6 and E7.  This causes the loss of the virally-induced 
replicative environment through a HPV controlled mechanism 6. 
1.1.6. HPV 16 E6 and E7 
HPV E6 is a small protein of only 150 residues 97 containing two domains, E6 N-terminal 
(E6N) and E6 C-terminal (E6C).  Each of these 75 amino acid regions encodes two zinc 
binding domains containing two cystine-X-X-cystine (CXXC) motifs 98.  Tandem copies of 
this carboxyl terminal motif are also found in the HPV E7 protein, suggesting a common 
evolutionary ancestry for both viral proteins 99.  
 
The E7 gene encodes approximately 100 amino acids forming a small acidic polypeptide that 
acts as a phosphoprotein.  Due to its short half-life of less than 2 hours, the E7 protein is 
found at low steady state levels within the cell 100.  The amino terminal of the protein contains 
a casein kinase consensus phosphorylation site 2, while the carboxyl terminal encodes the zinc 
binding domain shared with E6 101.  Many interactions of E7 with both nuclear and 
cytoplasmic proteins occur via the carboxyl region of the protein 2.  Immunofluorescent 
studies have shown that E7 is mainly nuclear.  However, the exact import mechanism is 
unclear as no obvious nuclear localization sequence has been identified 102.  A number of non-
nuclear E7 targets do exist, suggesting that at some point a fraction of E7 may be present in 
the cytoplasm 100.  Studies have shown that the absence of the E7 gene leads to a failure to 
amplify the viral DNA and reduced production of the L1 capsid protein 27.   
1.1.7. E6/ E7 Gene Transcription 
Most eukaryotic organisms produce monocistronic mRNA encoding only a single ORF.  
However, the presence of multiple ORFs in a single mRNA transcript (polycistronic) is seen 
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in some viral and cellular mRNA 103.  The human papillomavirus genome is transcribed as bi- 
or polycistronic sequences that encode multiple viral proteins 104, with the individual genes 
expressed by alternative splicing of the viral mRNA transcripts.  The splicing pattern varies 
with the phases of the viral life cycle, leading to the changes in protein expression seen during 
the viral infection 103.   
 
The high risk HPV types have been shown to express both the E6 and E7 genes from a single 
promoter, while in the low risk HPV types each gene contains its own promoter 105.  The 
E6/E7 mRNA transcript contain 3 exons and 2 introns 106, with the E6 start codon (AUG) 
located 5’ to the E7 start codon 107.  However, this pattern of E6/E7 transcription is not found 
within the low risk HPV types where each gene is transcribed from its own promoter 103,108.   
 
HPV 16 has been shown to produce three different E6/E7 transcripts as a consequence of 
alternative splicing of the pre-mRNA; the full length transcript E6/E7 can be alternatively 
spliced to form E6*I or E6*II 107,109.  The E6*I transcript is formed by the removal of intron 1 
64 located within the E6 ORF, at nucleotides (nt) 226-409; the E6*II form utilises the same 
splice donor site at nt 226, but an alternative splice donor site at nt 526 106,107.  The full length 
E6/E7 mRNA generates the 16kDa E6 protein with the translation of the E6*I transcript 
producing a truncated ~8kDa version of the protein that corresponds to the N-terminal region 
of the full E6 protein 110.   
 
In monocistronic mRNA, the initiation of translation occurs via ribosome scanning; however, 
in polycistronic mRNA where the common promoter is located upstream of the initial ORF, 
any subsequent translation of a downstream gene is inhibited by the presence of the first ORF 
108.  The E7 ORF, which is located downstream of the E6 ORF, can be translated from the full 
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E6/E7 and perhaps the E6*I mRNA transcript.  Translation of E7 is reported to occur at 25-
35% of the E6 level 103, and is thought to be achieved via a leaky scanning mechanism.  
Leaky scanning occurs where ribosomes bind at the 5’ end of the E6/E7 mRNA, but ignore 
the E6 start codon and continue to scan the transcript until the later E7 start codon is reached; 
here efficient and accurate translation of E7 can be initiated 103,108.  However, an alternative 
explanation is provided by Glahder et al (2003) 108, who have identified a putative E7 
promoter (P542) within the E6 ORF that, although weak, would appear to be able to regulate 
E7 expression, and therefore provide an alternative mechanism for independent initiation of 
E7 translation.   
 
The function of the E6*I transcript is unclear; it may simply be used as a template to produce 
the E7 protein 109.  Alternatively, the translated protein may act to attenuate the levels of the 
functional E6 protein by reducing the levels of the full length E6/E7, allowing equalisation of 
E6 and E7 protein expression 103.  It has been reported that the E6*I protein may also interfere 
with interaction between the full length E6 and cellular E6-AP, preventing the ubiquitin 
labelling of proteins for proteasomal degradation (section 1.3.1) 111,112.  E6*I would therefore 
permit the reactivation of a number of cellular proteins important in the stress response, 
including p53 and the anti-apoptotic proteins BAK 113, BAX 114, and c-Myc 115, allowing the 
initiation of cell cycle arrest and apoptosis.  
1.1.8. The Role of E6 and E7 in Carcinogenesis  
HPV E6 and E7 work together in both the normal viral life cycle and also during malignant 
progression.  Although these proteins interact with different cellular targets and undertake 
distinct roles in the viral lifecycle, the expression of both the E6 and E7 appears necessary for 
the efficient immortalisation of keratinocytes.  E6 has been shown to have a weak effect at the 
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promotional stage of carcinogenesis associated with the formation of benign tumours, but 
where benign tumours undergo malignant conversion E6 was found to act strongly 28.  
Therefore, although E6 has a reduced effect in the initial production of benign tumours, it 
does create a more rapid conversion from benign to malignant forms 28.  In contrast to E6, 
HPV E7 acts primarily at the early stages of carcinogenesis supporting the formation of 
benign tumours; its contribution to actual malignant conversion is low in comparison to the 
E6 protein 28.   
1.1.9. Integration of the HPV Genome into Host DNA 
Premalignant lesions typically contain episomal HPV 116 with the integration of the viral DNA 
forming a critical early event in oncogenic progression, leading to consequences for both host 
and virus 117,118.  Integration is an important step in HPV associated neoplasia, although alone 
it appears to be insufficient to cause malignant progression 119.  Integrated HPV can be 
present as single copy integration which can occur at more than one location as seen in the 
cancer cell line SiHa, which contains 2 copies of the viral genome 119.  Alternatively, 
integration of head-to-tail tandem repeats of the HPV genome can occur within the host 
genome as shown in the CaSki cell line, which contains 600 copies of the viral genome 119.  
Both types of integration pattern are seen in cell lines such as those mentioned, and also in 
vivo 119,120.  
 
Certain oncogenic viruses such as hepatitis B are associated with preferential integration close 
to host oncogenes or tumour suppressor genes such as hTERT and the platelet derived growth 
factor (PDGF) receptor 121.  Post-integration alterations in the regulation of these host genes 
can provide an advantage to the infecting virus 119.  Integration of HPV appears to convey no 
advantages to the virus itself, with the disruption of viral genes leading to non-productive 
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infections as later events required for virion production are not supported in the altered post-
integration environment 5.  In vitro, integration is associated with the development of genomic 
and phenotypic abnormalities similar to those seen in cervical neoplasia in vivo 117.   
 
The site of viral integration within the host genome is not associated with any specific 
genomic region or cellular motif 5,122, although it has been suggested that in some 
circumstances genes surrounding the integration site may, if appropriate, contribute to the 
development of pre-malignant lesions 123.  However, there does appear to be some preference 
for integration within areas of the host genome known as ‘common fragile sites’ (CFSs), with 
high risk HPV types integrating into known CFSs in at least 38% of cases studied 124.  These 
loci are areas of the normal chromosomal structure prone to breakage in response to stimuli 
such as tissue culture conditions and chemical agents.  These areas are characterised by 
constrictions, gaps, or breaks within the chromosome structure 125.  The preference for 
integration within these sites may be purely due to their fragile nature, or their proximity to 
advantageous host sequences 5.  As foreign DNA vectors show a similar frequency of 
integration within the CFSs (44%) it appears that these areas are relatively amenable to this 
type of integration event 5.  It is possible that E6 and E7 induced genetic instability may 
increase the frequency of CSF breakage and hence increase the opportunity for integration 
events 5.  A possible predisposition for integration into host genes involved in important 
cellular mechanisms such as cell division and differentiation has been identified 122.  Frequent 
transcription of these genes leads to a more open DNA conformation within those regions of 
the genome, making these areas more accessible to integration 122.   
 
In order to integrate, the viral genome must be linearised by cleavage of the circular episome 
leading to the disruption of E1 and E2 ORFs 126.  Evidence from cell lines such as W12, 
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suggests that successful integration does not occur in any other region of the viral genome 119.  
This implies that either the E2 gene represents a ‘recombinational hot spot’, or more likely 
that cells integrated through E2 disruption have a growth advantage over those where other 
regions of the viral genome are effected 119.  The mutational inactivation of E1/E2 has been 
shown to enhance the transforming potential of a number of papillomavirus types 127, leading 
to an increase in keratinocyte life span 128.   
 
Although the E6 and E7 genes are consistently maintained within the integrated viral genome, 
the loss of E2 transcriptional control of the p97 promoter leads to a notable increase in their 
expression, causing a range of effects on both virus and host 42 (section 1.5).  Integration can 
also cause the formation of a viral-cell fusion transcript, where the viral poly-A sequence 
located at the 3 ́end of the mRNA is removed 119.  This leads to an increase in the stability of 
the remaining E6/E7 mRNA due to the absence of the instability elements contained in this 
region 111,129, leading to further rises in viral oncogene levels 119.   
 
Where numerous separate integration events are present within the host genome, research 
suggests that selection occurs for cells where only one or at most two actively transcribing 
copies are present 5,30.  The remaining viral DNA is thought to become transcriptionally 
silenced via methylation of the viral URR 5,30.  Where integration of concatemers of viral 
DNA has occurred the viral sequences adjacent to the cellular DNA at the host-viral junction 
become disrupted in the E2 region.  The internal HPV genomes may contain intact copies of 
the E2 ORF 130.  However, it appears that only the viral sequences located at the host-viral 
junction containing the disrupted E2 ORF are transcriptionally active 30. 
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The episomal context in which integration of viral genomes occurs has been suggested to 
substantially influence its ability to affect both viral and host behaviour 5.  Overexpression of 
E2 experimentally appears to have little effect on transcription from episomal HPV 16.  
However, the addition of E2 to cells containing integrated HPV 16 shows that, within this 
context, E2 mediates a strong reduction in transcription 5,131.  Experimental data provides 
evidence for mixed populations of episomal and integrated HPV.  Peitsaro et al (2002) 118 
studied 31 lesions with 29 shown to contain mixed populations of episomal and integrated 
viral DNA.  Lesions containing a greater proportion of integrated sequences were shown to 
undergo more rapid carcinogenic progression 118.  Pett et al (2007) 5 have suggested that in a 
cell containing a mixed population of episomal and integrated HPV the episomally expressed 
E2 may be able to exert transcriptionally repressive effects over the integrated DNA, hence 
maintaining control of viral gene expression 132.  This is illustrated by the parental W12 cell 
line (section 1.6.3.1) in which the loss of remaining E2 expressing episomes occurs prior to 
the post-integration increases in E6 and E7 expression 133.  It appears that integration alone is 
insufficient for production of a predominantly integrated population.  To achieve this, a 
separate event involving the loss of any remaining episomes also seems to be required 133.   
1.2. Low and High Risk HPV 
The human papillomaviruses infect a range of both cutaneous and mucosal locations within 
the human body.  The cutaneous viruses are found in areas such as the surface of the hands 
and feet and are largely benign 42, while the mucosal types that infect the genital and oral 
regions have a greater propensity for malignancy.  
 
HPV types can be assigned into two main categories according to whether they pose a low or 
high risk of carcinogenesis 54.  Viruses within these two categories maintain many similarities, 
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but crucial differences have led to changes in certain aspects of their behaviour and 
subsequently their cancer risk.  Even within these risk categories there remains considerable 
variation in behaviour, particularly amongst the high risk viruses where persistence and 
malignant progression vary considerably 134.  The mucosal low risk genotypes such as HPV 6, 
11, 40, and 42 are associated with benign lesions such as anogenital warts (mucosal 
condylomata acuminata 135) which affect 1-2% of young adults in many countries 6.  
Cutaneous HPV 5 and 8 are classified as high risk and are associated with epidermodysplasia 
verruciformis (EV) which is especially common in immunocompromised individuals 
(reviewed in 9).  The high risk mucosal viruses include HPV 16, 18, 31, 33, 35, 45, 56, and 58 
6.  These high risk viral types are not only associated with benign lesion such as warts, but are 
also implicated in anogenital cancers such as carcinoma of the cervix 54,135-137 and oral cancers 
such as oropharyngeal carcinoma 138.  Two specific high risk types, HPV 16 and 18 are 
responsible for more than 90% of cervical and greater than 20% of oral cancers 106.   
1.2.1. Low Risk HPV 
Low risk HPVs, particularly types 6 and 11, are associated with the formation of benign 
lesions and are not seen as posing a significant risk of malignant progression.  However, these 
low risk types have been found associated with malignant lesions 139-145, and in the case of 
HPV 6 no functional differences have been found between the viral genome extracted from 
benign warts and those associated with malignant lesions 142.  
 
Within the high grade HPV infected lesions a major alteration in the behaviour of the host 
keratinocytes is seen.  In both the normal epithelium and benign lesions the dividing cells are 
confined to the basal layer, losing this ability to divide as they leave this layer and migrate up 
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the epithelium.  However, within the high risk lesions dividing cells are seen to spread up into 
the suprabasal layers of the epithelium 30. 
 
The behaviour of low risk viruses may be largely explained by the properties of their E6 and 
E7 viral proteins.  These proteins are potentially oncogenic, but in the low risk viruses E6 and 
E7 possess a lower binding efficiency than their high risk counterparts for cellular p53 and 
pRb 146,147 leading to a decrease in their ability to cause damaging cellular disruption.  The 
low and high risk types also show differences in the localization of E6 and E7 within the cell 
148.  Both the low risk proteins tend to form punctate patterns within the nucleus, 
corresponding to the PODs 148.  However, the high risk proteins show differential localization 
patterns; for example HPV 18 E6 is found in both the nucleus and cytoplasm, including some 
membrane locations, allowing the virus to interact with membrane-associated host proteins 
that often have roles in signalling pathways 148.  The HPV 18 E7 protein localises 
predominantly to the nucleus, forming a diffuse pattern 148.  The distribution of high risk E6 
throughout the cell allows interaction with a wider range of host proteins than the nuclear 
bound low risk types.  This is likely to lead to an increased ability to influence the host cell 
compared with a low risk infection 148.     
 
Most low risk HPV types characteristically do not possess a functional E5 protein, due to the 
absence of a definable homologous E5 ORF and/or a translation start codon 134.  As E5 is 
associated with increased transforming ability this absence likely contributes to the benign 
nature of the low risk infections (section 1.1.4). 
 
Replication in low risk viruses appears to be concentrated in a location close to the PODs 149.  
The function of the PODs is unknown, although they may have a general role in 
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carcinogenesis as they are disrupted in acute myelocytic leukaemia.  A range of viral proteins 
are targeted to these domains, including several regulatory proteins encoded by other DNA 
viruses 8 such as herpes simplex virus type 1 (HSV-1) 150.  These are targeted to the PODs at 
an early stage in the viral infection 8 and are thought to be vital to viral replication 151,152.  This 
localization of low risk HPV may allow them to better utilize the cellular structures and 
proteins found within the PODs for functions such as viral packaging 148.  This strong 
association of viral replication with the POD region of the nucleus is not seen in high risk 
HPV types and may contribute to the attenuated viral replication cycle seen with the high risk 
viruses in comparison with the low risk types 41. 
1.2.2. High Risk HPV  
The incidence of HPV infection varies between populations, but is reported to be between 20-
40% amongst young women (mean age 25yrs) 6,153, although the life time risk of HPV 
infection is approximately 80% 154.  HPV infections resolve within 18 months in 
approximately 80% of cases.  This in combination with the adaptation of the immune system, 
helps to account for the decrease in incidence with increasing age 6,155.  Despite the relatively 
high prevalence of HPV infections, in 2004 only 2726 cases of cervical cancer were 
diagnosed within the UK 156.  The high risk HPV types are aetiologically linked to more than 
99.7% of all cervical cancers 157, with HPV 16 the most commonly found 158.  
 
Where individuals are unable to clear a high risk HPV infection, cervical intraepithelial 
neoplasia (CIN) may develop; these lesions then form the precursors to cervical neoplasia.  A 
Costa Rican study found that 19.9% of the HPV 16 positive women were diagnosed with 
CIN3 or neoplasia either at the beginning of the study or within 5 years 134.  Persistent 
infection is associated with continuous expression of oncogenic E6 and E7 genes leading to 
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maintained stimulation of S-phase and cell proliferation, and sustained inhibition of the p53 
pathway (sections 1.1.4, 1.1.8-9, 1.13 and 1.5.1).  These factors may provide a mechanism by 
which unresolved mutations are able to accumulate within the cellular genome, potentially 
contributing to carcinogenic progression.  However, evidence also suggests that a more rapid 
onset mechanism may be present in some cases 6,159. 
        
 
 
Figure 1.4. The progression of a normal uninfected epithelium to a HPV invasive associated cervical 
cancer, indicating infection status and histological staging.  The expression of the HPV proteins within 
the undifferentiated and differentiating cells of the suprabasal epithelium are shown; the red arrows 
indicate the presence of the HPV oncogenes E6 and E7, the blue arrow the remaining early genes and 
the green arrow the late capsid proteins.   
 
HPV-associated carcinogenesis is a multi-step process where infected cells pass through 
several stages before forming a carcinogenic lesion 28.  Progression between the different 
grades is associated with alterations in the behaviour both of the virus and host cell.  The 
lowest grade lesions are described as low grade squamous intraepithelial lesions (LSIL) or 
CIN grade 1 (CIN1).  These can reversibly progress to high grade SIL (HSIL) also defined as 
CIN2/3.  Further irreversible progression to cervical neoplasia may then occur (figure 1.4).  
Initially viral infection leads to the formation of self limiting warts and precursor lesions 28.  
These are characterised by cellular abnormalities which are confined to locations within the 
epithelium with no invasion of the underlying tissue.  These CIN1 lesions are associated with 
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relatively normal viral gene expression patterns, often maintaining capsid protein production 
in the upper suprabasal layers, an occurrence less common in the higher grade lesions 6,160.  
Persistent infection, in combination with other factors, provides a possible mechanism to 
enable these lesions to progress to high grades where abnormal cells become apparent 
throughout the epithelium 28.  The CIN2/3 lesions display a greater alteration in viral gene 
expression, with increasing oncogenes levels, but a decrease in the remaining early and late 
viral proteins causes a notable reduction in the productive stages 6.  These high grade lesions 
may progress further to form an invasive tumour.  This often occurs after a prolonged viral 
infection where the cell is subjected to chronic overexpressed E6 and E7.  In most cases 
anogenital HPV infections are cleared within 1 to 2 years 134 with no lasting rise in cancer 
risk.  However, persistent infection with high risk HPV has been shown to be associated with 
a considerable increase in the risk of cancer formation 161.  The probability of a CIN2 lesions 
progressing to CIN3 is estimated to be around 20%, with a subsequent risk of further 
progression from CIN3 to neoplasia of 40% 6,162.  Research has shown that lesions regress in 
approximately 70% of CIN1 cases 163, and in 28% of CIN2/3 164.  
 
In addition to viral persistence, other risk factors are also suggested to play a role in the 
development of cervical neoplasia.  These include the presence of the glucocorticoid and 
progesterone hormones that influence viral gene expression or changes in methylation and 
chromatin organisation, altering viral gene expression of episomal and integrated genomes 6.  
Smoking has been suggested to increase the risk of HPV-associated anogenital neoplasia by 
both epidemiological studies 165 and via the identification of significant amounts of tobacco-
specific compounds such as nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone 
(NNK) in the cervical mucus of smokers 166,167.  
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The interaction of high risk HPV with the cellular regulators p53 and p21 is vital for the 
successful replication of the virus, but these interactions have important consequences for the 
host, particularly in the presence of integrated HPV.  The normal function of both p53 and 
p21 is described below, and the relationship with HPV discussed in sections 1.5.1-2. 
 
1.3. Cellular Regulation by p53 and p21 
1.3.1. p53 –‘The Guardian of the Genome’ 
The tumour suppressor gene p53, often termed ‘the guardian of the genome’ 168, plays a 
pivotal role in monitoring, regulation and decision making within the cell.  p53 is a member 
of a family of p53-related transcription factors which also includes p63 and p73 169; these 
proteins share the 3 principal functional domains as discussed below, with the central region 
most highly conserved within the group 169.  In response to a range of cellular stresses, p53 
interacts with and co-ordinates numerous cellular components in an attempt to protect the 
whole organism from the proliferation of cells containing DNA damage or potentially 
malignant changes 170.  p53 participates in deciding the course of action to be taken in 
response to the stress stimuli.  The cell may try and repair the damage and if successful can 
allow re-entry into the cell cycle.  However, if the stress is too great or repair unsuccessful the 
only available option may be to apoptose the cell.  This important cellular protein is thought 
to have varying direct or indirect roles in a wide range of processes including cell cycle 
regulation, genetic stability, blood vessel formation and apoptosis 171.  The absence or 
mutation of p53 is found in at least 50% of human cancers, illustrating the vital role of p53 
within cell cycle control 172,173.   
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p53 is a 393 amino acid protein which can be divided into 3 distinct structural domains; the 
amino-terminal domain, the central core region, and the carboxyl terminal domain 174.  The 
amino terminal region contains the p53 trans-activation domain and also the PXXP motif 
which has a role in the induction of p53-dependent apoptosis 175.  The central core domain 
located between residues 102-292 contains the vital DNA binding domain required for 
transcriptional activity 174.  The carboxyl terminal contains both the nuclear localisation 
signals and oligomerisation domains.  This region is particularly important for the assembly 
of activated p53 tetramers 174.  Also, sequences near the terminal end of this region are 
involved in the negative regulation of p53 DNA binding 175. 
 
Inactive p53 is maintained in a latent form 176 with a short half life determined by the rate of 
proteasomal digestion 138,177.  Proteasomes are found within both the nucleus and cytoplasm, 
and act as protease enzymes involved in the regulation of protein levels within the cell via 
degradation 178.  For efficient p53 degradation it appears that the export of the protein from 
the nucleus to the cytosolic proteasomes is preferable.  However, a reduced rate of 
degradation can be undertaken by the nuclear proteasomes 179.  The labelling of p53 for 
degradation is undertaken by the nuclear phosphoprotein Mdm2.  This prevents the interaction 
of p53 with transcription machinery and acts as a cellular E3 ubiquitin ligase (figure 1.5) 
180,181.  In turn, p53 regulates the expression of Mdm2, creating a negative feedback loop.  
Ubiquitination acts as a signal allowing the protein degradation machinery to recognise the 
unwanted labelled protein.  The labelling process is undertaken by a multi-enzymatic cascade 
as summarised in figure 1.5 182, utilising the group of cellular enzymes E1-4.  Initially the 
ubiquitin peptide is activated by the ubiquitin-activating enzyme E1.  It is subsequently 
transferred to the C-terminal of the target protein 171, either directly by one of the E2 
ubiquitin-conjugating enzymes, or indirectly via an E3 ubiquitin-protein ligase such as Mdm2 
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182.  Mdm2 is responsible for mono-ubiquitination of p53, but for degradation to occur further 
ubiquitin molecules must be added by the E4 ubiquitin ligase CBP (CREB binding 
protein)/p300 183.  The polyubiquitin chain is recognised by the 26S proteasome which 
degrades the labelled protein in a ATP-dependent manner 182,184. 
 
 
Figure 1.5: The ubiquitin/proteasome pathway for the degradation of proteins within the cell. Taken 
from Voges et al (1999) 185, reprinted, with permission from the Annual Review of Biochemistry, 
Volume 68 (c) 1999 by Annual Reviews www.annualreviews.org. 
 
p53 is known to shuttle between the nucleus and cytoplasm by ATP-dependent transport in an 
unstressed cell 186.  It is therefore unsurprising that the protein contains both nuclear 
localisation (NLS) and nuclear export signals (NES) within its sequence.  p53 is known to 
encode three NLS, which are rich in basic amino acids 186,187.  Also p53 contains two copies 
of the shorter NES, rich in hydrophobic leucine residues 188,189, with one NES is known to be 
located within the C-terminal tetramerisation domain of the protein 190.  When the cell is 
stressed, a bias develops allowing the accumulation of p53 within the nucleus utilising the 
NLS 176.  When not required, the p53 can be sequestered into the cytoplasm by a number of 
proteins, including Parc and mot2 that act as cytoplasmic anchors for p53 176. 
 
p53 can be activated by several different stimuli pathways 171, such as DNA damage in a 
protein kinase (ATM and Chk2) dependent manner 191, UV radiation, protein kinase inhibitors 
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in an ATR and casein kinase II dependent manner 192, or via incorrect growth signalling 
involving p14arf signalling 193,194.  These different activation mechanisms have a common 
response as p53 becomes transiently stabilised via phosphorylation of residues primarily 
within the N-terminal region of the protein, causing an inhibition of Mdm2-mediated 
degradation 138,171.  Stabilisation arises by phosphorylation of serine and threonine residues 
located mainly within the amino-terminal transactivation domain of p53, but also via 
acetylation or phosphorylation at the carboxyl terminus 138,171.  The requirement for post 
activation modification is reflected in the terminal sequences of the protein.  The amino 
terminal contains multiple phosphorylation sites, whilst the carboxyl terminal contains several 
phosphorylation, acetylation, glycosylation and sumoylation sites 176.  Altering the N-terminal 
sequences in this manner decreases Mdm2 binding and therefore aids the accumulation of p53 
171.  Modification of the C-terminal is likely to alter the conformation of this region, exposing 
the centrally located DNA binding motifs normally masked by the C-terminus 171.  Activation 
of p53 can also occur in response to p14arf signalling which causes a rise in protein levels by 
reducing degradation via relocation of Mdm2 to a different nuclear region 171. 
 
Activated p53 displays an alteration in its localisation from predominately cytoplasmic to 
nuclear enabling p53 to undertake transcriptional activity.  The nuclear localisation of p53 
therefore acts as an important regulatory mechanism 179,195.  Once in the nucleus p53 
assembles into tetramers via the interaction of the C-terminal oligomerisation domains.  This 
association masks the NES contained within this region and prevents nuclear export of p53, 
maintaining potentially transcriptionally active p53 within the nucleus 196,197.  In addition, 
enhanced nuclear accumulation and transcriptional activity can also be achieved by masking 
the NES by phosphorylation of the N-terminal at serine 15 198 and 20 176,199.  
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Activation of p53 initiates transcription from as many as 300 different promoter elements, 
leading to numerous downstream cellular effects 200 (reviewed in ref 201).  p53 therefore has 
the ability to influence a diverse range of cellular processes including cell cycle regulation, 
DNA repair, differentiation, development, gene amplification, DNA recombination, 
chromosome segregation, cell senescence and, where appropriate, apoptosis 170 (section 1.4).  
The transcriptional activity of p53 is highly regulated via a number of mechanisms, including 
transcription and translation, protein stability, and post-translational modifications 176.   
 
The context of p53 activation and the environment in which it occurs can influence the 
outcome of p53 signalling.  For example, activation of p53 in the presence of certain cellular 
proteins such as Myc inhibits transcription of the p21 protein, but allows the transcription of 
other p53 responsive genes, thus steering the cell towards a more directly apoptotic pathway 
instead of cell cycle arrest 202.  
1.3.2. The p21 Response 
An early event in p53 activation is the induction of cell cycle arrest.  This can be achieved via 
the p53-dependent transcription of the cell cycle regulator p21Waf1/CIP1, temporarily protecting 
the cell from p53-dependent apoptosis 203.  p21 is a member of the Cip/Kip family of cyclin-
dependent kinase inhibitors (CKIs), with the family also including the proteins p27Kip1 and 
p57Kip1 204.  This evolutionarily conserved protein contains 164 amino acids; the amino 
terminal region is required for the inhibition of the cyclin/cdk complex, whilst the C-terminal 
region binds proliferating cell nuclear antigen (PCNA) to inhibit DNA replication 204,205, and 
also contains a weaker second cyclin binding site 204 and a cyclin dependent kinase binding 
site 206. 
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The CKIs act by inhibiting members of the cyclin dependent kinase (cdk) family.  These 
proteins are required for the control of the G1/S and G2/M cell cycle checkpoints 
207.  Cdks 
become activated when bound by cyclin proteins; this active complex is then able to 
phosphorylate numerous cellular proteins including the pRb protein family.  pRb binds and 
prevents functioning of the cell transcription factor E2F 208.  Phosphorylation of pRb causes 
the release of bound E2F, allowing the transcription of genes whose products are required for 
subsequent phases of the cell cycle, such as the replication machinery during S-phase 208.  In 
order to prevent cell cycle progression, p21 binds the cdk-cyclin complex preventing the 
phosphorylation of pRb, and causing the retention of E2F and the absence of E2F initiated 
transcription 209,210.  Increased p21 can also cause lower levels of DNA synthesis due the 
sequestration of cyclin-dependent kinase-2, cyclin E and PCNA (a cofactor of DNA-
polymerase δ) into a quaternary complex 27,209.  p21 can interact or compete with many other 
proteins such as p300 transcriptional activator 211 and GADD45 a p53-responsive stress 
protein 212.  This enables p21 to influence diverse cellular pathways (reviewed in 204).  
 
The activity of p21 can be controlled by altering its transcription in either a p53-dependent or 
independent manner 213, or via post-transcriptional modifications such as mRNA stabilisation 
in response to ultraviolet C (UVC) 214 and protein stabilisation by kinases p38α and JNK 1 
204,215.  In the presence of viral infection the activation of p21 may represent a response to 
abnormal DNA synthesis within the suprabasal compartment, experimentally illustrated in 
organotypic rafts 27.  This p21 response has adverse consequences on the viral life cycle 
causing a reduction in the amount of possible viral replication by preventing entry into S-
phase and mitosis.   
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The p21 pathway can be activated in a p53-independent manner by several different agents 
leading to transcriptional activation of the p21 gene 204.  The stimulating agents include 
phorbol myristoyl acetate (PMA), transforming growth factor-β (TGF-β), calcium, 
progesterone, E2F, and Trichostain A (TSA, histone deacetylase inhibitor, reviewed 204).  This 
p53-independent effect can be mediated through activation of the Sp1 protein sub-family of 
transcription factors, which causes the transcription of a wide range of genes including p21 
204,216.   
1.4. Apoptosis 
Cells are governed by strict physiological mechanisms that control the rate of proliferation and 
cell homeostasis.  It is therefore vital that all cells have the intrinsic ability to undergo 
controlled cell death via apoptosis to maintain this homeostasis.  Apoptosis is a multi-step, 
multi-pathway programme, which is tightly controlled by a range of cellular proteins.  Faults or 
abrogation of the apoptotic system can lead to a net gain of abnormal cells which may 
ultimately lead to cancer.  
 
In normal cells the apoptotic pathways originate in response to a range of stimuli such as 
DNA damage, hypoxia, or nutrient depletion 111 (figure 1.6).  The intracellular component of 
apoptosis can be initiated via two main routes: the death receptor (extrinsic) or the 
mitochondrial (intrinsic) pathways, both sharing a common final pathway.  Both routes utilize 
the cysteine aspartyl-specific proteases (caspases) throughout the process.  These enzymes act 
within a cascade leading to the cleavage of specific cellular substrates 217.  Caspase-
independent methods of cell death do exist, but their molecular basis is less well understood 
218-220.  As the caspase free pathways share only some of the characteristics of apoptosis they 
are often defined as apoptosis/necrosis–like cell death or paraptosis 217.  The caspase family of 
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enzymes are part of a process which leads to the dismantling of the normal cellular structures 
causing biochemical and morphological changes within the cell that are characteristic of 
apoptosis 217.  Caspases are stored within the cell as inactive procaspases in order to protect 
the cell, but when required they are activated at the appropriate point in the cascade.  
Apoptotic signalling can occur through two distinct, but interacting signalling cascades; 
namely the ‘extrinsic’ or ‘intrinsic’ pathways, the route taken being highly dependent on the 
cell type and the type of upstream signalling received. 
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 Figure 1.6:  An outline of the basic apoptotic initiation pathways controlled by both pro-
apoptotic and anti-apoptotic proteins (based on 1), including the points of interaction by the 
HPV 16 proteins (see section 1.6.5 for further details).   
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1.4.1. Death Receptor Apoptotic Pathway 
The ‘death receptor’ or ‘extrinsic’ apoptotic pathway is mediated by receptors located on the 
cell surface 217.  The death receptors are members of the tumour necrosis factor receptor (TNF-
R) superfamily which contains at least 20 family members with varying functions 221.  The 
apoptosis related members of the superfamily contain an indicative intracellular ‘death domain’ 
of 80 amino acids involved in transmitting the apoptotic signal from the cell surface to the 
intracellular domain 221.  Pro-apoptotic ligands bind to appropriate cell surface receptors; these 
include CD95 (Fas/Apo-1 222), TNF receptor 1, TRAIL-R1 (TNF-related apoptosis-inducing 
ligand-R1), and TRAIL-R2, leading to oligomerisation of the receptors' death domain, 
facilitating interaction with the cytosolic adapter protein FADD (Fas-associated death domain 
protein, also known as MORT1) 111.  The TNF-R ligands also form a part of the wider TNF 
family 217, with ligand expression varying between cell types.  The Fas ligand (Fas-L) is known 
to be mainly expressed by T lymphocytes 223 whilst the TNF ligand is expressed primarily by 
macrophages 221, illustrating the important role of the immune system in the initiation of 
apoptosis.  Other ligands such as TRAIL have been shown to be expressed by many different 
cell types 221.  The recruitment of pro-caspase- 8 and -10 to the death domain–FADD 
assemblage creates the death–inducing signalling complex (DISC).  Within the DISC, FADD 
interacts directly with the inactive procaspase enzyme; subsequently the procaspase is cleaved 
to form the activated ‘initiator’ caspase.  DISC cleavage can be inhibited by FLIPs (FADD-like 
interleukin-1 -converting enzyme-like protease, also known as FLICE/ caspase-8 inhibitory 
proteins), which share homology with procaspase-8, allowing them to competitively inhibit 
caspase-8 activation 217,224-227. 
 
The quantity of activated caspase-8 produced by the CD95 pathway can vary between cell 
types.  Type I cells including the B lymphoblastoma cell line SKW6.4 and the T cell line H9, 
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produce sufficient caspase to activate downstream apoptotic mechanisms independently.  
However, in type II cells such as the T cell lines Jurkat and CEM, the levels of caspase-8 
activation are insufficient to independently initiate the full apoptotic cascade.  Within these 
type II cells DISC formation is temporarily delayed and occurs at a lower rate than type I cells.  
Therefore these cells require the pro-apoptotic signal to be amplified 228.  In type II cells, 
activated caspase-8 produced at the DISC causes the cleavage of cytosolic BID, a member of 
the Bcl-2 family.  Truncated BID is translocated to the mitochondrion and inserts into the 
membrane, where it activates BAX and BAK to cause mitochondrial release.  
1.4.2. Mitochondrial Apoptotic Pathway 
The mitochondrial or intrinsic apoptotic pathway is regulated by members of the Bcl-2 
family, whose release is controlled by upstream regulators such as p53.  The Bcl-2 family 
proteins can be either pro-apoptotic or anti-apoptotic 217, a summary of these pro- and anti-
apoptotic proteins is shown in Table 1.1.   
Anti-apoptotic Proteins Pro-apoptotic Proteins 
Bcl-2  BAX BLK 
Bcl-X BAK HRK/DP5 
Bcl-W BOK/MTD NIP3 
Mcl-1 BID  NIX 
A1/BFL-1 BAD NOXA 
BOO/DIVA BIM/BOD PUMA 
NR-13 Bcl-XS BMF 
Bcl-XL BIK/NBK  
 
Table 1.1: The anti-apoptotic and pro-apoptotic proteins that aid the control of the mitochondrial 
pathway. 217 
 
The archetypal family member Bcl-2 (B-cell leukaemia/lymphoma 2) contains a 
transmembrane and four Bcl-2 homology (BH) domains.  These regions can be used to 
classify the remaining family members 222.  The BH3 domain is common to all family 
members and is essential for the functioning of the proapoptic proteins 217,229,230.  The anti-
apoptotic proteins share BH domains 1, 2, 4 217.  Many of the Bcl-2 family members are 
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present within the outer mitochondrial membrane, where they function to stabilize the 
membrane that protects the cell from the toxic contents held within the mitochondria.  The 
pro-apoptotic proteins can be subdivided into two main groups; the BAX family incorporating 
BAX (Bcl-2 associated X), BAK (Bcl-2 homologous antagonist/killer) and BOK (Bcl-2-
related ovarian killer); and the BH3-only proteins including BID (Bcl-2 Interacting Domain), 
BAD (Bcl-2-antagonist of cell death), and BIM (Bcl-2-interacting mediator of cell death) 217.  
These pro-apoptotic proteins have the ability to shuttle between cellular locations, such as the 
cytoplasm for BAX, BAD, and BID, or the microtubules for BIM.  However, when apoptosis 
is induced they all translocate to the mitochondria 231.   
1.4.3. The Common Mitochondrial Pathway  
The release of pro-apoptotic factors from the mitochondria can be initiated by either the death 
receptor pathway (type II cells), the mitochondrial pathway or via other routes involving 
phosphatases, kinases or transcription factors (for example p53 and TR3/Nur-77/NGFI-B) 231, 
as shown in figure 1.6.  The exact nature of the interaction between the Bcl-2 family, other 
mitochondrial proteins and the membranes is still unclear.  The insertion of pro-apoptotic 
signal proteins into the mitochondrial membrane causes permeabilisation of both the outer 
(OMM) and inner (IMM) mitochondrial membranes 231.  The IMM effect is more transient 
and restricted to mitochondrial material of less than 1.5kDa, due to the importance of 
maintaining the electrochemical gradient for its vital role in cellular energy production 231.  
One model suggests that the permeabilisation of mitochondrial membranes is controlled by a 
permeability transition pore complex (PTPC).  This multi-protein complex contains an inner 
membrane component consisting of an adenine nucleotide translocator (ANT), a voltage-
dependent anion channel in OMM, and various other proteins 231.  The action of the PTPC 
may be regulated by an interaction with Bcl-2 217.  Alternatively, members of the pro-
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apoptotic BH3-only family act as death sensors in the cytoplasm or cytoskeleton 217.  In 
response to an apoptotic signal they interact with the BAX protein sub-family, initiating a 
conformational change and insertion of the proteins into the mitochondrial membrane.  Here 
they become oligomerised to form protein permeable channels 217.  The conformational 
change and oligomerisation of BAX and BAK are inhibited by the anti-apoptotic protein Bcl-
2 232.  The initial IMM permeabilisation may also lead to disruption of the osmotic balance of 
the organelle, causing swelling of the matrix and ultimately lysis of the OMM.  The changes 
seen within the mitochondria in response to the pro-apoptotic signalling may also lead to 
disruption of ATP production via interruption of the electron transport chain and the creation 
of reactive oxygen species 233.  These changes within the mitochondria may also further 
stimulate the cellular stress response, potentially increasing pro-apoptotic signalling. 
 
The increase in mitochondrial membrane permeability allows the release of a range of 
compounds from their store within the intermembranous space of the organelle 217.  Toxic 
compounds are normally held in these locations to prevent unauthorised cellular damage.  The 
mitochondrial compounds include apoptogenic factors such as cytochrome c, which is a 
caspase activator, SMAC (second mitochondria-derived activator of caspase)/DIABLO (direct 
IAP binding protein with low pI), also a caspase activator, and AIF (apoptosis-inducing 
factor) a nuclease activator 231,234,235.   
  
Within the cytoplasm, released cytochrome c interacts with cytosolic APAF1 (apoptotic 
protease activating factor-1) and subsequent binding of pro-caspase-9 then forms the 
apoptosome 217,236.  The binding of the pro-caspase to this structure allows it to be converted 
into an active initiator caspase, in an ATP-dependent manner 236.  
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One possible route for the inhibition of mitochondrion-induced apoptosis is to utilize extra 
cellular survival signals such as growth factors, cytokines, hormones, and adhesion molecule 
signals 217.  A lack of survival signals leads to a form of apoptosis known as ‘death by 
neglect’ 217.  These signals bind cytosolic PI3K (phosphatidylinositol 3-kinase), which 
activates AKT, causing deactivation of the BAD protein via phosphorylation 217.  The anti-
apoptotic Bcl-2 and Bcl-XL family members are normally located within the outer 
mitochondrial membrane and act to protect the cell from mitochondrial faults by preventing 
abnormal ion movement across the membrane 233.    
1.4.4. The Common Final Pathway 
As can be seen in figure 1.6 both the death receptor and mitochondrial pathways lead to the 
activation of a common group of ‘initiator’ caspases including caspases-8/9/10.  In order to 
allow the continued progression of apoptosis these enzymes cleave and hence activate the 
inactive forms of caspases-3/6/7 forming the executioner caspases 217.  These executioner 
caspases are then able to amplify the apoptotic signal by cleaving each other, creating a 
proteolytic cascade 237 and allowing active controlled cellular breakdown to commence.  
 
Apoptosis can be inhibited at the apoptosome or at the executioner caspase activation stage by 
the use of the IAP (inhibitor of apoptosis proteins) family of proteins.  As illustrated in figure 
1.6, these proteins bind caspases and prevent further function 217.  They may also act as an 
ubiquitin ligase, preventing apoptosis by promoting caspase degradation by the proteasome 217.  
In turn, the IAPs can be inhibited by the mitochondrially produced SMAC /DIABLO, which 
bind IAPs and prevent the inhibition of caspase function 217. 
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1.4.5. Cellular Consequences of Apoptosis 
 
 
Figure 1.7:  The images show time-lapse microscopy of a trophoblast cell undergoing apoptosis 
(Reproductive and Cardiovascular Disease Research Group, University of London 238).  Image D 
shows the ‘blebbing’ effect (marked by arrow) sometimes seen during cellular breakdown.   
 
The activated executioner caspases cleave cellular substrates (‘death substrates’) leading to 
the characteristic changes associated with apoptosis 231, as shown in figure 1.7.  As part of the 
apoptotic degradation, inhibition of the endonucleases is removed causing the cleavage of the 
nuclear lamins that form the lamina of the inner surface of the nuclear envelope 217.  This 
breakdown of the nuclear lamins forms a prerequisite to the later chromatin condensation and 
nuclear shrinkage 217.  The DNase CAD (caspase-activated deoxyribonuclease) and its 
inhibitor (ICAD) form a cytoplasmic complex inactivating the CAD under normal cellular 
conditions.  DNA fragmentation occurs when ICAD is cleaved by the executioner caspaseses 
releasing CAD to fragment DNA 217.  Cytoskeletal proteins such as actin, plectin, Rho kinase 
1 (ROCK1) and gelsolin are broken down, leading to cell fragmentation, blebbing and the 
formation of apoptotic bodies 217,236, as shown in figure 1.7d.  Changes within the plasma 
membrane allow the exposure of signals such as phosphatidylserine, and alteration of surface 
sugar molecules.  These changes act as signals to nearby phagocytic cells allowing 
recognition and engulfing of the apoptosed cell 239,240.  
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1.4.6. Apoptosis and p53  
The pro-apoptotic function of p53 forms a vital constituent of tumour suppression 222.  As an 
important cellular regulator it contributes to both the intrinsic and extrinsic apoptotic 
pathways in a number of ways.  p53 induces the direct or indirect transcriptional up regulation 
of a range of apoptosis related pro-apoptotic genes.  Within the early extrinsic pathway p53 
has been shown to transcriptionally upregulate the Fas component of the death receptor 
allowing increasing downstream apoptotic signalling 241.  However, this p53 function does not 
seem to be universal 222 and in some cases this induction of Fas is apparently not essential for 
p53-dependent apoptotic signalling 222,242,243.  The cell can achieve an initial rapid 
sensitisation to apoptotic signals by enhanced trafficking of the death receptor Fas protein 
from its stores within the Golgi 244, allowing a bridging response while de novo Fas 
transcription occurs.  Another of the death receptor types TRAIL-R2 (KILLER/ DR5) is also 
upregulated by p53.  Signals transduced though this receptor go on to activate a caspase-8-
dependent cascade 245 (reviewed by 246).  However, these receptors are only found within 
limited regions such as spleen, small intestine and thymus 247.  The caspase enzymes perform 
central roles within the apoptotic network, it is therefore unsurprising that p53 signalling leads 
to an increase in caspase activation by transcription-dependent (e.g. caspase-1 248) and 
independent mechanisms (e.g. by increasing mitochondrial cytochrome c release, which 
causes increase caspase-9 activation) 222,249.  
 
Pro-apoptotic proteins within the later extrinsic and also the intrinsic pathway are also 
upregulated in response to p53 signalling, allowing a more rapid induction of apoptosis.  
These targets include MAP kinase inhibitor PAC1 (phosphatase of activated cells 1) 250, Bcl-2 
family members (PUMA, NOXA, BID, BAX), death receptors 4/5 170, and apoptosome 
component APAF-1 170.  By regulating the transcription of pro-apoptotic BID protein, p53 can 
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promote the inclusion of the mitochondrial component in the death receptor pathway 222.  A 
number of either directly or indirectly by p53 inducible genes are involved in the control of 
mitochondrial membrane integrity, including members of the Bcl-2 family 170 (table 1.1).  
 
The induction of apoptosis by p53 can also be regulated in a transcription/protein synthesis 
independent manner.  It is likely that in normal cells the transcription dependent and 
independent p53 pathways work together towards the common goal 222.  This is mediated by 
the localisation of a small fraction of the activated p53 population to the mitochondria 251.  
The p53 fragment directly interacts with and inhibits the anti-apoptotic proteins Bcl-XL and 
Bcl-2, and also causes the oligomerisation of pro-apoptotic BAK.  These interactions lead to 
depolarisation and subsequent permeabilisation of the outer mitochondrial membrane to 
release cytochrome c and other pro-apoptotic mitochondrial products 170.   
 
The potentially p53-responsive p21 can act as a component of a pro- or anti-apoptotic 
cascades depending on the cellular requirements 204,252-254.  p21 is known to mediate and 
interact with the stress-activated protein kinase (SAPK) and p38 mitogen-activated protein 
kinase families of mitogen-activated protein kinases (MAPKs) 215, both of which have been 
implicated in apoptotic signalling 255. 
 
In order to reduce the anti-apoptotic influence of p21 on an already apoptotic cell, caspase-3 
256 inactivates the protein by cleaving its C-terminal nuclear localisation signal, and also 
relocating it from the nucleus to the cytoplasm 192,257.  This cleavage and relocation means 
that p21 is not only physically distanced from its transcriptional targets within the nucleus 257, 
but also the absence of the C-terminal domain means it is unable to facilitate the nuclear 
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localisation of the cyclin/cdk complex, thus preventing any possible attempts to steer the cell 
from its apoptotic path 258.   
1.5. The Influence of the Viral Genes on the Host Cell 
In order to successfully replicate within the host cell, HPV must interact with numerous host 
systems.  For replication to occur the virus must be present within a replication competent cell 
that is expressing the appropriate cellular machinery, for example by interacting with pRb.  
However, in making these cellular changes the cell's stress systems, such as those requiring 
p53, are activated, and therefore the virus must deal with these problems.  
1.5.1. HPV and the p53 Pathway 
The most dramatic effect on the p53 protein is seen in the presence of HPV E6, which induces 
the rapid ubiquitin-directed proteasomal degradation of p53.  The E6 protein does not directly 
bind p53; degradation is instead achieved by the interaction of E6 with the host protein E6-AP 
113.  This HECT domain (homologous to the E6-AP carboxyl terminal) protein acts as a 
cellular E3 ubiquitin ligase 113, functioning as a member of the proteasomal degradation 
pathway (section 1.3.1).  Although p53 is not a normal substrate for E6-AP, this ubiquitin 
ligase has been shown to interact with and facilitate the degradation of p53 259,260.  In the 
absence of HPV infection it is known to bind the cellular Src kinase family 261 and itself 262, 
but in the presence of HPV E6 this ubiquitin ligase is co-opted by the virus and induces the 
ubiquitination and subsequent degradation of p53 263.  HPV 18 E6 has been shown to cause 
the redistribution of both GFP-tagged p53 and E6 to the cytoplasm and also an apparent 
decrease in levels of p53-associated GFP fluorescence in the presence of E6 179.  Degradation 
of p53 interrupts a number of cellular pathways in which it normally functions, including 
those involved in the cellular stress response and genome protection.  In this way p53 
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inactivation may contribute to chromosomal instability such as translocations and aneuploidy, 
which are seen in the presence of E6 264.   
 
Unlike E6, the presence of HPV E7 does not alter the normal p53 nuclear localisation or block 
its nuclear export 138.  The increased levels of p53 seen in E7 expressing cells are not 
associated with a rise in levels of transcription 138.  Instead raised p53 levels are likely to be a 
consequence of the enhanced half-life of the protein leading to its stabilisation 138 and also 
possibly post-transcriptional modifications 265.  This stabilised p53 maintains a wild type 
conformation and is apparently still able to undergo Mdm2-mediated proteasomal degradation 
138.  This interaction of E7 with p53 causes a rise in p53 levels 177.  However, there is some 
uncertainly as to whether this bound p53 remains transcriptionally active 138,266.  Cells 
expressing the stabilised p53 grow rapidly, but do not appear to function normally during the 
apoptotic cascade where levels of the pro-apoptotic p53 targets BAX and TRAIL-R2 do not 
increase, and therefore the rate of spontaneous apoptosis remains unchanged 138.   
1.5.2. HPV and the Cell Cycle 
The papillomaviruses must disrupt the normal host control of cell cycle progression in order 
to replicate in normally replication-incompetent cells, as shown in figure 1.8.  The 
checkpoints which regulate cycle progression are normally controlled by a fine balance of 
positive and negative regulatory factors, which are vital for normal cellular function 182.  HPV 
E7 is the primary viral protein responsible for disrupting normal cell cycle regulation; this is 
achieved by interactions with a range of host proteins overcoming cell-derived inhibition of 
cell cycle progression.  However, without the cooperative efforts of several other viral 
proteins, particularly E6, the unscheduled proliferation induced by reactivation of the cell 
cycle would activate cycle arrest and/or apoptosis 267.  Although E7 is the primary viral 
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protein required to disrupt multiple mitotic checkpoints, the efficiency of this process is 
increased in the presence of the E6 protein.  Therefore the cycle checkpoints retain a greater 
degree of functionality in cells expressing only E7 268.  As this cell cycle effect appears to be 
largely dependent on the interaction of the viral proteins with p53 and pRb 268, the efficiency 
of this cell cycle control is likely to be reduced in low risk HPV types. 
 
 
 
Figure 1.8:  The eukaryotic cell cycle is influenced by many cellular factors such as the presence of 
cyclins and changes in phosphorylation.  The cycle has many points at which the high risk HPV genes 
can influence the host cell cycle.  Adapted from Southern and Herrington (2000) 53 with permission 
from Wiley-Blackwell Publishing. 
 
pRb is a cellular inhibitory protein that associates with a number of proteins including the E2F 
family of transcription factors.  The pRb-E2F complex helps to form the G1/S checkpoint 
controlling the initiation DNA synthesis 2; this is achieved by inhibiting E2F-induced 
transcription of a number of genes responsible for nucleotide synthesis (e.g. thymidine 
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kinase), replication (e.g. DNA polymerase α) and cell cycle progression (e.g. cyclin E, cyclin 
D1, c-myc, b-myb, and cdc2) 6,269.  In order to release E2F, pRb must be phosphorylated by 
CDK4/6 1 at specific sites in either the C-terminal region or within the insertion domain of the 
protein 111,270.  By binding within this region E7 can prevent the interaction of pRb with E2F 
271,272 and subsequently enable entry into S-phase.  A single E7 protein can bind efficiently to 
multiple units of pRb and its related proteins p107 and p130, via the interaction of its LXCXE 
motif with the A/B pocket domain of the pRb family 2,273,274.  Mutations within this region of 
E7 lead to a reduction in the ability of HPV to transform cells, indicating the importance of 
pRb inactivation during transformation 275.  Increased degradation of pRb by E7 results in 
atypically high levels of transcription with a rise in the expression of cyclins A and E 276, 
either via increased transcription.  In addition E7 is able to directly bind and activate the 
CDK/cyclin complexes independently of pRb 277,278.  E7 can therefore cause an increased 
level of active CDK2/cyclin A or CDK2/cyclin E complexes within the cell 276,278, helping to 
control entry into and progression through S-phase, and therefore increased levels enable free 
movement through S-phase 279.  The degradation of the other pocket proteins p107 and p130 
by E7 280,281 also assists in the HPV driven deregulation of the G1/S transition 
28.  When the 
inhibition of pRb and its related proteins is combined with E7 induced inactivation of cyclin 
dependent kinase inhibitors (CKIs) p21 and p27 282, the break down of the E2F repressor 
complex results in enhanced progression to DNA synthesis and cell division maintaining the 
replication competent environment.  
 
Levels of the p53 responsive protein p21, a CKI, are found to be elevated in cells containing 
wild-type HPV 27, aiding the manipulation of cell cycle checkpoints.  Both E6 and E7 are 
known to interact with p21 and its fellow CKI p27, to manipulate the G1/S checkpoint to 
allow progression 283,284.  The interaction of p21 with E7 is thought to occur via the carboxyl 
 46 
terminal of the E7 protein 283 binding to the C-terminal region of p21 191.  E7 competes with 
PCNA, as both processes require interaction via the same C-terminal region this potentially 
blocks PCNA-dependent inhibition of DNA synthesis and also prevents p21 from inhibiting 
the cyclin/cdk complex 204,285,286.  Interestingly it has been suggested that, during the 
productive phase of the viral life cycle, the E7 cell cycle functions may in fact be assisted by 
the presence of p21 27.  It has been suggested that p21 may act as a scaffolding factor for the 
assembly of cyclin-cyclin-dependent kinase complexes facilitating cell cycle progression 27.  
HPV E6 generates a relaxation the G2/M checkpoint probably by interference with the p53 
pathway, this allows an increased number of cells to enter mitosis with potential defects, such 
as multipolar spindles 287,288.  The ability of E7 to overcome the G2/M checkpoint appears to 
only be functional when either p21/p27 levels are low, or expression of E7 is sufficiently 
high.  Therefore this E7-mediated effect is more likely to occur in the presence of integrated 
virus 6,289.  The E5 protein has been shown to play a role in E6/E7 mediated cellular 
transformation, which is thought to be achieved by the inhibition of p21 48,290. 
 
HPV E7 has the ability to directly target pRb for proteasome degradation 291.  This may be 
achieved by the interaction of E7 with the 26S proteasome S4 subunit 2.  However, as S4 
binding mutants can still efficiently destabilise pRb, another mechanism may also be available 
for E7-induced pRb degradation 291.   
 
In contrast to the majority of HPV cell cycle related effects, the viral E2 and E4 proteins have 
the ability to assist in the reinstatement of the cycle checkpoints.  E4 has been shown in 
certain HPV types including 16 292 and 18 6,18,293  to initiate cycle arrest in G2 by preventing 
nuclear localisation of cyclin B/CDK1, and therefore counteract E7 induced proliferation 6.  In 
cells maintaining episomal HPV increased viral E2 transcription leads to activation of p53 and 
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pRb pathways 294, causing a reactivation of the G1/S checkpoint, cell senescence and under 
some circumstances apoptosis 294.  The association of E4 with E2 shown for HPV 16/18 
suggests that they may co-operate in the removal of the replicative environment aiding the 
later phases of a productive infection 6,295. 
1.5.3. HPV and Host Genome Replication 
 
 
Figure 1.9:  The HPV-16 E6 and E7 proteins cause the induction of genetic instability with the 
consequent probability of carcinogenic progression.  This is achieved through the abrogation of the 
p53 (p21) pathway which leads to increased production of cell cycle regulators, and subsequent 
disruption.  Image taken from Duensing and Munger, 2004 296 , copyright © 1999-2008 John Wiley & 
Sons, Inc.  Reprinted with permission of Wiley-Liss, Inc. a subsidary of John Wiley & Sons, Inc. 
 
The human papillomavirus must interact with several different parts of the cell cycle 
regulatory pathway in order to promote an environment suitable for HPV replication and 
virion production.  Several different HPV proteins contribute to this process; the roles of the 
central HPV oncogenes E6 and E7 are shown in figure 1.9. 
  
Activation 
Inactivation 
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HPV E5 is a trans-membrane protein that interacts with the vacuolar ATPase, preventing the 
influx of protons into acidic vesicles such as endosomes.  Consequently, the normal vesicle 
recycling pathways for signalling molecules such as EGF are disrupted and an environment 
beneficial for viral replication is maintained (reviewed in 6).   
 
E7 is known to associate with proteins required for cell proliferation such as histone 
deacetylases 297, acetyl transferases 297 and the AP-1 transcription complex 298, allowing the 
virus to drive cellular proliferation 6.  The interaction of E7 with the histone deacetylases and 
acetyl transferases are thought to involve the C-terminal region of the protein 297. 
 
High risk E6 proteins, but not their low risk counterparts, are known to associate with and 
cause the degradation of PDZ (PSD95/Discs Large/ZO-1) domain containing proteins, by E6 
binding a short 4 amino acid sequence at the C-terminus of these proteins 299.  The binding of 
PDZ proteins appears to enable HPV to mediate the reactivation of proliferation in the 
suprabasal layers 6,300.  PDZ proteins act as ‘molecular organising centres’, helping to co-
ordinate numerous signalling pathways 9.  This group of proteins includes the MAGUK 
proteins (SAP97/Dlg 301 and MAGI-1, -2 and -3 302), MUPP1 and hScribble 303,304, and are 
known to be involved in cell polarity, cell-cell contact and proliferation.  The PDZ proteins 
are also known to interact with other important cellular pathways, for example MAGI-2 and -
3 interact with PTEN (phosphatase and tensin homolog), which forms a component of the 
protein kinase B (PKB/Akt) signalling pathway 305.  By down regulating PTEN, the PDZ 
proteins are able to influence the cell contact induced PKB signalling, directly effecting the 
regulation of growth and polarity.  Interacting with other signalling pathways, allows the PDZ 
proteins to influence cell cycle progression and apoptosis (reviewed in 306), metastasis 
(reviewed in 307), and many other cellular pathways.  
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Prolonged expression of the high risk HPV types is associated with the accumulation of 
genetic abnormalities.  Genetic instabilities are found in even the earliest abnormal lesions.  
However, changes such as the gain of chromosome 3q are usually found only in the more 
invasive tumours 9,308,309.  High risk, but not low risk E7 has the ability to cause rapid 
disruption of both the centrosomes and centrioles 9,310, with the E6-associated alterations 
being acquired over a more prolonged time period 218.  Centrosome abnormalities are seen at 
low levels even in episomal lesions, but increase substantially in number upon integration 
310,311.  The centrosomes and centrioles are required for both the production of microtubule 
organising centres and the mitotic spindle pole bodies, therefore any alteration in their 
synthesis leads to abnormal numbers of both microtubular structures 2,296.  Because of their 
importance, any disruption can potentially lead to chromosomal alterations and genomic 
instabilities such as multinucleation 312 and aneuploidisation, subsequent centrosome related 
mitotic faults and possible chromosome instability 312, with the consequent increased risk of 
malignancy. 
 
Telomeres are located at the termini of the eukaryotic chromosome and are important for 
maintaining chromosome stability during gene replication.  Telomeres are maintained by the 
enzyme telomerase, whose activity is controlled primarily by regulating the expression of the 
telomerase catalytic component human reverse transcriptase (hTERT) 313.  In most somatic 
cells telomerase function is lost and hence telomere shortening occurs with every cell division 
providing a possible mechanism for cell aging 314.  The reactivation of hTERT is a common 
feature of most malignant cells and the associated renewal of the telomere allows these cells 
to become immortal 9.  The induction of abnormal replication by the papillomavirus will 
cause a rapid shortening of the cellular telomere, providing a potential trigger for cell cycle 
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arrest and apoptosis, and therefore must be counteracted by the virus.  The HPV E6 protein 
has the ability to induce telomerase activity via increased transcription of hTERT 9,314, hence 
removing restrictions on the lifespan of the infected cells.  Further increases in hTERT 
expression in the presence of both E6 and E7 suggests that E7 may also have a role in this 
process 314.  To counteract excessive telomerase activity the viral E2 protein has been shown 
to inhibit the hTERT promoter, providing an additional mechanism for maintaining the 
control of virally infected cells 313.  Therefore, HPV integration is associated with an increase 
in telomerase expression due to both a decrease in inhibition of hTERT by E2 loss and an 
increase in hTERT expression associated with enhanced levels of E6 and E7.  
 
The transforming ability of the virus is further aided by the interaction of HPV E6 with 
proteins involved in epithelial cell organisation (fibulin-1 315), DNA repair (XRCC1 316), and 
cellular differentiation 317.  In the case of cellular differentiation the effect is partially p53-
independent, with in vitro experiments showing that E6 expressing cells have an increased 
resistance to calcium induced cell differentiation 317.   
1.5.4. HPV and Cellular Structure 
Some cellular proteins found associated with E6 are involved in cell-cell interactions and 
contribute to maintaining cell morphology 28.  Under the control of E6 the atypical 
functioning of these proteins may contribute to transformation and the abnormal morphology 
of HPV-infected cells.  These cellular proteins include E6 binding protein 318, Paxillin 319, the 
human homologue of Drosophila discs large (hDlg) a tumour suppressor protein 301, and E6 
target protein 1 320.  E6 also interacts with host proteins involved in cell-cell adhesion, polarity 
and proliferation control (e.g. hDlg 301); these interactions aid the transformation of the host 
cell.   
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The association of E4 with the keratin intermediate filaments has been suggested to lead to the 
disruption of the whole keratin network, forming koilocytosis, a cytoplasmic halo effect 
produced primarily by perinuclear vacuolation 54.  This viral interference with the cell 
cytoskeleton network may occur to aid the release of mature virions from the tough epithelial 
cells 42. 
1.5.5. The Influence of HPV on Apoptosis 
For the virus to survive and successfully replicate it has to interact with, manipulate, and 
disrupt numerous cellular components and processes.  One of the biggest problems faced by 
the virus is the constant threat of cell-induced apoptosis.  Whether or not apoptosis occurs is a 
fine balance between pro- and anti-apoptotic signals, being mediated directly by the death 
receptor or mitochondrial pathways and indirectly via signals such as p53 and pRb.  In order 
to control cellular behaviour, HPV must interact with and subdue all of these different 
components of the wider apoptotic pathway.  The abnormal replication induced by E7 in 
particular leads to a pro-apoptotic response, as shown in E7 containing cells subjected to 
reduced growth factors 9,321.  In a normal infection the E6 protein forms the central figure in 
counteracting the cellular response to the virus.  In cancer cell lines such as HeLa and SiHa, 
inhibition of E6 causes apoptosis, illustrating the vital role of this protein in maintaining post-
integration cell survival in HPV infected cells 322.  The suppression of the apoptotic response 
appears to be the primary responsibility of the HPV E6 protein, although other viral proteins 
also contribute to the response.  HPV E7 appears to be able to act in either a pro- or anti-
apoptotic manner depending on the predominant signalling environment 323. 
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1.5.5.1. Anti-apoptotic HPV Behaviour 
The recreation of a replication-competent state in the cells of the suprabasal region is detected 
by the cell and leads to the activation of the protective apoptotic response.  To survive, the 
virus must counteract this apoptotic response not only by interacting with regulatory proteins 
such as p53 and pRb, but also by manipulating proteins directly involved in the death receptor 
and mitochondrial apoptotic pathways as shown in figure 1.6.   
 
HPV 16 E5 has been shown to inhibit ligand-mediated apoptosis occurring via the death 
receptor pathway.  However, as the E5 protein is often lost during integration 324, the anti-
apoptotic effects of E5 are likely to occur only during the natural viral life cycle 111, and 
sufficient alternative anti-apoptotic mechanisms are available within the cancer cell lines to 
prevent apoptosis.  When HaCaT cells infected with E5 expression construct are grown in 
both monolayer 45 and raft culture 325, they display a reduction in FasL or TRAIL mediated 
apoptotic signalling 325.  This is thought to be achieved by either reducing the expression of 
the both the CD95-receptor and Fas-receptors or by impairing DISC formation 325.  
 
The HPV E6 protein plays a key role in preventing apoptosis in HPV infected cells by the 
inactivation of a number of pro-apoptotic proteins via the ubiquitin proteasome pathway 111.  
E6 is known to protect cells from apoptosis mediated via TNF-α (Tumour necrosis factor-α) 
signalling 326.  This effect is not achieved by a decrease in the levels of the TNF-receptor, but 
by inhibiting the ability of the cytosolic death domain of the receptor to interact with the 
FADD protein.  This can be achieved by the E6 protein binding the C-terminal region of the 
TNF-death domain 111,323, the death effector domain of the FADD protein 110 or via the 
accelerated degradation of  the FADD protein 110.  By reducing the action of the FADD 
protein the virus can prevent the activation of pro-caspase-8 and hence inhibit the apoptotic 
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cascade.  Evidence suggests that E6 may also interact with the complete DISC complex, 
preventing activation of procaspase-8 110.  Within the mitochondrial pathway the E6 protein is 
known to associate with the pro-apoptotic proteins BAK and BAX 6 and HPV 18 E6 has been 
shown to label BAK for proteasomal degradation using the E6-AP ubiquitin pathway 114.  The 
telomerase enzyme, normally inactive in the majority of adult cells, is reactivated by the E6 
protein 327 late in carcinogenesis to allow renewed telomere production; this enables 
continued DNA replication and removes a possible trigger for cellular senescence and 
apoptosis 327,328.   
 
E6 and E7 are thought to contribute to the inhibition of apoptosis by upregulation of the c-IAP 
329 and also by preventing TNF-α mediated pro-caspase-8 activation probably by an 
interaction at the level of the DISC complex 323,330,331. 
1.5.5.2. The Pro-Apoptotic Functions of HPV 
The viral anti-apoptotic functions are important for the success of the HPV life cycle.  
However, during a normal productive infection the virus also requires virally mediated 
apoptosis to occur (figure 1.6).  
 
The HPV 16 E1^E4 protein aids apoptosis by binding the mitochondria and inducing 
detachment of these organelles from the microtubule network, resulting in the formation of a 
single large mitochondrial cluster adjacent to the nucleus 332.  This clustering is followed by a 
marked reduction in the mitochondrial membrane potential and the induction of apoptosis via 
release of mitochondrial pro-apoptotic compounds 332.  E1^E4 has also been shown to bind to 
and collapse the cytokeratin network 332.  
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Although the primary roles of E6 and E7 involve the prevention of apoptosis, they also appear 
to have some pro-apoptotic functions.  In TNF-sensitive ovarian cancer cells E6 is able to 
cause induction of apoptosis associated with the inhibition of NF-κB activation 333, suggesting 
a role for NF-κB signalling in the anti-apoptotic pathway.  Also, E6 induced cell death is 
associated with the down regulation of p21 334, directing the cell away from cell cycle arrest 
and towards apoptosis.  As discussed in section 1.1.7 the truncated E6*I protein 111,335 is able 
to reduce the degradation of p53 and pro-apoptotic proteins such as BAK or BAX 111, and 
hence increase the presence of these pro-apoptotic stimuli.  The HPV E7 protein has been 
shown to induce apoptosis in the presence or absence of TNF-α 336, this has been suggested to 
occur via both p53-dependent and independent pathways 336-338.  Possible routes for E7-
induced cell death may involve the sensitivity of the cells to TRAIL 339 and FAS 340 induced 
apoptosis 111.  
 
The E2 protein has been shown to play an important role in the induction of apoptosis in HPV 
infected cells, with the loss of this function during HPV integration likely to play a role in the 
development of malignancies.  E2 induced apoptosis is thought to occur primarily via the 
death receptor pathway, leading to the initiation of pro-caspase-8 activation 341.  In the case of 
HPV 18 E2 this is thought to occur via interaction of the N-terminal region of E2 with 
members of the death receptor pathway 342.  The pro-apoptotic function of E2 is not thought to 
require either the DNA binding or transactivation functions of the protein 342,343.  This 
phenomenon has been seen not only in immortalised cell lines, but also in primary human 
keratinocytes 342.  In HPV positive and negative cell lines HPV 16 E2 has been shown to 
induce apoptosis via a p53-dependent pathway 338,344, with the apoptotic response abrogated 
by the introduction of dominant negative p53 or the absence of additional p53 in p53-null 
lines 132,345.  However, in HPV 18 and BPV 1 E2-induced cell death appears to occur in a p53-
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independent manner, with the presence of dominant negative p53 having little effect on the 
level of apoptosis 346.  These apparent differences in the p53-dependence of the E2-induced 
apoptosis may reflect differences in the innate properties of the E2 proteins between the 
different papillomavirus types.  Pro-apoptotic signalling has been shown to be amplified by a 
truncated form of E2 produced by caspase cleavage 341.  
 
One possible role for HPV induced apoptosis is in aiding the release of viral progeny at the 
epithelial surface 342.  When keratinocytes terminally differentiate they undergo a form of 
apoptosis where the dead cells are retained to form the cornified layers of the upper 
epithelium.  This normal epithelial differentiation produces an environment which is 
inefficient for virion release.  Therefore by inducing normal apoptosis of these cells the virus 
induces a form of cellular destruction that promotes efficient virion release 342.  In particular 
the presence of E2 and E1^E4 proteins within the upper epithelial layers 347 suggests an 
important role for these protein in this process.  The virus also relies heavily on a healthy 
cellular environment, so the induction of apoptosis may also be viewed as a measure by which 
the virus limits the numbers of progeny release and therefore limits detrimental effects upon 
the host 111.   
1.6. p53 Activation in HPV Infected Cells: A Strategy for the 
Treatment of HPV-Associated Disease   
Current management of HPV-associated cervical abnormalities is highly dependent on the 
early detection of abnormal pre-cancerous or cancerous cells via the cervical smear test 348.  
However, the original Papanicolaou (Pap) smear is particularly prone to technical issues such 
as insufficient cells or the presence of infection, leading to the need for repeat sampling, 
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therefore, in the UK a phased introduced of liquid based cytology is underway to increased 
the reliability of the smear test and reducing the requirement for repeat testing 349.   
 
The current treatments offered to those found to have cellular abnormities is highly dependent 
upon the nature of the changes found.  If mild cellular changes are detected by the cervical 
smear, a colposcopy may be undertaken immediately or after the repeated presence of 
abnormalities at a 6 month review 349.  However, moderate or severe cellular changes are 
investigated immediately by colposcopy, at which additional tissue biopsies may also be taken 
349.   
 
Where abnormal cells are found they can be removed from isolated parts of the cervix using 
laser ablation, cold coagulation or cryotherapy.  However, where they are found to be more 
widespread or of a higher grade, more invasive techniques such as LLETZ (large loop 
excision of the transformation zone), cone biopsy or hysterectomy maybe utilised.  If 
malignant cells are detected the treatment is dependant on the stage of the cancer.  At the 
earliest stages hysterectomy (or cone biopsy in very early lesions) alone may be undertaken, 
but as the cancer stage increases treatment may involve more invasive surgery, radiotherapy 
or chemotherapy, either individually or combined 349. 
 
An additional tool to help in the reduction of HPV-associated disease will be provided by the 
recently introduced bivalent and quadravalent vaccines.  Both Cervarix (GlaxoSmithKline, 
HPV 16/18) and Gardasil (Merck & Co, HPV 6/11/16/18) are based on administration of 
HPV L1 virus-like particles, leading to the generation of high titres of neutralising antibodies 
that are reported to efficiently prevent infection 348,350.  It appears that this protective effect 
may not be type specific, with some evidence of cross-protection against some, but not all, 
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alternative HPV types 348,350 (e.g. HPV 31 and 45 for Cervarix 351 and HPV 45 for Gardasil 
352).  A greater cross-protection may be provide by vaccines based on the L2 capsid protein; 
however, research suggests that these vaccines illicit a lower level of neutralising antibodies 
than their L1 counterparts (reviewed by 348).   
 
Even with the introduction of vaccination programmes in a number of countries, including the 
UK, HPV-associated neoplasia remains a viable treat to the population.  In most counties 
vaccination is primarily aimed at 12-13 year old girls, with some ‘catch up’ programmes for 
13-18yrs (NHS, UK, accessed 08/10/2008), leaving a the large pool of unvaccinated men and 
women at risk of HPV infection.  In addition to the absence of cross-protection against the 
whole range of high risk HPVs, these vaccines have been found to be inefficient in women 
previously infected with HPV 16/18 353 and have an unknown the duration of protection 350.  
Consequently, even those who receive either type of prophylactic vaccination remain at risk 
from HPV-associated disease and thus continued smear testing is advised (NHS, UK, 
accessed 08/10/2008).   
 
The early treatment of high risk HPV infection or HPV-associated lesions provides possible 
novel routes for the prevention of potentially malignant lesions, which may otherwise require 
the use of more invasive curative or palliative treatments.  One possible therapeutic route is to 
inhibit virus only or virus-host interactions, inhibiting the viral life cycle or enabling a cellular 
response.  This could be achieved in several ways including vaccination, prevention of viral 
segregation by interference with the E2 protein, or the inhibition of E6 and E7 by 
complimentary anti-sense transcripts 109. 
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This aim could also be achieved by inducing apoptosis of infected cells, thus preventing the 
spread of infection and reducing the potential for malignant progression.  As p53 and its 
downstream proteins form vital components of the apoptotic pathway, they provide several 
possible treatment routes to reactivate cellular responses.  A possible route to prevent the 
degradation of p53 is to interrupt proteasome activity, preventing the degradation p53 by the 
proteasome 182.  This effect can be achieved using specific proteasomal inhibitors such the 
Streptomyces metabolites, lactacystin 354 or via the inhibition of the nuclear phosphoprotein 
Mdm2.  As discussed in section 1.3.1, Mdm2 binds p53 and facilitates ubiquitin-mediated 
degradation and may provide a possible route for the enhancement of the p53 response 182.  
Members of the nutlin family of drugs prevent the interaction between Mdm2 and p53, thus 
inhibiting the proteasomal degradation of p53 355-357.   
 
HPV-dependent and independent degradation of p53 is primarily undertaken by proteasomes 
located within the cytoplasm of the cell (sections 1.3.1 and 1.5.1), with nuclear export 
performing an important role in the degradation of p53.  If nuclear export can be inhibited, 
p53 will accumulate in the nucleus and potentially facilitate an increase in the transcription of 
pro-apoptotic genes.   
1.6.1. Nuclear Export 
The nuclear envelope allows cells to compartmentalise many functions to provide an 
additional level of regulation by nuclear admission or exclusion.  The transfer of mRNA and 
proteins from the nucleus to the cytoplasm is vital for numerous cellular processes such as 
translation, cell signalling and apoptosis.  The presence of compartments within the cell 
necessitates mechanisms to facilitate exchange; in the case of nucleo-cytoplasmic transfer the 
nuclear pore complex is employed.  The nuclear pore is an approximately 125MDa complex 
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found spanning the nuclear envelope 358, maintaining a partially open state to allow the 
passive diffusion of some small proteins or mRNAs 358.  However, the majority of nuclear 
pore transport utilises GTP-dependent mechanisms 358, requiring the presence of appropriate 
transport signal sequences (section 1.3.1).   
 
Nuclear transport via the pore complex is mediated by receptors of the karyopherin family 
(also known as importins and exportins according to the direction of transport).  These 
molecules act as chaperones, binding the transportable proteins (or mRNA) and facilitating 
their transport through the nuclear envelope 358.  Individual karyopherins have the ability to 
bind specific cargo 358 and in the majority of cases are mono-directional 359.  Karyopherin 
mediated transport is regulated by the small Ran type GTPase, with directionality associated 
with differently phosphorylated forms of the enzyme 360.  Export from the nucleus is 
associated with Ran bound to GTP (Ran-GTP), while import requires Ran bound to GDP 
(Ran-GDP) 360.   
 
Nuclear export employs a range of exportins such as CRM1, CAS1/Cse1 and Exp6 360,361, 
each associating with their own cargo.  Cargo specificity is regulated primarily by the NES, 
with the presence of large hydrophobic residues, most commonly leucines, forming a 
conserved feature of these signals 360.  The actual amino acid sequence of the NES appears to 
vary considerably between individual exportins, providing a level of specificity to the export 
system 360.  To facilitate nuclear export the karyopherins first interact with Ran-GTP.  They 
then bind the cargo protein via its NES 362 as illustrated in figure 1.10.  In CRM1 the binding 
of Ran-GTP is thought to take place in the CRIME (CRM1 importin-β etc) domain of the 
protein 363, with NES interaction thought to occur via the central conserved region of the 
protein 186.  Once export is complete the complex is dissociated by the conversion of Ran-
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GTP into Ran-GDP by the enzymes RanBP1 or Nup358/RanBP2 360,364,365.  This conversion 
liberates the exported cargo and Ran-GDP, which is then available for import of material into 
the nucleus. 
 
 
Figure 1.10:  A summary of the CRM1 mediated nuclear export via the REV type nuclear pore. 
 
The karyopherin CRM1 (chromosomal region maintenance 1) (36) /exportin 1 has been 
identified as a NES receptor 366, acting as a universal and conserved mechanism that forms a 
critical component of the nuclear export mechanisms of numerous different cell types 367,368.  
This protein was first described in cold sensitive stains of the yeast Schizosaccharomyces 
pombe (S. pombe), where mutations in the CRM1 gene led to deformation of chromosomes 
369.  Transcription of CRM1 varies throughout the cell cycle, reaching maximum expression 
during G2/M where CRM1 participates in pre-mitotic signalling 
370.  However, CRM1 protein 
levels have been shown to remain constant throughout the cell cycle 370.  CRM1 recognises a 
leucine-rich NES of the REV type found within a huge range of proteins 371 and also RNA 358.  
Numerous different cargos utilise CRM1-mediated transport including important cellular 
proteins required for cell cycle regulation or transcription such as p53 360,371.  CRM1 has also 
been shown to export viral proteins such as the HIV REV protein 372.  The affinity of most 
REV type NES cargos for the CRM1 protein is lower than in most other exportin-substrate 
complexes 360.  However, stronger interactions have been shown to be disadvantageous as 
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they prevent dissociation of the CRM1-Ran-GTP-cargo complex from the nuclear pore 373 and 
hence prevent the release of the cargo into the cytoplasm.   
 
Treatment with a nuclear export inhibitor could provide a potentially novel treatment for 
HPV-associated neoplasia.  The drug Leptomycin B (LMB) is a known inhibitor of nuclear 
export and has previously been shown to inhibit nuclear export of p53 182 and induce 
apoptosis in a number of HPV positive and negative cell lines 374,375.    
1.6.2. Leptomycin B 
 
    
Figure 1.11: Molecular structure of LMB. (CID: 6436291) 
 
LMB, also known as elactocin, CI 940, or PD 114720 is an unsaturated, branched-chained 
fatty acid formed as secondary metabolite by the fungus-like bacterium Streptomyces 371 
(figure 1.11).  This potent antifungal antibiotic is known to block the eukaryotic cell cycle 134, 
and is able to inhibit nuclear export of the HIV-1 REV protein, REV-dependent pre-mRNA 
134, and a range of other proteins.  LMB inhibits nuclear export at low nM concentrations by 
interacting with CRM1 134,376, preventing an association between CRM1, Ran-GTP and the 
cargo protein 182,371,377 (figure 1.12).  The actions of LMB appear to be specific to CRM1, 
with nuclear import appearing to function normally 134.   
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Figure 1.12: A summary of the effect of LMB on CRM1-mediated nuclear export via the REV type 
nuclear export pore. 
 
LMB binds CRM1 via its α,β unsaturated δ-lactone region, which interacts with the 
sulphydryl group of the conserved CRM1 cysteine 528 368.  This interaction is probably 
achieved by disrupting the hydrogen bonding of cysteine 528 by alkylation 186.  The important 
role of the conserved cysteine is illustrated in S. pombe by the LMB-insensitivity caused by 
the substitution this critical residue for a serine 186,371.  The interaction of LMB and CRM1 
may prevent the formation of an exportable CRM1-Ran-GTP-cargo complex.  This may be 
achieved by LMB preventing conformational changes in exportin that normally occur in 
response to the binding of an appropriate NES containing protein 186.     
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Protein Function Ref Protein Function Ref 
REV HIV protein 378 Mdm2 p53 inhibitor 190 
Actin Cytoskeletal 379 p27 CDK inhibitor 380 
c-Abl Tyrosine kinase 381 Cdc25 cdc2 phosphatase 382 
Cyclin-B1 Cell cycle regulation 383 COX2 prostaglandin synthase 384 
p53 Tumour suppressor 385 BRCA1 Tumour suppressor 386 
p73 Tumour suppressor 387 BRCA2 Tumour suppressor 388 
PKA Protein Kinase A  372 hTERT Subunit of telomerase 389 
MPF 
Megakaryocyte 
potentiation factor 
390 IAP1/2 Caspase inhibitors 391 
IκBα PKA inhibitor 392 XIAP 
IAP family member and 
caspase inhibitor 
393 
MEK1 
mitogen-activated 
protein kinase kinase 1  
367 Survivin 
IAP family member and 
caspase inhibitor 
394 
MAPK 
Mitogen-activated 
protein (MAP) kinase 
395 
HPV 16 
E2 
Viral regulatory protein 396 
hGTSE-1 
Human G2 and S 
phase-expressed-1 
397    
Table 1.2:  Some of the proteins reported to utilise CRM1-mediated nuclear export and to accumulate 
in response to LMB. 
 
As shown in table 1.2 LMB influences the localization of a number of proteins which require 
nucleo-cytoplasmic shuttling 182,376.  The disruption of p53 signalling has been suggested to 
play an important role in the induction of LMB-induced cell death 182,375.  The addition of 
LMB to wild type primary human keratinocytes has shown that no apoptosis, genotoxicity or 
long-term effects on cell growth occur 374.  LMB treatment of primary human keratinocytes 
(PHKs) transduced with HPV 16 E7 or E6/E7, and HPV 16 infected cancer cell lines CaSki 
and SiHa leads to an accumulation of p53 in the nucleus and the induction of apoptosis 
203,385,398.  Increased levels of apoptosis in response to LMB have also been demonstrated in 
other non-HPV associated cell lines such as human leukaemia cells (U937) 399, prostatic 
cancer cell line LNCaP 375 and in cells expressing the abnormal BCR-ABL fusion protein 400.  
In these cases, the primary cause of the sensitivity to LMB is not the presence of a viral 
infection, but carcinogenic transformation or the addition of constructs expressing the 
products of abnormal gene translocations.  The common link between all these cases of 
 64 
increased sensitivity is the considerable alterations occurring in vital cell regulatory systems 
which appear to be sufficient to alter the LMB related behaviour of the cells.   
 
Phase I clinical trials have shown that intravenous treatment with LMB caused ‘anorexia and 
malaise’ leading to a recommendation for no further trials of intravenous LMB 401.  However, 
topical application of LMB is thought be a promising approach for the development of a novel 
anti-cancer treatment 182.  It has been suggested that LMB would be most efficient at treating 
tumours containing wild type p53 such as that found in high risk HPV infected cells 374 or 
alternatively cells that contain alterations in cellular systems such as the BCR-Abl cells.  
However, some of the effects seen in response to LMB may not be primarily due to 
accumulation of p53; the disrupted shuttling of other CRM1 exportable proteins may provide 
a considerable contribution to the LMB-induced effects, causing the disruption of a range of 
cellular processes 182.   
 
Most cell lines established from cervical cancers contain integrated HPV 16/18 sequences 
(CaSki, SiHa and HeLa) and provide useful models for the behaviour of HPV in a malignant 
environment.  These cells have provided insights into many aspects of the virus including its 
genome, transcription and life cycle.  However, these models do not allow investigation of the 
earlier pre-malignant events important in the development of both a normal productive 
infection and cervical cancer.  The W12 line and its derivatives provide an alternative model 
for the study of HPV-associated neoplasia.  These cells are immortal and formed from a 
natural infection, and therefore provide a valuable and unique resource to study the 
mechanisms associated with HPV infection in non-malignant cells 51,117. 
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1.6.3 The W12 Keratinocytes a Model of Cervical Neoplasia 
1.6.3.1. The Parental W12 Cell Line 
The parental W12 cell line was derived by Stanley et al (1989) 18 from a low grade SIL 
histologically diagnosed as a CIN 1 lesion 117.  The tissue was obtained from a 22 year old 
female patient with a history of vulval condylomata and abnormal cervical smears, showing 
mild atypia and koilocytosis, with the biopsy taken from the anterior lip of the cervix close to 
the squamocolumnar junction 18.  The W12 line was established from the tissue biopsy 
cultured on lethally irradiated Swiss 3T3 feeder cells, the cells formed colonies that displayed 
typical basal keratinocyte morphology in monolayer culture 18.  However, these cells remain 
dependent on a feeder layer to maintain this normal keratinocyte behaviour 18.  When cultured 
it was found that normal keratinocyte behaviour could be encouraged by the addition of 
cholera toxin to increase plating efficiency and epidermal growth factor to increase colony 
size.  During in vivo culture the differentiated parental W12 cells have been shown to be 
capable of producing HPV virions 402.  At early passage the parental W12 cell line harbours at 
least 100 copies of the episomal HPV 16 genome and has been shown to express the HPV E7 
protein 19,117.  Uncut W12 DNA analysis indicates that the native episomal DNA occurs in 
primarily the supercoiled or open-circular forms 18,27,117, containing no major deletions, 
insertions or re-arrangements.  When digested with BamHI the genome is cut once, forming 
an indicative 7.9kb band after Southern blot analysis 133.  Subsequent analysis of the parental 
population has suggested that it is heterogeneous in nature, with cells containing episomal 
and/or integrated HPV genomes 119. 
 
As has been observed in the malignant progression of a typical HPV infection in vivo, the 
HPV 16 episomes contained within the parental W12 cells undergo spontaneous integration 
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into the host DNA during long term culture 133.  This viral integration in the W12 cells is 
associated with an increased colony forming efficiency and growth rate, along with a 
subsequent accumulation of cytogenetic abnormalities similar to those seen in vivo 117.  When 
parental W12 cells are maintained in culture in the presence of lethally irradiated Swiss 3T3 
feeder cells, the genome status of the cells gradually alters from one of almost entirely 
episomal HPV (at approximately passage 10), though a mixed population of episomal and 
integrated viral genomes (at approximately passage 14), to a purely integrated HPV culture at 
approximately passage 22 117.  The parental W12 culture by approximately passage 14 is 
likely to consist of a heterogeneous population, containing a mixture of cells with both 
episomal and integrated HPV 18,119. 
 
HPV integration in the parental W12 lines has been shown to be associated with increased 
expression of the HPV E7 and loss of  HPV E2 117.  Integration also leads to a 12.3 fold 
increase in the expression of insulin-like growth factor (IGF)-II and 4.7 fold increase in the 
epidermal growth factor receptor (EGFR) 117.  The increase in both of these factors may help 
to stimulate the growth of the W12 cells following integration, and may reflect changes 
occurring during in vivo carcinogenesis 117. 
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1.6.3.2. The W12 Derivatives  
Derivative Clone Number Viral Copy Number Integration Type 
W12 Derivatives 
E50 20850 1000 N/A 
E63 20863 1000 N/A 
I02 201402 5 1 
I22 20822 3 1 
I31 20831 60 2 
I61 20861 30 2 
HPV 16 containing cell lines 
SiHa N/A 2 1 
CaSki N/A 600 2 
Table 1.3:  A summary of the major properties of the episomal and integrated W12 derivatives, along 
side two HPV 16 infected cancer cell lines known to contain the viral genome integrated in a similar 
manner to the W12 derivatives 119. 
 
The W12 derivatives are made up of two episomal (E50 and E63) and four integrated cell lines 
(I02, I22, I31 and I61) which provide a model of early HPV-associated changes.  The W12 
derivatives were cloned by Jeon et al (1995) 119 by the selection of individual colonies from 
growing cultures of the W12 parental line.  A summary of their major properties are shown in 
table 1.3.  All derivatives, with the exception of I02 were selected from parental W12 cells at 
early passages 14 or 15.  The I02 line was formed from a later passage 17 of the parental line, 
from which all the derived clones contained the same integration event involving disruption of 
the E2 ORF 119.  This same integration event was also found in the passage 17 population of 
parental cells, suggesting that this integration event had become dominant within the late 
passage parental W12 population 119.  In order to prevent integration of HPV DNA in the 
episomal derivatives the cells must be maintained in specialised complete F-medium.  Under 
these conditions the viral episomes have been shown to be stably expressed at the same level 
for at least 100 cell generations 119.   
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Integrated W12 derivatives can also be classified by the type of integration event that has 
occurred.  Both type 1 and 2 integration have also been noted in vivo and are associated with 
amplification of the viral and nearby host sequences 119.  The cells with type 1 integration 
contain single copies of the viral genome integrated at each event causing disruption within 
the E2 ORF; this form of integration is present in the I02 and I22 W12 derivatives and also the 
cervical carcinoma-derived cell line SiHa 119.  In the I22 cell line, viral genome cleavage has 
been mapped to nucleotide 3732 and it appears the integration has occurred in a region of the 
host genome with no homology to known gene coding sequences 119.  The I31 and I61 
derivatives have undergone type 2 integration, also seen in the cervical carcinoma-derived cell 
line CaSki.  This type of integration is associated with the insertion of head-to-tail tandem 
repeats (concatemers) of full length viral DNA flanked by disrupted viral sequences 119.  Jeon 
et al (1995) 119 suggest integration and disruption of the E2 ORF in the type 2 integrants; 
although this appears likely the exact location of the disruption could not be confirmed due to 
the presence of multiple full length viral sequences.  
 
The published E6 levels of the W12 derivatives suggest that, integration is associated with a 
substantial increase in E6 expression compared with the episomal W12 lines, expression was 
particularly high in the type 2 integrated I61 derivative 
403.  The integrated lines, with the 
exception of I02, also displayed much greater expression of the E7 protein compared with the 
episomal lines, with E7 shown to strongly contribute to the growth advantage of the integrated 
cells 119.  Increased E6 and E7 levels may contribute to the selective growth advantage of 
these cells with integrated derivatives expressing higher levels displaying greater growth 
advantage over the episomal lines.  The higher levels of the E6/E7 proteins is facilitated by 
the disruption of E2 which is likely to have occurred in both types of integration; however, 
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other factors may also play a role in the growth advantage of the cells containing integrated 
sequences including increased mRNA stability 119,129 and the clonal nature of the derivatives.  
 
W12 cells can be induced to differentiate in monolayer by culturing at high density in 1.2mM 
calcium 65.  Alternatively the cells can be grown in organotypic raft culture to produce a 
model of a squamous epithelium.  Within the suprabasal layers of episomal W12 rafts large 
dysplastic cells with enlarged nuclei have been observed 27, which show low levels of staining 
for markers of differentiation such as K10, involurin and filaggrin 27.  The rafted episomal 
W12 derivatives have also been shown to be capable of producing virus-like particles 404.  
Although both the parental W12 line and its episomal or integrated derivatives can be induced 
to differentiate, they fail to form colonies in soft agar, indicating that even where integration 
has occurred the cells appear to remain non-tumourigenic 27 and therefore provide a good 
model for the early stages of cervical cancer. 
1.6.4. The Predicted Affect of LMB on HPV 16 Infected Cells 
As treatment of normal cells with LMB has been shown to induce a recoverable cell cycle 
arrest but not apoptosis 374, the HPV infection must mediate the response to LMB in some 
way.  The rise in p53 reported in a number of cell lines is a predicted mechanism for LMB- 
induced apoptosis.   
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Figure 1.13:  The predicted affect of LMB on cells infected with HPV 16.  The shuttling of p53 
between the nucleus and the cytoplasm is shown in normal uninfected cells and cells infected with 
HPV 16 in the presence and absence of LMB.   
 
In normal uninfected cells, p53 is one of a number of proteins known to shuttle between the 
nucleus and the cytoplasm, utilising the CRM1-mediated nuclear export.  In the absence of 
cellular stress p53 levels are low due to a short half life maintained by proteasomal 
degradation (section 1.3.1).  LMB treatment of these cells will lead to the accumulation of 
p53, but due to the low resting levels this LMB-induced build-up of p53 should be insufficient 
to initiate apoptosis.  Infection with HPV 16 is associated with viral interference in a number 
of cellular pathways, particularly those involved with cell cycle control primarily via E7 
(section 1.5.2) and also the possible induction of chromosomal instability associated with E6 
and E7 expression (section 1.5.3).  These disruptions initiate a cellular response co-ordinated 
primarily by p53, which itself is neutralised by HPV proteins including E6 (section 1.5.1) as 
illustrated in figure 1.13.  Treatment of HPV 16 infected cells with LMB should prevent the 
CRM1-mediated export of p53 from the nucleus by HPV E6.  When combined with the 
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greater background levels of p53, increased levels of apoptosis are likely to be induced (figure 
1.13). 
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Chapter 2: Materials and Methods 
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Unless otherwise stated all chemicals are from BDH, see appendix A for full details of 
suppliers.   
2.1. Ethics, Health and Safety, and Genetic Modification 
Where relevant, research was undertaken with appropriate assessments of the ethical 
considerations and health and safety (COSHH) regulations, including those specifically 
concerning the use of genetically modified organisms and radioactive material.   
2.2. Cell lines 
The cell lines used during these studies are described briefly here, further details on the 
culture of these cells can be found in section 2.4. 
2.2.1. W12 Derivatives 
The W12 cervical keratinocyte derivatives were a kind gift from P. Lambert (University of 
Wisconsin, USA) and are described in further detail in section 1.9.2.  The W12 derivatives 
studied were clones 20850 (E50), 20863 (E63), 201402 (I02), 20822 (I22), 20831 (I31), and 
20861 (I61) 
119.                                            
2.2.2. J2 3T3  
J2 3T3 is an immortal mouse fibroblast cell line used to provide feeder support for culture of 
W12 derivatives in both monolayer and raft culture.  These cells were a kind gift from Fiona 
Watt (London Research Institute, London, UK).   
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2.2.3. CaSki 
CaSki is an adherent human cervical epithelial cell line obtained from ATCC (CRL-1550).  
These cells are derived from a metastatic epidermoid carcinoma of the small bowel mesentery 
of a 40 year old Caucasian female 405.  They contain integrated HPV 16 at approximately 600 
copies per cell, although there are some reports suggesting that HPV 18 type sequences may 
also be present 406. 
2.2.4. SiHa 
SiHa is an adherent human epithelial cell line derived from a grade II cervical squamous cell 
carcinoma acquired from ATCC (HTB-35).  The cell line was established using post-surgery 
primary tumour fragments from a 55 year old female Japanese patient 407.  They contain 
integrated HPV 16 at approximately 1 to 2 copies per cell and have been shown to be 
hypertriploid 407. 
2.2.5. Primary Human Keratinocytes  
Normal human epidermal keratinocytes were derived from human neonatal foreskin obtained 
during surgical operations (PromoCell).  For ethics documentation please see appendix D.   
2.2.6. PHKs Transduced with HPV 16 E7 or E6/E7 
PHKs were retrovirally transduced with either the HPV 16 E7 or E6/E7 using retroviral 
transduction (transductions undertaken by R. Lyman as described by Gray et al (2007) 374).  
The HPV 16 E7 and E6/E7 constructs are contained within Moloney murine leukaemia virus 
(Mo-MuLV) derived retroviral vectors which are stably expressed in packaging cell lines 
obtained from the ATCC (CRL 2202-7), as described by Halbert et al (1991) 408 . 
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2.2.7. U2OS 
The human osteosarcoma cell line U2OS was derived in 1964 from a moderately 
differentiated sarcoma of the tibia from a 15 year old female (HTB-96).  U2OS cells display 
an epithelioid morphology and express wild type p53 and pRb 409,410.   
2.2.8. U2OS Transfected with HPV 16 E2 
U2OS cells transfected with neomycin resistant pCMV4-HPV 16 E2 or empty pCMV4 vector 
were a kind gift of Prof I. Morgan (University of Glasgow, UK) 411.  The clones stably 
express either HPV 16 E2 (clones HPV-16E2-B3/A4) or empty pCMV4 (clones Vec-1-3/D3).   
2.2.9. RetroPack PT67 Retroviral Packaging line 
RetroPack PT67 cells are a NIH/3T3 fibroblast based cell line which express the 10A1 viral 
envelope.  These cells contain the viral genes encoding structural proteins gag, pol and env 
required for viral envelope production, but are deficient in the RNA packaging signal (Ψ+).  
The retroviral vector includes the gene of interest but also contains the retroviral packaging 
signal, transcription and processing components.  When the vector is inserted into PT67 cells 
they produce replication incompetent infectious viral particles at high titres.  The separation 
of the packaging signal from the gag, pol and env genes minimises the chances of replication 
competent virions being produced via the recombination of the two sets of retroviral genes.    
2.3. LMB 
The drug Leptomycin B (LMB) was a kind gift from Novartis, in collaboration with Dr. S. 
Lain (University of Dundee, UK).  LMB stock solutions were stored at -80ºC as 10mM, 
1mM, or 0.1mM stocks in absolute alcohol.  Immediately before use, the LMB was diluted in 
the appropriate medium to form working solutions of 200nM or 100µM.  All alcohol stocks 
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were maintained on dry ice when removed from -80 ºC to reduce potential evaporation.  
Treatment doses used during these studies are summarised in Table 2.1: see individual 
experimental protocols for further details. 
 
Experiment Section Concentration of 
LMB 
Length of 
Treatment 
Results 
Chapters 
Morphology 2.5 2nM 40h 3 
Raft Culture 2.6 50nM 72h 3/4/5 
Immunocytochemistry 2.10 2nM 38h 4 
Colony Survival 2.11 2nM/20nM/50nM/100nM 40h 3 
Analysis of Protein –
standard 
2.12 2nM 38h 5 
Analysis of Protein -
time course 
2.12.7.2 2nM 12h/24h/36h 
/48h 
4/5 
Analysis of Protein -
Dnp53 
2.12.7.5 2nM 38h 6 
Luciferase Assay 2.19.2 2nM 12-26h 6 
Table 2.1:  LMB treatment concentrations and times used in the experiments described with the 
appropriate results chapters. 
2.4. Tissue Culture 
2.4.1. Normal Cell Culture 
All cell lines were maintained in culture as described here unless otherwise stated.   
Cells were grown in T75 (80cm3) tissue culture flasks (NUNC) in a 37C humidified 
environment with 5% CO2.  Cultures were maintained in Dulbecco’s modified essential 
medium plus supplements (complete DMEM, appendix B1.1.).  Fresh medium at room 
temperature was provided every ~48h, with all waste media and other liquid cell culture waste 
treated with 2% Virkon (Fisher Scientific) for approximately 24h prior to disposal. 
Cells were passaged when cultures reached approximately 70-80% confluence, as 
qualitatively assessed by phase contrast microscopy.  Flasks were washed briefly in 3ml 
trypsin-EDTA (TE, 0.05 % (w/v) trypsin and 0.53mM EDTA, Gibco/Invitrogen) and 
incubated with a further 1ml TE (37C, 5% CO2) for 5 min or until detached (not exceeding 
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10min).  Detached cells were resuspended in up to 15ml complete DMEM, and centrifuged at 
145g for 5min.  The supernatant was discarded and the cells resuspended in 3ml complete 
DMEM, before seeding at desired density.  
For specific seeding densities a Coulter counter (Z series, Beckman Coulter) was used.  To 
quantify cell numbers 40µl of the cell suspension was combined with 20ml coulter isoton 
solution (Beckman Coulter).  Counting was achieved using a 350fl aperture with all readings 
taken in triplicate and the mean used to determine cell number. 
2.4.2. W12 Cell Culture 
The culture of W12 cells requires the presence of a mitomycin C (mtc, Sigma-Aldrich) treated 
J2 3T3 feeder layer.  Before use the mtc was first diluted in 5mQ water (dH2O) to form a 
200μg/ml stock and stored at 4C for a maximum of 14 days.  Growing J2 3T3 cultures were 
treated with 1:100 of the 200μg/ml mtc stock (2μg/ml final concentration) and incubated for 3 
hours in normal culture conditions.  Cells were then passaged as described above and seeded 
into T75 flasks containing incomplete F-medium at 1-2 x 105.  The mtc treated feeder cells 
were left overnight in standard culture conditions before the addition of W12 cells.  To 
passage, the W12 cultures were first incubated for 1min at room temperature in 0.02% (w/v) 
EDTA and washed briefly with 1x phosphate buffered saline (1xPBS, Oxoid).  Cells were 
then trypsinised as described in section 2.4.1, although due to the highly adherent nature of 
the W12 cells, cultures were trypsinised for a maximum of 10min with any remaining 
adherent cells removed by scrapping.  After collection by centrifugation the cells were seeded 
onto the feeder layer at between 5x105 – 1x106.  Approximately 24 hours later 1:1000 of 
10µg/ml Epidermal Growth factor (EGF, Sigma-Aldrich) was added to the W12 flasks giving 
a final concentration of 10ng/ml and forming complete F-medium.  Fresh complete F-medium 
was provided approximately every 48h. 
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2.4.3. PHK+ HPV 16 E7 or E6/7 Cell Culture  
Retrovirally transduced PHK cells were produced by R. Lyman, using supernatant derived 
from pLXSN-E7 or E6/7 containing PA317 packaging cells (ATCC, CRL-2203/5) in a 
manner described in section 2.8.  Transduced PHK cells were grown in standard culture 
conditions using keratinocyte growth medium 2 (KGM2, PromoCell) until cultures were 60-
80% confluent, as qualitatively assessed by phase contrast microscopy.  All solutions used to 
passage the primary cells were sourced from PromoCell and pre-warmed to 37 ºC prior to use.  
Cells were first rinsed with 5ml Hanks’ balanced salts solution (HBSS), followed by 
incubation in 5ml trypsin-EDTA (0.04% (w/v) trypsin and 0.03% (w/v) EDTA) initially at 37 
ºC for 2min, then at room temperature for up to a total of 10min.  When approximately 50% 
of the cells were detached, the flask was gently tapped to loosen remaining attached cells.  
5ml of the trypsin neutralising solution (TNS) was added and the collected cells centrifuged at 
145g for 4min at room temperature.  After removal of supernatant, the cells were resuspended 
in 3ml KGM2 and seeded into flasks at appropriate seeding density, dependant on 
experimental requirements.  Fresh KGM2 was provided to growing cells approximately every 
48h. 
2.4.4. Cryogenic Storage of Cell Lines 
For long term storage, cells were harvested as described as described in section 2.4.3, and 
centrifuged cells resuspended in 3ml of the appropriate medium containing 10% (v/v) DMSO.  
Cryotubes (NUNC) with 0.5-1ml of the DMSO-containing cell suspension were then chilled 
to -80ºC at a rate of 1ºC/minute using an isopropanol-containing ‘Mr. Frosty’ (Nalgene) and 
after 24h vials were transferred to liquid nitrogen for long term storage. 
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The PHKs were frozen for long term storage using a specialised protocol.  After harvesting as 
described in section 2.4.3, the pelleted cells (at approximately 1-5 x 105) were resuspended in 
Cryo-SFM (PromoCell) then transferred to -80ºC and then liquid nitrogen as described above. 
2.4.5. Rescue of Cryogenically Stored Cell Lines 
All cells with the exception of the PT67 lines were defrosted by rapid thawing in a 37ºC water 
bath, then transferred into culture flasks containing the appropriate pre-warmed medium.  The 
W12 derivatives were defrosted onto pre-treated feeder cells prepared as described in section 
2.4.2.  To remove the cryo-preservative, the medium on defrosted cells was changed after 24h 
of standard culture.  The PT67 packaging lines were defrosted at 37ºC, with 1ml of warmed 
medium then added into the cryotube and the contents transferred into a 15ml falcon tube with 
a further 5ml of medium.  The cells were then centrifuged at 145g for 5min, resuspended and 
transferred into a T75 flask. 
2.5. Morphological Effects of LMB  
The W12 derivatives were grown as described above in T25 flasks until approximately 70% 
confluent.  The cells were then treated with 2nM LMB for 40h in normal culture conditions.  
Treated cultures and untreated controls were then visually assessed for the effects of LMB on 
each cell line, with a photographic record made using a digital camera (Nikon Coolpix 4500) 
at x200 magnification. 
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2.6. Organotypic Raft Culture 
While at the air-liquid interface raft cultures were particularly vulnerable to infection, 
therefore special care was taken to double swab all equipment with 70% ethanol and/or 
autoclave as necessary.   
2.6.1. Preparation of Collagen Plugs (Day 1) 
As collagen solidifies at room temperature, all equipment in contact with collagen was pre-
chilled on ice prior to and during the procedure.  To prepare the plugs J2 3T3 fibroblasts were 
trypsinised and cell number established as previously described (section 2.4.1), 5x105 cells 
per plug were transferred to a fresh 15ml falcon tube and re-centrifuged.  The fibroblasts were 
resuspended in 1ml 10x DMEM (10.5g 10x DMEM Powder (Gibco/Invitrogen) in 10.5ml 
dH2O) and 1ml 10x Recon buffer (1.1g sodium bicarbonate and 2.4g HEPES in 50ml dH2O, 
0.22µm filter sterilised before use).  Prior to use the collagen (rat tail, type 1, Upstate/ 
Millipore) was diluted on ice with 0.02M glacial acetic acid to a final concentration of 
4mg/ml allowing 2ml diluted collagen per plug.  The resuspended cells were then gently 
added to the diluted collagen and mixed carefully by inverting to avoid bubbles within the 
collagen, returning to ice regularly during mixing to prevent premature solidification.  2ml of 
collagen-cell mix was transferred into the appropriate number of wells of a sterile 6-well plate 
and rocked to spread evenly.  To maintain a sterile environment the 6-well plate was placed 
into a sterile, humidified, and gassed environment.  This was achieved by placing a sheet of 
autoclaved paper moistened with sterile autoclaved 18MQ water into a 70% ethanol sterilised 
Tupperware box, which was then manually gassed with 5%CO2/air and sealed before removal 
from the culture hood.  Collagen plugs were then maintained at 37ºC overnight to allow full 
solidification of the collagen. 
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2.6.2. Addition of W12 Cells to Collagen Plug (Day 2-8) 
To complete the plug preparation, W12 cells were passaged as described in section 2.4.2 and 
resuspended in F-medium at approximately 1x 106/ml; 2ml of this suspension was then added 
to each plug which were then returned to the sterile humidified environment for 24h.  At this 
point the EGF was added to the medium of each well as described in section 2.4.2 and the 
rafts left for a further 3 days before fresh complete F-medium was provided.  The W12 cells 
were left to establish on the surface of the plug for a further 3 days before transfer. 
2.6.3 Transfer of Plugs to Raft Mesh (Day 9) 
 
 
Figure 2.1: The arrangement of the keratinocyte-covered collagen plug at the air liquid interface on a 
raft mesh platform. 
 
 
The rafts were raised to the air liquid interface by transfer to a wire mesh platform (figure 
2.1).  The platform was produced by bending the edges of a 78mm diameter wire mesh disc 
(40 Meshed 0.01mm diameter wire, Johnson Screens), forming four approximately 5mm high 
legs (autoclave sterilised).  
To transfer, the mesh platform was placed into a 90mm tissue culture Petri dish with 
approximately 18-20ml of complete F-medium sufficient to reach the base of, but not to cover 
the mesh.  In the 6-well plates, the medium was removed from above the keratinocyte plugs 
and the raft was then detached from the sides of the well.  A pair of sterile spatulas was then 
used to transfer the plugs from the 6-well plate to the mesh, ensuring that the keratinocytes 
surface seeded remained uppermost.  Rafts were returned to the sterile humidified 
environment and left for 14 days to form an epithelium-like structure, with fresh complete F-
medium provided every 2 days.  24 days after transfer (day 32) rafts were treated with 50nM 
LMB for 72h, with drug administered into the medium below the rafts.  After treatment, rafts 
Mesh platform 
Collagen plug 
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were fixed in 10 % neutral buffered formalin for 24h and transferred to the departmental 
histology service to be embedded in paraffin wax.  5μm sections of the embedded rafts 
stained by haematoxylin and eosin were also provided by the histology service in order to 
assess the raft structure. 
2.7. Stable Transfection of Cultured Cells  
2.7.1. Dominant Negative p53 Plasmid 
The retroviral packaging line PT67 was transfected with the dominant negative p53 construct 
pBabe-R248W (Dnp53, a kind gift from Dr E. Androphy, University of Massachusetts, USA) 
412 or the pBabe construct (ADDgene).  The transfection protocol was also undertaken in the 
absence of DNA (negative control) to allow the assessment of any transfection related 
cytotoxicity and also as a positive control for the effects of the mammalian antibiotic 
puromycin on untransfected cells.   
2.7.2. Puromycin Dose Response 
In order to establish the puromycin dose required to induce death in the PT67 and W12 
derivatives, a dose response experiment was undertaken.  The PT67 cells and the W12 
derivatives E50 and I22 were seeded in 6-well plates and treated with 0, 2, 4, 6, 8 and 10μg/ml 
of puromycin with the rate of cell loss monitored for approximately 72h to determine the 
optimal dose. 
2.7.3. Transfection of Packaging Cells 
The PT67 cells were seeded at 5x104 in a 6-well plate and grown until 60-80% confluent, with 
fresh media provided on the day of transfection.  For each well the transfection reagent was 
prepared by diluting 3μl of GeneJammer (Stratagene) in 97μl of incomplete DMEM (in the 
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absence of fetal calf serum and penicillin-streptomycin-glutamine) with the reagent added 
directly into the media.  The reagent/media solution was then incubated at room temperature 
for 5min, followed by the addition of 2μg of Dnp53 or pBabe plasmid DNA (section 2.17).  
The transfection solution was incubated for a further 40min at room temperature, then added 
dropwise to the appropriate cultures.  The cells were then grown under normal conditions for 
24-48h until semi-confluent; cells were then passaged into a T75 flask and left for a further 
24h under normal culture conditions prior to the commencement of puromycin treatment.  
Initially cells were treated at 2μg/ml puromycin, but after 9 days viable cells still remained in 
the control flasks which formed colonies when selection was removed.  Therefore cells were 
passaged at 12 days after the start of selection, and selection continued at the higher 
concentration of 3μg/ml.  At this treatment level the remaining control cells died rapidly and 
the vector only cells grew well.  This treatment proved too toxic for the p53 compromised 
cells which required re-transfection and selection with 2.5μg/ml puromycin for 6 days.  
Transfected cells were cryo-preserved (section 2.4.4) and cells retained for DNA extraction to 
assess the presence of the construct in the stably transduced cells (section 2.15.4).   
2.8. Stable Transduction of W12 and PHK Cells 
Retroviral transduction of the Dnp53 plasmid or pBabe plasmid was undertaken on the W12 
derivatives E50, I22 and I31 and also the previously transduced PHK lines expressing E7 and 
E6/E7.   
2.8.1. Transduction 
Two T75 flasks each of the Dnp53, pBabe and wild type transfected PT67 cells were cultured 
as previously described until approximately 70-100% confluent.  The W12 and PHK cells 
were passaged into T25 culture flasks: W12 derivatives at 9x104 (on feeder cells as described 
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previously) and PHK cells at 4.7x104.  Cultures were grown until colonies contained 
approximately 4 cells.  At this point the medium on the PT67 cultures was removed and one 
set given incomplete F-medium (for transduction of the W12 cells), and the other given 
KGM2 (for transduction of PHK lines).  These flasks were then left overnight to accumulate 
virions within the supernatant.   
The following day the colonies within the W12 and PHK flasks were typically at the 8 cell 
stage and ready to be transduced.  The retroviral supernatant containing the virions was 
removed from the PT67 flasks and passed though a 0.45μm Millex-HA filter (Millipore) to 
remove any contaminating fibroblasts.  Polybrene (hexadimethrine bromide, Sigma-Aldrich) 
was diluted to 12μg/ml in F-medium or KGM2 and combined 1:1 with the appropriate 
retroviral supernatant in the W12 or PHK flasks.  The cultures were left in contact with the 
retroviral supernatant for approximately 10h for transduction to occur, after which the 
retroviral media was removed and cultures were left overnight prior to selection.   
2.8.2. Selection of Transduced Cells 
Transduced cells were selected using the mammalian antibiotic puromycin.  The W12 
derivatives were treated at 0.5μg/ml, whilst the PHK lines were treated at 1μg/ml puromycin 
(M. Lewis, Liverpool).   
The J2 3T3 feeder cells were untransduced and therefore susceptible to antibiotic treatment.  
Therefore, post-transduction W12 cells were grown in conditioned media provided by 
culturing J2 3T3 in the presence of incomplete F-media for at least 24h then filtering 
(0.45μm) to eliminate contaminating fibroblasts with storage at 4C.  When required the 
media was diluted in complete F-medium (~1:3) and the appropriate volume of EGF and 
puromycin (if required) were added.  Cultures were passaged when approximately 70% 
confluent and maintained under selection until the control flask contained no live cells.  To 
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confirm that selection was complete, puromycin treatment was removed, the flasks rinsed 
with 1xPBS and fresh media provided: the control flask was then monitored for any colony 
formation.  Where colonies were initially detected, selection was reapplied to all cultures at 
0.25μg/ml for 36h followed by 0.3μg/ml for a further 24h.   
After selection was removed the Dnp53 and pBabe only transduced cells were cultured as 
normal, with the W12 cells maintained in conditioned media until cultures were confluent, 
when cells were cryo-preserved (section 2.4.4).  
2.8.3. Stable Transduction of U20S Cells 
The transduction with Dnp53 was repeated with the U2OS cell line as described above, but 
with the following modifications.  Cells were passaged into T25 flasks at approximately 
2x105 and transduced with DMEM containing transduction solutions.  Post-transduction cells 
were selected for 7 days with 1µg/ml puromycin, rinsed and left for 24h before passaging into 
fresh T75 flasks and also aliquots taken for cryo-preservation. 
2.9. Southern Blot 
The Southern blot analysis of DNA was optimised using BamHI purified HPV 16 DNA 
(pEFHPV-16W12E, GenBank Accession No. AF125673, kind gift of P. Lambert, University 
of Wisconsin, USA).  Sample and plasmid DNA production and purification are described in 
sections 2.17 and 2.18.  W12 plasmid DNA at concentrations of 10ng, 1ng, 100pg, 10pg, and 
1pg was used to optimise the protocol and establish sensitivity of the 32P labelled probe.  After 
optimisation the experimental protocol was undertaken using Hirt extracted W12 cellular 
DNA, with the purified plasmid DNA utilised as both probe and positive control sample. 
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2.9.1. Hirt Extraction of DNA 
Hirt extraction 413 of W12 DNA was undertaken to obtain samples enriched with low 
molecular weight episomal HPV DNA.  The W12 derivatives E50, E63, and I22 were grown in 
T75 flasks as described previously, until approximately 70% confluent.  To harvest, flasks 
were washed twice with 1xPBS, then incubated for 5min in 800μl of Hirt solution (0.6% 
(w/v) SDS and 10mM EDTA).  Flasks were then scraped and the cells collected into a 1.5ml 
microcentrofuge tube.  200μl of 5M sodium chloride was then added and shaken to mix.  The 
samples were incubated overnight at 4C to allow the precipitation of genomic DNA and 
cellular debris.  The next day the samples were centrifuged at 9878g for 30min at 4C and the 
supernatant was transferred to a fresh 1.5ml microcentrofuge tube, discarding the pellet.  
Phenol/chloroform extraction of the DNA was undertaken by transferring each sample into 
two fresh tubes each containing 500μl of phenol/chloroform.  Samples were vortexed for 
approximately 2min, then centrifuged for 15min at 9878g.  The upper phase of the sample 
was carefully removed and transferred into a fresh microcentrofuge tube containing 100μl of 
3M sodium acetate (pH 5.2) and 1ml 100% ethanol.  This mix was then incubated at -20C 
for approximately 1h to precipitate the DNA.  The samples were centrifuged at 9878g for 
30min, with the supernatant carefully removed and discarded.  The DNA pellet was washed 
with 500μl of 70% ethanol shaking briefly to resuspend the pellet, then centrifuged at 9878g 
for 20min.  The majority of the supernatant was removed and the pellet air dried for 
approximately 10min.  Each sample was then resuspended in 50μl of dH2O and the DNA 
from the same sample pooled, before storing at -20C.   
2.9.2 DNA Quantification 
The Hirt extracted DNA was quantified using the Qubit Fluorometer HS DNA (Invitrogen).  
Fresh Quant-iT working solution was produced by diluting Quant-iT dsDNA BR reagent 
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1:200 in dsDNA BR buffer.  10μl of each of the two HS dsDNA standards and 10μl of a 1:10 
dilution of the extracted DNA were diluted in 190μl of the Quant-iT working solution, then 
vortexed for 2-3s, before incubation at room temperature for 2min.  The fluorometer HS 
setting was selected and the machine calibrated using the two standards, the sample readings 
were then taken and DNA concentrations established using the following equation:- 
 
2.9.3. BamHI Purification of W12 Plasmid DNA 
The W12 plasmid pEFHPV-16W12E is cloned into the pUC18 vector at BamHI restriction 
sites 19.  Therefore to excise (purify) the W12 DNA from the plasmid backbone BamHI 
digestion and gel purification were undertaken.  2µg of the W12 plasmid DNA (sections 2.17 
and 2.18) was digested with 10 units of BamHI (Promega) in the presence of 0.1mg/ml 
acetylated bovine serum albumin (Promega) in a 40µl reaction.  The digestion was performed 
for 4h at 37ºC then stored at -20ºC. 
Purified W12 plasmid DNA was separated from the plasmid backbone on a 1% agarose gel 
alongside hyperladder I (75V, ~2h).  When sufficiently separated the bands were visualised 
using a UV lamp (Ultratec) and the insert DNA band excised into a 1.5ml microcentrofuge 
tube.  The purified DNA was then extracted from the gel using QIAquick Gel Extraction kit 
(Qiagen).  The gel slice was weighed and 300μl of buffer QG per 100mg of gel was added 
and the gel heated at 50C until the gel had melted (~10min).  To this 100μl of isopropanol 
per 100mg of gel was added and the sample applied to the QIAquick column which was 
centrifuged for 1min at 9878g in a microcentrofuge with the through flow discarded.  To 
remove any remaining traces of agarose a further 500μl of buffer QG was added to the 
column and then centrifuged at 9878g for a further 1min.  The column was dried by spinning 
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at 9878g for 1min before the DNA was eluted into a clean 1.5ml microcentrofuge tube by the 
addition of 50μl autoclaved 18MQ H2O followed by a 1min spin at 9878g.  The DNA was 
then stored at -20C. 
2.9.4. BamHI and HindIII Digestion 
In order to assess the status of the HPV genomes the Hirt extracted DNA underwent digestion 
with either the single HPV cutter BamHI (Promega), or the non-HPV cutter HindIII 
(Promega).  For each sample 2.4μg of Hirt extracted DNA was digested with 24 units of 
BamHI or HindIII, in the presence of 0.1mg/ml acetylated bovine serum albumin in a 50μl 
reaction.  The solution was mixed and centrifuged briefly before incubating at 37C for 4h, 
with the DNA stored at -20C.  Full length W12 purified plasmid DNA was also digested 
with both BamHI and HindIII as described above for control purposes.   
2.9.5. Gel Electrophoresis 
To separate the DNA by base pair size the Hirt extracted DNA (digested or undigested) and 
plasmid DNA samples were heated at 56C for 3 min and loaded onto a 1% agarose midi gel 
(section 2.12).  Electrophoresis was then undertaken at 100V for 7.5h with progression 
assessed under UV light.  When electrophoresis was complete the position of the DNA on the 
gel was photographically recorded, excess gel removed and the upper right hand corner of the 
gel removed for orientation. 
2.9.6. Alkaline Transfer 
In preparation for transfer the agarose gel was rinsed twice in dH2O and the DNA depurinated 
in 30ml 0.25M HCl with gentle agitation for 30min.  The gel was washed twice in dH2O then 
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incubated with gentle agitation in 30ml alkaline transfer buffer (0.4M NaOH and 1M NaCl) 
for 35min, with fresh buffer provided after 15min.         
                     
      
Figure 2.2:  The assembly of a Southern blot passive transfer apparatus for the transfer of DNA from 
agarose gel to hybond-N+ membrane. 
 
The transfer apparatus was set up as shown in figure 2.2, in a box containing approximately 
1L of alkaline transfer buffer.  The base section of Whatman paper was gel width, but 
approximately 5 gel widths long to act as a wick for the passive upwards transfer of buffer.  
The gel was placed onto the base sheet with the cut corner of the gel to the left, and to prevent 
aberrant movement of buffer, the area surrounding the gel was sealed with nescofilm.  
Hybond-N+ membrane (GE Healthcare) was pre-cut (including cut corner for orientation) 
then placed onto the gel, followed by 3 further sheets of Whatman paper.  The surface of the 
stack was rolled with a Perspex rod to remove any bubbles.  Finally 8cm of paper towels and 
an approximately 400g weight were added and the apparatus left overnight at room 
temperature for passive transfer of the DNA.  After transfer the positions of the lanes were 
marked on the membrane which was then washed twice in 2x SSC (from 10x stock: 175.3g 
sodium chloride and 88.2g sodium citrate in 1L dH2O pH7), air dried and stored at 4C until 
ready for hybridisation.   
400g weight 
8cm of blue 
paper towels 
Hybond-N+ 
membrane 
Long piece of 
Whatman paper 
Small box 
Gel tray 
3 sheets of 
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Gel  
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2.9.7. Probe Preparation 
The 32P labelled probe was produced by random priming of the BamHI purified W12 plasmid 
DNA (section 2.9.3) with α[5’-32P] labelled dCTP (500µCi/18.5MBq, PerkinElmer).  25ng of 
purified W12 plasmid DNA in 30μl dH2O was mixed with approximately 125ng 10x 
hexanucleotide mix (Roche) and denatured at 95C for 2min followed by transfer to ice for 
1min.  After a brief spin the remaining constituents of the random prime mix were added: 
100μM of a 5mM stock dNTP solution (1:1:1 dTTP, dATP and dGTP), 1 in 5 of random 
priming buffer (appendix B3.1, note 10mM DTT was added at immediately prior to use) and 
50μCi [α-32P] dCTP (10mCi/ml stock).  The reaction was made up to 50μl with 18MQ dH2O 
before the addition of 5 units of DNA polymerase 1 large (Klenow) fragment (Promega).  The 
labelling mix was incubated at room temperature for 60min, with the reaction was stopped by 
the addition of 10μl stop buffer (appendix B3.2). 
2.9.7.1 Probe Purification 
Unincorporated nucleotides were removed using the NucAway spin column system 
(Ambion).  The column was hydrated by the addition of 650μl dH2O, vortexed and bubbles 
removed by flicking.  The column was then incubated at room temperature for 15min and 
stored at 4C.  Immediately prior to use the hydrated column was centrifuged at ~750g for 
2min to remove excess fluid.  The probe was added to the column and centrifuged for 2min at 
750g.  The column was rinsed with 60μl of dH2O and re-centrifuged with combined fractions 
of purified probe stored at 4C.   
2.9.8. Southern Blot Hybridisation 
The sample-containing membrane was removed from 4C and rinsed once in 6x SSC.  The 
hybridisation solution was prepared as described in appendix B3.4, with 100.9µl salmon 
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sperm DNA (Sigma-Aldrich) denatured at 99C for 10min immediately before addition to 
10ml of hybridisation solution, pre-warmed to 68C.  The membrane was blocked in the 
prepared hybridisation solution at 68C for 3h in a rolling hybridiser (Hybaid).  The 32P 
labelled probe was denatured at 99C for 5min and chilled on ice, before addition to 10ml of 
fresh hybridisation solution prepared as described above.  The membrane was then left to 
hybridise in the presence of the probe overnight at 68C. 
2.9.9. Southern Blot Detection 
The membrane was removed from the hybridisation solution and washed twice with shaking 
at 37C for 5min in prewarmed 2x SSC with 0.1% (w/v) SDS.  The membrane was then 
wrapped in cling film in preparation for detection.  Initial detection was obtained using Instant 
Imager phosphoImager (Packard) exposed for approximately 3h.  After the initial reading the 
membrane was then transferred to an X-ray cassette with film and left to develop for 1-6 days 
at -80C to reduce background disturbance.  The film was developed using the standard 
protocol (section 2.11.5). 
2.10. Immunocytochemistry  
2.10.1. Immunocytochemistry of Monolayer cells 
W12 derivatives were cultured on Lab-Tek chamber slides (Nunc) which provide both a 
media chamber for cell culture and a rubber gasket (figure 2.3).  The gasket acts as a seal 
during cell culture and can also provide a barrier to retain small amounts of liquid during 
staining protocols if required. 
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Figure 2.3: The components of a Lab-Tec chamber slide used for monolayer immunocytochemistry. 
 
2.10.1.1. Staining systems 
Two different staining systems were utilised for immunocytochemistry; the slides were either 
stained within a humidified chamber or Shandon sequenza system (Thermo Electron).  When 
using the humidified system the chamber slide rubber gasket was retained to act as a barrier to 
maintain liquid coverage, with incubations undertaken in an inverted box lined with 
dampened tissue to provide the required humidified environment.   
Alternatively, the chamber slide gasket was removed and the Shandon sequenza system was 
used.  Here slides were loaded into the slide coverplate under 1xPBS and transferred into a 
slide rack which clamps together the slide and coverplate holding the two surfaces in close 
proximity.  This system utilises gravity flow to draw fluid from the upper chamber of the 
coverplate into close contact with slide, maintaining an even coverage of the cells until the 
next solution is added to the upper chamber.   
The two staining systems require different fluid volumes in order to maintain a constant 
coverage of the slide surface: for antibodies the humidified chamber used 250µl of diluted 
antibody, whereas the Shandon system required only 150μl.  For slide washes, for the 
humidified chamber system two 1xPBS rinses were undertaken manually in separate Coplin 
jars for 2 minutes each; for the Shandon system two additions of approximately 2ml 1xPBS 
into the upper chamber were used allowing each to drain under gravity.   
2.10.1.2. Preparation and Staining Protocol 
The chamber slides were seeded with 1.5x102 mtc treated feeder cells in 2ml of complete F-
media as previously described.  The following day W12 cells were passaged (section 2.4.2) 
Tissue culture lid 
Media chamber 
Rubber gasket 
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and seeded onto the mtc treated feeder layer at 1.5 x 102, with EGF added ~24h after 
passaging (section 2.4.2).  Cultures were grown until approximately 60% confluent then 
treated with 2nM LMB for 38h under normal culture conditions.   
After treatment the slides were separated from the media chamber and where required the 
slide gasket was removed before transferring to 1xPBS.  Cells were fixed in ice cold methanol 
for 30mins at –20 C, rinsed twice in 1xPBS, and blocked in PBT (1xPBS + 1 % BSA (bovine 
serum albumin)) for 10mins.  When staining for activated caspase-3 (act-casp-3) a peroxidase 
block was required to reduce innate peroxidase activity associated with higher background 
staining with this antibody.  The block was achieved by incubating slides for 10min at room 
temperature in 67% methanol, 3% hydrogen peroxide solution.  The primary antibodies were 
incubated for 1h at antibody specific dilutions (for further details see appendix B4.1.1 and 
B4.2.1).  Slides were then rinsed twice in 1xPBS before incubation with the appropriate 
biotinylated secondary antibody for 30mins diluted in PBT (appendix B4.1.2).  Slides then 
received a further two washes with 1xPBS before incubation with 500μl streptavidin-HRP 
(1:150, Dako) for 30 mins.  Detection was carried out using a 3-amino-9-ethylcarbazole 
(AEC) staining kit (Sigma-Aldrich-Aldrich) utilising the peroxidase functions of the 
streptavidin-HRP to catalyse the conversion of the AEC substrate to an insoluble red end 
product.  After a final rinse in dH2O slides in the Shandon system were removed from the 
cassettes, and all slides counterstained in haematoxylin (VectorLabs) for approximately 20s.  
Slides were then rinsed several times in tap water, air dried and coverslips mounted using 
glycerol buffer (1:1 Glycerol:1xPBS) sealed using clear nail varnish.  
To assess apoptosis the positively stained cells were counted systematically from one edge of 
the slide at x500 magnification.  Slides were counted until the proportion of positive cells 
reached a plateau, as assessed using the running mean method. 
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2.10.2. Immunocytochemistry of Raft Cultures 
Prior to immunocytochemistry, antigen retrieval was performed on 5μm thick sections of 
paraffin embedded raft cultures.  Slides were initially baked for 1hour at 60ºC, before washing 
twice for 5min in histoclear solution (VWR).  Slides were then subjected to two 100% ethanol 
washes (2min each) and a 2min 100% methanol wash.  All washes were undertaken on a 
gently rocking platform.  In preparation for antigen retrieval 1L of 0.01M citric acid (pH6) 
was preheated for 10min at full power in an 850 W microwave, bringing the citric acid to 
correct temperature for retrieval.  Dewaxed slides were transferred to cold tap water and 
gently brought to retrieval temperature by the gradual addition of hot water over approx 2-
5min.  The prepared slides were then transferred to the pressure cooker (Launch Diagnostics) 
containing the pre-warmed 0.01M citric acid and slides were gently agitated to remove any 
bubbles present.  Slides were then microwaved at pressure on full power for approximately 
18min.  Slides were transferred from the pressure cooker directly to hot tap water and gently 
cooled to room temperature by the gradual addition of cold tap water before proceeding.   
Slides were loaded into the Shandon staining system (using 1x Tris buffered saline (1xTBS) 
in place of 1xPBS) and any endogenous peroxidase activity was blocked as previously 
described (section 2.10.1.2).  Immunocytochemistry was undertaken on the rafts using the 
ABC elite Vectorstain mouse or universal staining kits, dependent on the primary.  The rafts 
were blocked in the appropriate 1xTBS diluted serum (1.5% Vectorstain serum) for 20min, 
before incubation with 150µl primary antibody diluted in blocking solution for 30min 
(appendix B4.1.1 and B4.2.1).  Slides were washed twice with 1xTBS, before incubating for a 
further 30min with the appropriate biotinylated secondary antibody, diluted 1:200 in blocking 
solution.  The biotinylated secondary antibodies used were a component of the staining kit 
and not those listed in appendix B4.1.2.  After the secondary antibody the rafts were again 
washed twice with1xTBS and incubated for 30min in the ABC solution (5ml TBS, 2 drops of 
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reagent A and 2 drops of reagent B prepared 30min before use).  Finally two 1xTBS washes 
were undertaken before detection with the AEC staining kit as described in section 2.10.1.2.  
Coverslips were mounted using glycerol buffer and sealed with clear nail varnish. 
2.11. Colony Survival Assay 
The effect of LMB on the colony forming ability of the W12 derivatives, transduced PHKs 
and HPV infected cancer cell lines CaSki and SiHa was assessed by the colony survival assay.  
Initially colony forming ability of the E63 and I22 was tested at different seeding densities to 
determine the appropriate number of cells to seed after LMB treatment.  Cells were seeded in 
90mm Petri dishes as described below at approximately 300, 600, 900, 1200 and 1500 cells, 
and the colony numbers formed were assessed.  
For the experimental colony survival assay mtc treated feeder cells were seeded at 5 x 104 in 
T25 flasks (section 2.4.2) with 6.5x105 E63 or I22, and the PHK cells expressing E7 were 
seeded at 4x105/T25 flask.  Cells were cultured as normal until approximately 50% confluent: 
at this point the more rapidly growing CaSki and SiHa cell lines were seeded into T25 flasks 
at 2.5x105/flask.  Cultures were grown for a further 2 days until approximately 70-80% 
confluent before treatment with 0nM, 2nM, 20nM, 50nM or 100nM LMB for 40h in standard 
culture conditions.  After treatment the flasks were rinsed twice with 1xPBS and fresh media 
provided.  Post-treatment cultures were then left overnight to recover before passaging.  The 
treated cells were seeded into a 90mm Petri dish at a density of approximately 200 cells, with 
pre-prepared mtc treated feeder cells provided where required.  Cells were then cultured under 
standard conditions until visible colonies formed in all plates.  The media was then removed, 
the plates rinsed in 1xPBS and cells fixed in ice cold methanol for 30min.  Colonies were 
stained with 5% (v/v) Giemsa (BDH) for 10min and rinsed in dH2O.  The colony number was 
counted and colony size measured on scanned images (HP psc 1215 scanner) using Scion 
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Image program, with all measurements in mm2.  Where required microscopic identification of 
colonies was undertaken using phase contrast microscopy, with the morphologically different 
J2 3T3 cells disregarded. 
2.12. Analysis of Protein Expression  
2.12.1. Sample Preparation 
2.12.1.1. Cell Harvesting 
Cells were grown using an appropriate culture protocol until semi confluent and treated with 
LMB as indicated in sections 2.4 and 2.12.7.  To harvest media was transferred to a 15ml 
falcon tube to collect any cells in suspension and centrifuged at 145g for 5min, the 
supernatant discarded, and the resultant pellet was stored on ice.  Adherent cells were 
harvested by double scraping, with each followed by collection of cells in 4ml 1xPBS and 
addition to the appropriate pellet.  Flasks were given a final 4ml 1xPBS wash and the 
collected cells were centrifuged as previously described.  The resultant supernatant was 
discarded, the pellet resuspended in 1ml 1xPBS and transferred to a 1.5ml microcentrofuge.  
Samples were given a final spin at maximum speed in a microcentrifuge for 5min, the 
supernatant discarded and pellets snap frozen in liquid nitrogen and stored at -80C. 
2.12.1.2. Cell Lysis 
The cell pellets were disrupted by flicking, then lysed by the addition of 50-200μl of Laemmli 
reducing sample buffer (RSB, see appendix B1.5).  To complete the lysis the samples were 
passed though a 25 gauge needle approximately 10 times, and heated at 95C for 5min: the 
resultant lysates were then stored at -20C.   
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2.12.1.3. Protein Quantification 
Protein levels were quantified using a Qubit Fluorometer (Invitrogen).  Quant-iT working 
solution was prepared by diluting the protein reagent 1:200 in the appropriate buffer, allowing 
200μl for each of the 3 protein standards and samples.  The protein standards were prepared 
by diluting 10μl of the appropriate standard in 190μl of the Quant-iT working solution, 
producing a total assay volume of 200μl: solutions were then vortexed for 2-3s.  For each 
experimental sample a 1:10 dilution of protein lysate was prepared (1μl sample and 9μl dH2O) 
and combined with 190μl of the Quant-iT working solution before vortexing for 2-3s.  
Standards and experimental samples were then incubated for a minimum of 15min at room 
temperature.  The fluorometer was calibrated using the 3 protein standards: the experimental 
samples were then measured in μg/ml.  If protein concentrations were outside the 
fluorometer’s quantifiable range the quantification was repeated using either neat sample or 
1:100 dilution as required.  Final protein quantities were calculated using the following 
equation:- 
 
 
2.12.2. Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis  
Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS-PAGE) was 
undertaken using the Hoefer Mighty Small mini electrophoresis system (Hoefer), to separate 
the proteins according to their molecular weight, prior to Western analysis.  Firstly the 
resolving gel was prepared (see appendix B2.1), with the gel percentage determined by the 
molecular weight of the target proteins: for details of gel percentages used for these studies 
please see appendix B4.2.2.  The resolving gel was overlaid with a layer of 70% ethanol to 
level the gel surface and prevent drying, then left to polymerise at room temperature for a 
minimum of 30min.  Once polymerised, the ethanol was removed and the stacking gel 
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prepared as listed in appendix B2.3.  When added to the surface of the resolving gel either a 
10 well (standard analysis) or 15 well (time course) 1.5mm comb was inserted into the 
resolving gel and left to polymerise for at least 15min. 
2.12.2.1. Gel Sample Preparation 
Gel samples were prepared using 20μg of the experimental protein lysate, made up to the 
loading volume with appropriate volume of bromophenol blue containing reducing sample 
buffer (approximately 0.001% (w/v) bromphenol blue).  Loading volumes varied according to 
well number, 20μl for 10 wells and 17μl for 15 wells.  Prior to loading, proteins were 
denatured at 95C for 5min, and centrifuged briefly.  The broad range prestained protein 
marker (New England Biolabs) was prepared by diluting 4μl of marker in 13μl (15 well) or 
16μl (10 well) of loading buffer.   
2.12.2.2. Acrylamide Gel Electrophoresis 
Gels were loaded into the running rig containing 1x running buffer prepared from 10x stock 
buffer (100ml in 900ml, see appendix B2.5).  Electrophoresis was initially undertaken at 
100mV until samples entered the resolving gel (after approximately 15min).  The voltage was 
then increased to 150mV and the gels were left for approximately 1h or until samples had run 
a sufficient distance to provide suitable separation (as assessed by the progression of the 
bromophenol blue stain and protein standard).   
2.12.3. Transfer of Proteins to PDVF membrane 
Hybond-P PDVF membrane (GE Healthcare) was cut to size and orientated by the removal of 
one corner.  To activate the PDVF membrane, it was soaked for 10s in 100% methanol and 
rinsed for 5min in dH2O, then equilibrated for at least 10min in 1x transfer buffer.  1L 1x 
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transfer buffer was prepared by combining 100ml 10x transfer buffer (appendix B2.5) in 50ml 
100% methanol and 850ml dH2O. 
 
After the termination of electrophoresis, gels were removed, the stacking section discarded, 
and the upper right corner of the gel removed to provide orientation.  The resolving gel was 
transferred to a large container of 1x transfer buffer and soaked briefly.  The transfer stack 
was assembled as shown in figure 2.4, ensuring that the black side of the cassette formed the 
base of the stack.  Whatman blotting paper was cut to size, and along with the transfer 
sponges was briefly soaked in 1x transfer buffer before use.  After the positioning of the upper 
Whatman paper over the membrane, the surface was rolled to remove any bubbles. 
 
                                                             
 
Figure 2.4:  The assembly of the stack for the transfer of protein from SDS-PAGE gel to PDVF 
membrane.        
          
 
The Hoefer transfer rig was filled with approximately 1L of 1x transfer buffer and the loaded 
transfer cassette was placed into the rig hinge side up with the black side facing forward.  
Protein transfer was achieved by applying a constant current of 100mV for 1h: the unit was 
cooled by passing running tap water through the base of the transfer rig.  When the transfer 
was complete the gel was discarded and the positions of the molecular weight marker bands 
were marked on the membrane.  The appearance of the ladder on the membrane was 
indicative of a successful transfer: this was confirmed by visualising the transferred protein by 
soaking the membrane for approximately 2min in Ponceau S solution (0.1% Ponceau S (w/v), 
5% acetic acid (v/v)).  This was followed by several washes in 1x PBS with 0.1% Tween-20 
Gel 
 Sponge 
Whatman paper 
Membrane 
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(PBST).  If the protein lanes displayed considerable unequal loading or disruption by bubbles 
then the membrane was discarded.   
2.12.4. Western Blotting 
The membrane was blocked for 1h in approximately 20ml PBST containing 5% (w/v) semi-
skimmed powdered milk (mPBST) at room temperature.  The blot was then incubated 
overnight at 4C in 5-10ml of the primary antibody, diluted in fresh blocking solution at an 
antibody-dependent dilution (appendix B4.2.2).  The primary antibody solution was then 
removed and the membrane washed twice washes in approximately 50ml of PBST for 
approximately 15min per wash.  The membrane was then incubated with 5-10ml of the 
appropriate HRP-conjugated secondary antibody (Pierce) at 1:10 000 in PBST/mPBST 
(appendix B4.2.2) for 1h at room temperature.  Finally the blot underwent six larger volume 
10min washes in PBST to remove excess secondary antibody.  All incubations and washes 
were undertaken with gentle rocking. 
2.12.5. Detection   
Bands were visualised with Immobilon Western chemiluminescent HRP substrate detection 
system (Millipore), mixing the luminol and peroxide solutions in a 1:1 ratio.  The signal was 
detected on Fuji film X-ray film (Fisher) exposed for an antibody-dependent period of time 
(appendix B4.4), then developed by incubating in Kodak GBX developer (Sigma-Aldrich) for 
1min, then 1-2min in Kodak Unifix (Sigma-Aldrich) finally rinsing briefly in tap water.  
Developed films were then scanned using a HP psc 1215 and, where necessary, quantification 
was achieved using ImageJ software (National Institute of Health (NIH), USA) with all 
measurements given as integrated density in arbitrary units (AU) normalised against β-Actin. 
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2.12.6. Stripping and Reprobing of Membranes 
Where a membrane required reprobing for an alternative protein of a similar molecular 
weight, the membrane was stripped.  This was achieved using 4 washes in 10% (v/v) glacial 
acetic acid for 5-10min each, followed by at least 4x10min washes in 10ml PBST.  After 
stripping, the membrane was blocked again before proceeding with the addition of the new 
primary antibody.  In all the western blots shown in this thesis the membrane was stripped 
before reprobing for β-Actin.  
Where the molecular weight of the additional protein was sufficiently different from the initial 
protein and did not interfere with the detection of the second protein, the membrane was 
washed twice for 10min in 1xPBS prior to the addition of the new primary antibody, with no 
repeat blocking required. 
2.12.7. Experiment-Specific Protocol Variations 
2.12.7.1. Analysis of Cytokeratin 18 Protein Expression 
In order to utilise the M30 antibody, the expression and any variation in the levels of 
cytokeratin 18 (CK18) were assessed using protein lysates from all the W12 derivatives.  The 
expression of CK18 within the PHK cells has been confirmed by Gray et al (2006) 374. 
2.12.7.2. Time Course Analysis of Protein  
In order to analyse the progression of the apoptotic response over time, a 48h time course was 
performed.  All flasks were provided with fresh medium immediately prior to LMB treatment 
and to obtain baseline protein expression one flask from each cell line was harvested at this 
point.  Further flasks were then treated with 2nM LMB and harvested at 12h, 24h, 36h, and 
48h after treatment alongside time matched untreated controls.  Cells were harvested and 
analysed as described in the standard protein assay, with 15 well acrylamide gel 
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electrophoresis.  For the analysis of M30 and act-casp-3 individual membranes were used; 
however for p53 and p21 the same membrane was utilised unstripped. 
This protocol was repeated to analyse the contribution of mtc treated J2 3T3 feeder cells to 
the LMB-induced effects, with treated E7 transduced PHKs used as a positive control.  Mtc 
treated J2 3T3 cells were seeded at the same concentration used for the W12 cell time course 
and maintain under W12 culture conditions.  J2 fibroblasts and E7-transduced cells were 
treated with 2nM LMB for 48h and harvested as normal.  The expression of act-casp-3, M30 
and β-actin in 25µl of J2 lysate (maximum loading volume) and 20µg of E7 lysate were 
assessed as previously described. 
2.12.7.3. Low Confluence Analysis of HPV 16 E2 Protein  
To assess expression of the HPV 16 E2 protein in the W12 derivatives, the cells were cultured 
as normal without LMB treatment.  To obtain maximum E2 expression, the W12 derivatives 
were harvested while highly subconfluent (approximately 50% as qualitatively assessed by 
phase contrast microscopy).  U2OS cells transfected with HPV 16 E2 (clone E2B3) or 
pCMV4 (clone D3) were utilised as positive and negative controls for E2 expression.  Due to 
the presence of non-specific bands in the predicted E2 region of the membrane on initial gels 
using the mini electrophoresis system, an 8% SDS-PAGE midi gel (Hoefer SE600) was used 
to provide maximum separation within this region of the gel.  The protein analysis was 
undertaken as described above, with the following exceptions.  Due to the increased size of 
the midi gel both the resolving and stacking gels were left for 1h (instead of 30min) to 
polymerise.  Samples consisted of 15μg of E2 expressing and vector only U2OS lysates, 
along with 70μg of the low confluence W12 lysates (made up to 30μl).  Samples were loaded 
alongside 12μl of molecular weight marker, and run at 25mA for approximately 5.5h.  To 
reduce any heat damage to the protein due to prolonged electrophoresis the rig was cooled by 
the circulation of running tap water and placement of the rig in an ice bath.  After 
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electrophoresis the gel was trimmed.  In order to maximise protein transfer the trimmed gel 
was soaked for approximately 15min in transfer buffer to remove any contaminating SDS 
(section 2.12.3).  Membrane blocking was carried out as described in section 2.12.4 for 1.5h 
prior to addition of the primary antibody TGV261.  The membranes were incubated overnight 
at 4C in 12ml of diluted primary antibody to ensure complete coverage of the membrane 
(appendix B4.4).  To maximise detection and to minimise background staining, the secondary 
antibody was diluted in 3% mPBST.  As in vivo expression of the E2 protein is very low, 
maximum sensitivity was achieved during detection using the supersensitive SuperSignal 
West Femto Maximum Sensitivity Substrate (Pierce) mixing the luminal, peroxide and 1xPBS 
in a 1:1:5 ratio, and detected initially for 10min followed by a further 1h exposure.  To further 
increase sensitivity and reduce background the x-ray cassette was lined with reflective 
material.   
2.12.7.4. Alkaline Phosphatase Digestion of Protein  
To assess the phosphorylation state of the p21 protein in the W12 derivatives, an alkaline 
phosphatase digestion was undertaken.  Digestion was undertaken on 20μg of non-time course 
protein lysate (prepared as described in section 2.12.1.); the samples were incubated with 1 
unit of calf intestinal alkaline phosphatase (CIAP) (Promega) and 1μl of the appropriate 
buffer for 30min at 37oC.  Digested protein was stored at -20oC before being analysed as 
described for the standard protein assay. 
2.12.7.5. Analysis of p21 Protein using C-Terminal and Internally Located Antibodies 
To assess the expression of the p21 doublet 40µg of time course lysate (12h+LMB, section 
2.12.7.2) from W12 derivatives E50, E63, I02 and I31, separated in duplicate by SDS-PAGE 
(section 2.12.2) and transferred to PDVF (section 2.12.3).  The membrane was cut and 
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western analysis was undertaken using either the C-terminal antibody SX118 or internally 
located antibody EA10 (see appendix B4.4), as described in section 2.12.7.2.  
2.12.7.6. LMB Treatment U2OS Cells 
Any potential LMB response in the U2OS cell line and any role of HPV 16 E2 in the LMB 
response was analysed by treatment of U2OS cells transfected with HPV 16 E2 (clone E2B3), 
pCMV4 vector (clone D3) and non-time course W12 derivatives, with 2nM LMB for 38h 
(section 2.3).  Cultures were harvested and protein analysis undertaken for activated caspase-3 
and M30 by western blot, as described in section 2.12.1-6.  In this case the membrane 
blocking which was undertaken overnight at 4C, with the antibodies incubated at room 
temperature for 1h. 
2.12.7.7. LMB Treatment of Dominant Negative p53 Cells 
The contribution of the p53 response to LMB induced apoptosis was assessed by the 
treatment of wild type (wt) and Dnp53 (and vector only) transduced W12 derivatives E50, I22 
and I31, and the PHK lines containing E7 and E6/E7.  Dnp53, pBabe only and wt cultures 
were grown in T25 flasks until approximately 60-70% confluent; cells were then treated for 
38h with 2nM LMB as described in section 2.3.  Cultures were harvested as described 
previously with lysis undertaken in 15ml falcon tubes followed by transfer to 1.5ml 
microcentrofuge tubes for storage.  As the experiment was undertaken on cells seeded in T25 
flasks, quantification was undertaken using the Qubit system with 1µl of neat lysate due to 
lower cell numbers.  Alterations in expression of the apoptotic markers act-casp-3 and M30 
were then assessed as described in sections 2.12.4-6, with the exception of M30 where the 
membrane was blocked overnight at 4C, with antibody incubation at room temperature for 
1h. 
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2.13. Agarose Gel Electrophoresis 
Agarose gel electrophoresis was undertaken to separate DNA templates by base pair size 
using an agarose gel matrix.  The gels were made by combining 1% (w/v) agarose (Bioline) 
with 1x Tris-Borate-EDTA (TBE, Sigma-Aldrich) from 10x stock solution.  The gel mix was 
heated in an 850w microwave at medium power until the agarose melted to form a clear 
solution (1-3min); for details see table 2.2. 
Table 2.2:  The quantities of gel components require for the production of 1 or 2% agarose mini and 
midi gels used in gel electrophoresis.   
 
To detect the presence of DNA, 0.05% ethidium bromide (Sigma-Aldrich) was added and the 
gel poured into the gel tray with the appropriate comb.  Gels were allowed to set for at least 
30min before use.  Either Agragel mini (Biometra) or HU13 midi (SCIE-PlAS) rigs were used 
according to the number of samples and amount of band separation required. 
Electrophoresis was undertaken in an appropriate volume of 1x TBE sufficient to cover the 
surface of the gel.  To load, 8μl of sample was combined with 2µl of 5x loading buffer; each 
gel was also loaded with 4μl hyperladder I or II (Bioline).  Samples were then subjected to 
80- 150V depending on the size of the gel and required resolution, for approximately 1-1.5h 
or until sufficiently separated.  The passage of DNA through the gel was assessed by 
illumination under UV (302nM) light and photographic records acquired using the Syngene 
UV Transilluminator system (Syngene).   
 Total volume 10x TBE Water 1% Agarose Ethidium Bromide 
Mini gel 50ml 5ml 45ml 0.5g 2.5μl 
Midi gel 150ml 15ml 135ml 1.5g 7.5μl 
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2.14. Extraction of DNA and RNA from Cultured Cells 
Cells were cultured as normal until approximately 70-80% confluent and harvested as 
previously described (section 2.4).  After centrifugation cells were resuspended in 0.5-1ml 1x 
PBS and transferred into a 1.5ml microcentrofuge tube.  The cell suspension was then 
centrifuged at 9878g for 5min and the supernatant discarded.  If the DNA/RNA extraction 
was not to be carried out immediately, the cell pellet was snap frozen in liquid nitrogen and 
stored at -80C.   
2.14.1. DNA Extraction 
DNA was extracted using the Wizard genomic DNA Purification Kit (Promega).  To each cell 
pellet 600μl of nuclei lysis solution was added and mixed until no clumps remained.  
Contaminating RNA was removed with 3μl of RNase solution incubated at 37C for 30min.  
The sample was allowed to equilibrate to room temperature for 5min before 200μl of protein 
precipitation solution was added and the sample vortexed briefly to mix.  The sample was 
then incubated for 5min on ice and centrifuged at 9878g for 4min to pellet the precipitated 
protein.  The DNA containing supernatant was transferred to a fresh 1.5ml microcentrofuge 
tube containing 600μl of room temperature isopropanol and mixed.  The solution was 
centrifuged for 1min at 9878g and the supernatant carefully removed and discarded.  The 
DNA pellet was then washed in 600μl of 70% ethanol, and centrifuged at 9878g for 1min.  
The ethanol wash was discarded and the pellet air dried for approximately 15min, with the 
DNA resuspended in 100μl of rehydration solution and left to rehydrate overnight at 4C, 
with long term storage at -20C. 
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2.14.2. RNA Extraction 
RNA extraction was undertaken using the RNeasy Minikit (Qiagen).  The harvested cells 
were mixed with 600μl of buffer RLT (including 1:100 of β-mercaptoethanol (Sigma-
Aldrich)).  The sample was homogenised by passing the lysate 10 times though a 20 gauge 
needle fitted to a sterile 1ml syringe and 600μl of 70% ethanol then added.  Up to 700μl of the 
sample was then placed onto the RNeasy mini column and centrifuged at 9878g for 15s: the 
through flow was discarded and the process repeated with the remainder of the sample.  The 
column was washed by the addition of 700μl of buffer RW1 followed by a 15s spin.  Two 
further 500μl washes with buffer RPE were performed with each followed by a 2min 
centrifuge at 9878g.  To ensure that any remaining wash solution was removed an additional 
1min spin was also undertaken.  The RNA was eluted into a fresh 1.5ml microcentrifuge tube 
by the addition of 50μl autoclaved 18MQ water followed by centrifugation for 1 min at 
9878g; this was repeated with a further 50μl of dH2O with the resulting RNA stored at -80C.   
2.15. Reverse Transcription 
In order to analyse mRNA expression, reverse transcription of extracted RNA was undertaken 
using reverse transcriptase derived from avian myeloblastosis virus (AMV, Roche).  Reverse 
transcription and PCR reactions were all undertaken in thin walled 0.2ml microcentrifuge 
tubes (Fisher).  All dH2O and equipment including blocked pipette tips (ART 10 reach, VWR) 
were subjected to UV light treatment (autocrosslink setting, UV stratalinker 2400, Statagene) 
to reduce the presence of contaminating DNA, DNase or RNase.  DNase digestion, reverse 
transcription and PCR reactions were all undertaken in a Biometra Tpersonal thermal cycler 
(Biometra), with the heated lid temperature set at 10C above the maximum reaction 
temperature. 
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2.15.1. DNase Digestion of RNA 
To remove contaminating genomic DNA from the extracted RNA a DNase digest was 
undertaken using RQ1 RNase-free DNase (Promega).  The digest was undertaken using 6μg 
of RNA mixed with 3µl of 10x RQ1 reaction buffer and 6 units of RQ1 DNase in a 30µl 
reaction.  The digestion mix was centrifuged briefly before incubating at 37ºC for 30min; 1µl 
RQ1 DNase stop solution was then added followed by a 10min incubation at 65°C.  The 
digested RNA was then stored at -80C.   
2.15.2. Reverse Transcription 
The reverse transcription reaction was undertaken on the DNase digested RNA both in the 
presence (RT+) and absence (RT-) of AMV reverse transcriptase to control for the presence 
of any remaining genomic DNA (gDNA) contamination.  To reverse transcribe, 1µg of 
digested RNA was combined with 1µl of 10x hexanucleotide mix (0.06A200U/ul, Roche) in a 
reaction volume of 13µl, with two reactions for each cell line to provide RNA for RT+ and 
RT- reactions.  The sample was then denatured at 65ºC for 10min and transferred directly to 
ice for 1min.  Two master mix solutions were then prepared: in the RT- master mix the AMV 
component was replace with an equivalent volume of dH2O.  The master mix for 8 samples 
was as follows; 4.5 µl protector RNase inhibitor (20U/reaction, Roche), 36µl AMV buffer 
(Roche), 18µl of 10mM PCR nucleotide mix (Roche), and where appropriate 4.5µl AMV 
(10U/reaction). 
 
The reverse transcription mix was prepared by combining the 13µl RNA/hexamer mix with 
7µl of the appropriate master mix solution and centrifuging briefly.  The reverse transcription 
was undertaken by heating for 10min at 25ºC, 30min at 55ºC and then immediate transfer to 
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ice.  The AMV enzyme was inactivated by heating at 95ºC for 2min, with the resulting cDNA 
stored at -20ºC. 
2.16. Polymerase Chain Reaction  
Polymerase Chain Reaction (PCR) was undertaken using template DNA from either the host, 
the viral genome (gDNA) or reverse transcribed mRNA (cDNA).  Where cDNA was used the 
PCR reaction was undertaken on both the RT+ and RT- samples, using primers for the gene 
of interest and the housekeeping gene beta-2-microglobulin (B2M) to detect DNA 
contamination in either the RT+ or RT- samples.  CaSki cell gDNA was also used in the PCR 
reactions as a positive control for the primer of interest and B2M.  
2.16.1 E2 PCR and RT-PCR 
Analysis of E2 within the viral genomic DNA was undertaken using 0.5μl of E50, E63 and 
CaSki template, and 1μl I02, I22, I31, I61 and SiHa template, while analysis of cDNA was 
undertaken using 1μl (50ng) of the reverse transcribed cDNA.  The template DNA was 
combined with 12.5μl of PCR ReadyMix containing 3mM magnesium chloride (Sigma-
Aldrich-Aldrich), 2μl of forward and reverse primers (Sigma-Aldrich, Table 2.3) in a reaction 
volume of 25μl.   
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Target Direction Primer Primer Sequence (5’-3’) Band Size Ref 
E2  
Amplimer A 
Forward A1 AGGACGAGGACAAG
GAAAA 
A1-A2 = 
476bp  
 
Graham et 
al, 2000 414 
Reverse A2 ACTTGACCCTCTACC
ACAGTTACT 
E2  
Amplimer B 
Forward B1 TTGTGAAGAAGCATC
AGTAACT 
B1-B2 = 
478bp 
B1-C2 = 
702bp 
Graham et 
al, 2000 414 
Reverse B2 TAAAGTATTAGCATC
ACCTT 
E2 
Amplimer C 
Forward C1 GTAATAGTAACACTA
CACCCATA 
C1-C2 = 
277bp 
 
Graham et 
al, 2000 414 
Reverse C2 GGATGCAGTATCAA
GATTTGTT 
E2 - 
Additional 
Reverse C3 GGACGTATTAATAG
GCAGAC 
C1-C3 = 
345bp 
B1-C3 = 
770bp 
N/A 
B2M Forward B2M1 ACTGAATTCACCCCC
ACTGA 
gDNA = 
740bp 
cDNA = 
114bp 
Zhang et al, 
2005 415 
Reverse B2M2 CCTCCATGATGCTGC
TTACA 
 
Table 2.3: Primers used for the amplification of the E2 ORF by PCR or RT-PCR including B2M 
control. B2M sizes are given for genomic (gDNA) and reverse transcribed (cDNA) templates.   
 
Amplification was undertaken using the following program:- 
1. Initial denaturation at 94ºC for 1min 
2. Denature at 94ºC for 1min  
3. Anneal at primer dependent temperature for 50s (see table 2.4) 
4. Elongate at 72ºC for 1m 30s (repeat steps 2-4 34 times) 
5. Final incubation at 72ºC for 10min 
6. Pause at 4ºC 
 
 Annealing Temp 
E2 Amplimer A 58C 
E2 Amplimer B 54C 
E2 Amplimer C 55C 
E2 Additional 58C 
B2M 54 - 58C 
Table 2.4: The annealing temperatures, agarose gel percentages and hyperladders used in the PCR 
analysis for the E2 amplimers.  For details of primers see appendix B5.  
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The PCR products were analysed by running on a 1% agarose gel with hyperladder II (for 
further details see agarose gel electrophoresis section 2.12.).   
2.16.2. E6/E7 PCR and RT-PCR 
Amplification of the E6/E7 ORF products described in Selinka et al 1998 109 was undertaken 
as described for E2 PCR using 1μl (50ng) of reverse transcribed cDNA.  
 
Target Direction Primer 
Name 
Primer Sequence 
(5’-3’) 
Band Size Ref 
E6/E7 Forward S3 ACAGTTATGCAC
AGAGCTGC 
E6/E7 = 525bp 
E6*I = 434bp 
E6*II  = 226bp 
 
Selinka 
et al, 
1998 109 Reverse S4 CTCCTCCTCTGA
GCTGTCAT 
B2M Forward B2M1 ACTGAATTCACC
CCCACTGA 
gDNA = 740bp 
cDNA = 114bp 
Zhang et 
al, 2005 
415 
 
Table 2.5:  Primers used for the amplification of the E6/E7 ORF by PCR or RT-PCR including the 
beta-2-microglobulin (B2M) control. Band sizes for B2M are given for viral genomic (gDNA) and 
reverse transcribed (cDNA) templates.   
 
The PCR was undertaken using the primers in table 2.5, combined with the program below 
and products analysed on a 1% agarose gel using hyperladder I. 
 
1. Initial denaturation 94ºC for 3min 
2. Denature at 94ºC for 1min  
3. Anneal at 55ºC temperature for 45s 
4. Elongate at 72ºC for 1min (repeat steps 2-4 29 times) 
5. Final incubation at 72ºC for 10min 
6.      Pause at 4ºC 
2.16.3. E7 RT-PCR 
Amplification of the E7 ORF products was undertaken as described for E2 PCR using 1μl of 
reverse transcribed cDNA derived from PHK transduced with E7 or E6/E7.  Primers as 
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described by Nees et al (2000) 416 are shown below (table 2.6), were annealed at 58C, with 
products analysed on 1% agarose gels alongside hyperladder II. 
 
Target Direction Primer 
Name 
Primer Sequence 
(5’-3’) 
Band Size Reference 
E7 Forward E7-1 ATGACAGCTCAG
AGGAGGAG 
E7 = 176bp 
 
Nees et al, 
2000 416 
Reverse E7-2 TCATAGTGTGCCC
ATTAACAG 
B2M Forward B2M1 ACTGAATTCACCC
CCACTGA 
gDNA = 
740bp 
cDNA = 
114bp 
Zhang et al, 
2005 415 
Reverse B2M2 CCTCCATGATGCT
GCTTACA 
 
Table 2.6: Primers used for the amplification of the E7 ORF by RT-PCR, including the B2M control. 
Band sizes for B2M are given for viral genomic (gDNA) and reverse transcribed (cDNA) templates.   
 
2.16.4 Dnp53R248W PCR 
PCR analysis was undertaken to detect the presence of the Dnp53R248W plasmid using 0.1μg 
of template from the PT67, W12, PHK, and U2OS cells containing either Dnp53 or vector 
only.  PCR was undertaken using primers shown in table 2.7 and the E2 programme (2.16.1) 
with an annealing temperature of 68C.  PCR products were analysed on 1% agarose gels 
alongside hyperladder I. 
 
 
Table 2.7 Primers used for the amplification of the Dnp53R248W by PCR from transfected cells. 
Target Direction Primer 
Name 
Primer Sequence 
(5’-3’) 
Band Size Source 
Dnp53R248W Forward pLXSN2S TTCATCTGGACCT
GGGTCTTCAGT 
467bp Androphy, 
USA 
Reverse P53A TCAAGCCCTTTGT
ACACCCTAAGC 
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2.17. Transformation and Culture of Bacteria 
2.17.1. Preparation of LB-Agar Plates  
LB-Agar was prepared by mixing Miller’s LB broth base (Luria broth base, Invitrogen) with 
1.2% (w/v) Select agar (Invitrogen) and autoclave sterilised.  When required the agar was 
melted in a microwave at medium power until completely dissolved and placed into a water 
bath to equilibrate to 50oC.  Where appropriate, ampicillin was added to plates to a final 
concentration of 50μg/ ml (stock solution of 50mg/ml).  Approximately 30ml of either plain 
agar (for control plates) or agar with ampicillin were poured into 90mm Petri dishes and left 
to set for at least 30min.    
2.17.2. Bacterial Transformation 
Bacterial transformation was undertaken using XL Ultra competent E.coli (Stratagene), stored 
at -80C.  All the plasmids (table 2.8) were resistant to ampicillin, which was used to select 
successfully transformed bacterial cells.  A non-transformed bacterial control was also 
undertaken to confirm antibiotic selection. 
 
Plasmid Use 
pEFHPV-16W12E W12 plasmid DNA 
Dnp53R248W Dominant negative p53 
pBabe-puro Vector only control  for Dnp53 
pSynp53 p53 driven firefly luciferase reporter 
pRL-CMV Renilla luciferase 
Table 2.8: Plasmids used for bacterial transformation. 
 
To transform, 2μl of beta-mercaptoethanol was added to 50μl aliquots of competent cells and 
incubated on ice for a total of 10min, stirring every 2min.  Approximately 50ng of plasmid 
DNA was then added and the mixture incubated on ice for 30min.  The bacterial cells were 
then heat-shocked at 42oC for 30 seconds and placed immediately on ice for 2min.  To the 
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heat shocked bacteria 950μl of LB broth (25g/L LB broth mix (Invitrogen) autoclave 
sterilised) was added and the samples shaken at 37oC, ~250rpm for 1h.  The samples were 
then centrifuged at 500g for 3min, approximately 800μl of the supernatant was removed and 
the pellet resuspended in the remaining ~200μl of the remaining broth.   
 
Freshly transformed or previously transformed cells (from glycerol stocks or bacterial stabs) 
were plated onto LB-agar plates containing 50μg/ml ampicillin and left to grow overnight at 
37oC to allow selection of transformed colonies. 
2.17.3. Bulk Growth of Transformed Bacterial Colonies 
Bacteria from glycerol stocks or selected agar plate colonies were grown in 3-6ml of LB broth 
containing 1μl/ml ampicillin in preparation for plasmid extraction.  Either a scraping from a 
glycerol stock or a single colony from a plate was used to inoculate the bacterial culture.  The 
bacteria were then grown overnight (~18h) at 37oC shaking at 220rpm, and the plasmid DNA 
extracted as described in section 2.17.   
2.17.4. Long Term Storage of Transformed Bacteria 
Once transformed the bacteria were stored as glycerol stocks at -80C.  Stocks were produced 
by mixing ~ 600μl of the overnight bacteria culture with 400μl of 50% (v/v) sterile glycerol in 
a 1.5ml cryotube. 
2.18. Extraction of Plasmid DNA 
Extraction of plasmid DNA from transformed bacteria was undertaken using the Plasmid 
Mini Kit (Qiagen).  The bacterial culture was transferred into a 1.5ml microcentrofuge tube 
by spinning 1.5ml aliquots at 8000g (5min), with the supernatant removed and discarded.  The 
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bacterial pellets were then resuspended in 300μl of buffer P1 and disrupted.  To this solution 
300μl of buffer P2 was added and the sample incubated for 5min at room temperature.  The 
protein was precipitated by the addition of 300μl of chilled buffer P3, mixed by inverting and 
incubated on ice for 5min.  Samples were remixed before centrifuging for 10min at 9878g.  
The resultant supernatant was transferred onto a QIAGEN-tip 20 (equilibrated in advance by 
the addition of 1ml buffer QBT) and left to empty under gravitational flow.  The column was 
washed by 4 separate 1ml additions of buffer QC, and the DNA eluted from the column into a 
clean 1.5ml microcentrifuge tube by 800μl of buffer QF.  The DNA was precipitated with 
560μl of room temperature isopropanol and collected by centrifuging at 9878g for 30min.  
The supernatant was discarded, the pellet washed in 1ml 70% ethanol and centrifuged for 
30min at 9878g.  After the ethanol was removed the DNA pellet was air dried for 5min, then 
resuspended in 50μl of autoclaved 18MQ dH2O and rehydrated at room temperature overnight 
before storage at -20C. 
2.19. p53 Reporter Assay of Dnp53R248W 
In order to confirm the DNA binding deficiency of dominant negative p53 (Dnp53R248W) a 
p53 driven luciferase reporter system was used.  The pSynp53 plasmid (kind gift from K. 
Gaston, University of Bristol)417 contains the p53 promoter upstream of the firefly luciferase 
gene and hence acts as a reporter of p53 DNA binding by the production of the 61kDa firefly 
luciferase protein.  Dual transfection with Renilla luciferase (pRL-CMV, kind gift of J. Parish, 
University of St Andrews) provided an internal control for transfection efficiency.   
2.19.1. Transfection with pSyn-53 and pRL-CMV 
For each Dnp53 transduced cell line, Dnp53, vector only, and wild type cells were seeded into 
6 wells each of a 6-well plate.  Cells were then cultured until approximately 50% confluent 
 116 
before transfection as described in section 2.7.3 (in the absence of antibiotic selection).  For 
each transduced line cells were either transiently transfected with pSynp53 and pRL-CMV 
(figure 9) or left untransfected.  After 24-48h fresh media was provided.  Subsequently half 
the transfected and untransfected cells were treated with 2nM LMB prior to harvest (table 
2.9). 
Experiment pSynp53 pRL-
CMV 
Transfection 
time 
Treatment 
Time 
Wt U2OS, 
PHK E7 
1µg 50ng 48h 12h 
Dnp53 U2OS 1µg 50ng 24h 26h 
 
Table 2.9:  Protocol details for the preparation of samples for dual luciferase assay using pSynp53 and 
pRL-CMV. 
 
2.19.2. Dual-Luciferase Reporter assay for p53 Activity  
To harvest, the medium was removed and wells rinsed with 0.5-1ml 1xPBS.  To lyse the cells, 
500µl of 1x passive lysis buffer (Promega) was added and the plate rocked at room 
temperature for approximately 15-30min.  The lysates were transferred to 1.5ml 
microcentrifuge tubes and stored at 4ºC.  Detection of luciferase activity was undertaken 
using the Dual-Luciferase reporter assay system (Promega).  The luminescence signal was 
detected using the Flurostar Optima microplate reader (BMG LABTECH), programmed with 
a 2 second pre-measurement delay and a 10 second per well measurement period.  To detect 
the firefly signal 100µl of Luciferase Assay Reagent II (LARII) was combined with 20µl of 
cell lysate in a black microtest 96-well plate (Becton and Dickinson), pipetting 3 times and 
luminescent readings taken.  The Renilla luciferase was detected by the addition of 100µl of 
1x Stop&Glo reagent (1 volume Stop&Glo substrate to 50 volumes Stop&Glo buffer) to the 
existing samples in the 96-well plate, gently vortexed and measurements repeated.  
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To assess the activation of pSynp53 the mean of the control (untransfected) wells was 
calculated and subtracted from each transfected sample for both pSynp53 and pRL-CMV 
readings giving the adjusted values for each.  To correct for variations in transfection 
efficiency the adjusted pSynp53 value was divided by the adjusted pRL-CMV to give the 
final reading.    
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Chapter 3:  The Status of HPV 16 in Cells Expressing 
Episomal and Integrated Viral Genomes 
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3.1. Introduction  
The W12 derivatives provide a useful model of the early stages of HPV 16-associated 
neoplasia.  The presence of the whole HPV 16 genome derived from a low grade lesion means 
these derivatives act as an alternative to cells expressing only selected viral genes such as the 
E7 and E6/E7 transduced PHKs, and HPV-associated cancer cell lines such as CaSki and 
SiHa.  Integration of the normally episomal genome with its subsequent effects on viral gene 
expression is thought to have important consequences for the formation of potentially 
malignant lesions and may also influence their response to LMB.  It is therefore important to 
confirm the status of the HPV 16 genome within the W12 derivatives.  As E2, E6 and E7 all 
appear to play important roles in the response to integration it is of interest to establish the 
expression of these viral genes within the cell lines studied.   
3.2. Methods 
The assessment of HPV integration in the W12 derivatives was undertaken by Southern blot 
analysis using 32P labelled HPV DNA probe as described in section 2.9.  E2 protein 
expression was detected via SDS-PAGE in combination with Western blot analysis as 
described in section 2.12, with the status of the E2 and E6/E7 genes assessed using 
polymerase chain reaction (PCR, section 2.16) on genomic DNA or reverse transcribed 
cDNA, as described in sections 2.14-2.16. 
 120 
3.3. Results 
3.3.1. Analysis of the Physical State of HPV 16 in the W12 Derivatives 
Southern blot analysis of the episomal W12 derivatives E50 and E63, in combination with 
representatives of type 1 (I22) and type 2 integration (I31), was undertaken to confirm the 
physical status of the HPV genome (figure 3.1).  Predominantly episomal viral genomes 
within the uncut episomal W12 derivatives were indicated by the presence of high levels of 
both the open circular and supercoiled forms of HPV 16 DNA 418.  The presence of episomes 
was confirmed by the production of a 7.9kb band after BamHI digestion 131, consistent with 
linearisation of the viral genomes by cutting at a single site within the HPV genome (nt 6150 
in HPV 16 129).  However, the E63 derivative did show the presence of some remnant 
supercoiled DNA after BamHI treatment.  This may represent incomplete digestion or the 
presence of some integrated HPV sequences within these cells.  If this band represents the 
presence of integrated sequences, this may provide a possible explanation for the presence of 
higher E7 protein levels in E63 (0.12) than in E50 (0.017) as reported by Jeon et al (1995)
119.  
The E50 and E63 viral genomes appear largely insensitive to digestion with HindIII.  The 
restriction sites of this enzyme are known to be present within host human DNA but absent 
from the HPV genome; therefore the episomal derivatives are negative for the host-virus 
hybrid sequences associated with integration.  A slight downwards shift was present within 
both the episomal derivatives compared with the undigested samples; however, this band 
alteration was notably less than that present within the HindIII digested integrated derivatives.  
This shift within the episomal lines is possibly to be due differences in the salt concentration 
between the digested and undigested samples, with changes in salt concentrations associated 
with the buffers required for HindIII digestion.   
 
 121 
 
 
Figure 3.1:  Southern blot analysis of the genome status of W12 derivatives.  DNA from W12 
derivatives E50, E63, I22 and I31 was Hirt extracted and run as either undigested (U), BamH1 digested 
(B) or HindIII digested (H).  HPV 16 plasmid DNA (pEFHPV-16W12E) either BamH1 or HindIII 
digested were utilised as a control marker (Plasmid).  (a) Extracts from the episomal W12 derivatives 
and plasmid control (3 day exposure), and (b) extracts containing integrated viral genomes (6 day 
exposure).  The positions of open-circular (OC), supercoiled (SC) and linear (L) forms of HPV 16 
DNA are indicated on the left of the figure.   
 
Hirt extraction was used to enrich samples for low molecular weight DNA including the 
episomal viral genomes.  As a consequence the integrated HPV genomes present in I22 and I31 
were more difficult to detect during this procedure, therefore longer exposure times were 
required (6 days instead of 3 days) as shown in figure 3.1b.  Neither representative integrated 
derivative displayed open-coiled HPV DNA in the undigested samples.  Full-length HPV 
sequences were not identified in I22 after BamHI digestion, consistent with the presence of the 
single copy type 1 integration of HPV 16 (section 1.6.3).  As previously noted by Jeon et al 
(1995) 119, full-length HPV genomes were present in I31 DNA after BamHI digestion, 
indicating the presence of type 2 integrated HPV containing multiple full length viral 
genomes (section 1.6.3.2).  Digestion with HindIII led to a downwards shift in band size 
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indicating the presence of host-virus junction fragments in both integrated lines, although the 
effect was most visible in I31. 
3.3.2. The Status of HPV 16 E2 in the W12 Derivatives  
During the integration of the HPV genome the normally episomal DNA must be linearised at 
some point in its sequence.  This process often involves the disruption of the E2 ORF, with 
wide spread consequences for both the virus and host 414, and subsequently any model of HPV 
infection.   
3.3.2.1. The Status and Transcription of the E2 ORF  
 
 
 
Figure 3.2:  A schematic overview of the distribution of the E2 amplimers A, B and C across the E2 
ORF.  The initial nucleotide (nt) of each primer is shown along with its respective PCR product and 
size. 
 
 
The E2 ORF was amplified in three overlapping fragments (amplimers A, B and C) as 
published by Graham and Herrington (2000) 414 from either genomic DNA (gDNA) or reverse 
transcribed cDNA (figure 3.2).  When a cDNA template was used the housekeeping gene 
beta-2-microglobulin (B2M) was also included as a control for genomic DNA contamination.  
B2M is a constitutively expressed cellular protein utilised as a control during RT-PCR.  As 
the B2M primers span an intron, any contaminating gDNA should be indicated by the 
presence of a 740bp band in addition to the 114bp cDNA product.  Therefore, B2M PCR 
analysis of cDNA provides a dual control, confirming the presence of a suitable quality cDNA 
template and also detecting gDNA contamination.   
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Figure 3.3:  The status of E2 within the W12 derivatives and control lines CaSki and SiHa.  (a) The 
amplification of the E2 ORF from genomic DNA.  (b) The E2 ORF expression from mRNA in the 
presence (+) or absence (-) of reverse transcription.  The lower panel of each set displays the results of 
B2M PCR, with the higher band present in lane D showing the result of B2M amplification from 
genomic DNA.  Hyperladder II was used as a DNA ladder in the above gels. 
 
 
As previously shown by Graham and Herrington (2000) 414, the CaSki cell line displayed the 
presence of the complete E2 ORF by DNA PCR, whist only the C-terminal amplimer was 
present within the SiHa cell line (figure 3.3a).  The E50 and E63 W12 derivatives were found to 
encode and transcribe all three amplimer regions after PCR and RT-PCR analysis (figure 3.3a 
(a) 
  (b) 
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and b), representing the complete E2 ORF.  The status and transcription of the E2 ORF varied 
between the integrated derivatives, broadly defined by integration type.  Both the type 1 
integrated derivatives I02 and I22 showed an absence of amplimer region C in both genomic 
and cDNA templates, with the I02 cell line also found to be deficient in amplimer B.  Cells 
containing type 2 integrated HPV (I31 and I61) appeared to contain amplifiable sequences from 
all three of the PCR regions of E2 ORF, although both DNA and mRNA analysis indicated a 
notable reduction in the level of amplimer C.  The detection of the C-terminal region in I31 
and I61 appeared to be temperature dependent; at 58ºC strong signals were detected in the 
episomal derivatives and control lines, but signals were barely visible in I31 and I61.  By 
decreasing the annealing temp to 55ºC, band intensity was increased in the type 2 cells, but 
remained notably lower than the episomal and control lines.  This annealing temperature 
sensitive response may indicate the presence of small alterations in sequence either within the 
actual primer binding site or in the immediate area, leading to a reduction in the efficiency of 
primer binding.   
 
 
Figure 3.4:  Variations in E2 amplimer C detection from viral genomic DNA using different primer 
combinations.  The PCR using the original amplimer C primer combination (C1-C2 414) is shown in 
the upper panel, with the effects of replacing the reverse primer with C3 shown in the lower panel. 
Hyperladder II was used in to determine band size in both gels. 
 
 
To investigate the possible source of the variation in amplimer C, a primer was designed 46bp 
downstream of C2 (primer C3, see 2.16.1) to determine if any possible mutations were located 
within the region of the C2 primer.  As shown in figure 3.4, the alteration in primer location 
had little apparent effect on the expression of the I31 derivative, although I61 and SiHa both 
appeared to show slight increases in expression of the extended amplimer C. 
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Figure 3.5:  Variations in E2 amplimer B/C region detection from viral genomic DNA with different 
primer combinations.  PCR results using the original amplimer B primer combination (B1-B2 414) are 
shown in the upper panel, in the lower panel the reverse primer B2 was replace with primer C2.  
Hyperladder II was used to determine band size. 
 
 
The expression of the C1-C3 product suggested that sequence alterations away from the C2 
primer location may also contribute to the lowered expression of amplimer C.  When the 
upstream B1 primer was combined with C2 some rescue of the I61 expression in comparison 
to C1-C2 levels was again seen; however, little change in I31 was apparent (figure 3.5).  These 
experiments also showed that in the presence of the B1-C2 primer combination little or no 
expression could be detected in I22 and SiHa representing a loss of the normally expressed 
amplimers B and C respectively.   
3.3.2.2. E2 Protein Expression 
E2 protein expression in cell lines such as the transfected U2OS clones can be easily detected 
using the TGV261 E2 antibody.  These cell lines are based on vectors containing promoters 
such CMV in U2OS E2, and are associated with high levels of protein expression with greater 
ease of detection.  However, as the W12 cells are derived from a naturally infected lesion and 
express relatively low in vivo levels of HPV 16 E2, detection from whole cell lysates has 
proven difficult.  Attempts during these studies to detect E2 using the standard western 
blotting technique proved unsuccessful; although E2 expression was detected in the positive 
control transfected U2OS cells.  In addition to the problems associated with low E2 
expression, the W12 derivatives also displayed a non-specific band in the region of 47kDa, 
making identification of low level E2 expression problematic.  In order to successfully detect 
E2 several alterations the standard protocol were required as described in section 2.12.7.3.  To 
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provide maximum E2 expression W12 cells were harvested when highly subconfluent; this 
ensured that these cells were rapidly growing.  Reduced growth associated with greater 
confluence may lead to a decrease in E2 expression due to reduced requirement for E2-
mediated regulation of E6/E7.  The levels of available E2 were further raised by the use of 
increased amounts of W12 lysate (increased from 20 to 70µg), the utilisation of a higher 
sensitivity chemiluminescent detection system, and a highly reflective surface during signal 
detection.  In addition, protein separation was undertaken on an 8% midi SDS-PAGE gel 
allowing greater resolution within the 32-47kDa range, providing maximum distance between 
E2 and the non-specific band.  The above alterations to the standard protocol allowed the 
detection of E2 protein from whole cell lysates of the W12 derivatives, as shown in figure 3.6.   
 
 
 
Figure 3.6:  The expression of the E2 protein in the W12 derivatives and U2OS cells transfected with 
HPV 16 E2 or pCMV4 (U2OS Vec). 
 
 
As predicted, E2 protein expression was confined to those W12 derivatives containing 
episomal HPV genomes, with no detectable protein expression in those with type 1 or type 2 
integration (figure 3.6).  However, even within the episomal lines expressing the E2 protein, 
the levels detected were particularly low. 
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3.3.3. Analysis of the HPV 16 E7 and E6/E7 Status of the Transduced 
Primary Human Keratinocytes 
Primary human keratinocytes were transduced with HPV 16 E7 or E6/E7 and utilised to 
optimise the detection of the E6/E7 PCR and confirm the status of these cells.  cDNA from 
the cultured cells was subjected to RT-PCR was undertaken using E7 and E6/E7 specific 
primers. The E6 and E7 genes are transcribed as a single mRNA transcript with differential 
splicing leading to three main products, the unspliced full length E6/E7 (525bp), and two 
major splice products E6*I (343bp) and E6*II (226bp).   
 
 
 
Figure 3.7:  RT-PCR for E7 (upper panel) and E6/E7 (lower panel) using cDNA from E7 or E6/E7 
transduced cell or wild type (wt) PHKs.  Reverse transcription was undertaken in the presence (+) and 
absence (-) of reverse transcriptase, in the absence of template (0) and using CaSki gDNA (D) as a 
positive control.  Amplification of the house keeping control B2M was undertaken concurrently on all 
samples. 
 
 
In both E7 and E6/E7 RT-PCR no expression of the HPV oncogenes was detected in the wild 
type PHK, whilst both were present in some form in the CaSki DNA control (figure 3.7).  
HPV E7 alone was found to be present in cDNA derived from the both the E7 and E6/E7 
transduced PHKs.  E6/E7 transcripts were detected only within the appropriately transduced 
E6/E7 PHKs.  In the E6/E7 transduced cells all three mRNA splice products were detected, 
with only the unspliced full length 525bp band present within the genomic CaSki DNA.  The 
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full length E6/E7 and the E6*I splice products appeared to be equally represented within the 
mRNA, with the lower E6*II splice transcript notably less abundant. 
3.3.4. Transcription of HPV 16 E6/E7 in the W12 Derivatives 
 
 
 
Figure 3.8:  The expression of E6/E7 in the W12 derivatives which displayed the three splice variants 
E6/E7, E6*I and E6*II.  The RT-PCR was undertaken in the presence (+) or absence (-) of reverse 
transcription in the W12 derivatives, CaSki (C) and SiHa (S), with CaSki gDNA control (D).  B2M 
amplification from all samples is shown in the lower panel, with Hyperladder II used throughout.    
 
 
All three E6/E7 splice products were identified in the cDNA derived from W12 derivatives 
and the cancer cell lines CaSki and SiHa, but as expected only full length E6/E7 detected in 
CaSki gDNA (figure 3.8).  Interestingly the full length E6/E7 appears to be expressed in the 
form a doublet which can also be seen in E6/E7 RT-PCR undertaken by Tang et al (2006) 106.  
As the upper band appear consistent with that amplified from the CaSki DNA control, the 
smaller PCR product may represent an alternative splice variant of the full length E6/E7 
whose function remains unclear.  Differences in the expression of the three transcripts were 
apparent within and between cell lines studied.  In both the W12 derivatives and cancer cell 
lines E6*I was the dominant form, with the full length E6/E7 transcripts showing both the 
lowest overall levels and the majority of the intercellular variation.  Lower full length E6/E7 
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transcript expression was detected in E63, I22 and I61, with particularly low levels in I61 
derivative confirming previous observations by Doorbar et al (1990) 419. 
3.4. Discussion 
To provide a suitable model for the study of early HPV 16 associated neoplasia and the 
changes associated with integration, it is important to confirm the integration status of the 
W12 derivatives as proposed by Jeon et al (1995) 119 and functionality of the E2, E6 and E7 
genes.  Integration of the normally episomal HPV genome requires the linearisation which 
predominantly occurs within the E2 ORF 414.  This leads to a loss of E2 function with 
consequences for regulation of the oncogenic E6 and E7 genes and increased propensity for 
malignant progression.  The aim of these studies was to confirm the status of the HPV 16 
genome and the viral E2, E6 and E7 genes in the W12 derivatives and transduced primary 
cells (PHKs).  
 
The episomal or integrated status of the W12 derivatives was confirmed directly via Southern 
blot analysis and indirectly by the status of the E2 ORF and its protein expression.  Within the 
E50 and E63 derivatives the presence of the indicative open-circular, supercoiled and linear 
forms of the HPV 16 genome after Southern analysis, in combination with the presence of the 
translated E2 ORF, confirmed the presence of predominately episomal genomes.  The 
reportedly integrated W12 derivatives lacked open-circular viral genomes indicative of 
episomal HPV and no E2 protein expression could be identified, consistent with their 
integrated status.  Those cells containing type 1 integrated HPV 16 failed to display linearised 
HPV after to BamHI digestion and also exhibited greater disruption to the E2 ORF, consistent 
with single copy integration.  As previously reported by Jeon et al (1995) 119 the genome 
status of the type 2 integrated W12 derivatives I31 and I61 was complicated by the presence of 
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tandem repeats of the HPV 16 genome.  However, BamHI and HindIII digestion produced 
band shifts suggestive of the presence of full-length genomes in addition to host-virus 
junctions.  This complex integrated status was further confirmed by the presence and apparent 
transcription of all three fragments of E2 ORF in both I31 and I61.   
 
Variation in the disruption of the E2 ORF was found within the integrated W12 derivatives 
suggesting that even within integration types there remain considerable differences in the site 
of integration and the amount of disruption caused.  There appears to be a preference in the 
type 1 integrated cells for integration within the central or C-terminal regions of the E2 ORF, 
with the C-terminal region disrupted in both lines.  The I22 derivative showed an absence of 
the C fragment only (nt 3597-3873), consistent with the published integration site of nt 3732 
119.  However, the I02 derivative displayed more prominent disruption, with integration 
appearing to have affected both the central and C-terminal regions (nt 3172-3873) as 
illustrated by the absence of amplimers B and C.  The majority of the W12 derivatives were 
cloned from parental cells at passage 14/15, but I02 was derived from a later passage 17 of the 
parental line which may contribute to the greater level of damage detected within these cells.  
Jeon et al (1995) 119 have suggested that this I02 derivative may contain sequences from an 
additional integration event.  This may explain the disruption detected in both the central and 
C–terminal regions of the sequence, and provide a mechanism for the reported dominance of 
this integration pattern in high passage cultures of the parental cell line 119.   
 
Previous attempts by Jeon et al (1995) 119 failed to map the integration site within the type 2 
integrated W12 derivatives due to the presence of concatemers of HPV 16, although S1 
nuclease analysis did suggest integration within the E2 ORF.  In the current study all three E2 
DNA PCR products were amplifiable from the type 2 W12 derivatives I31 and I61, but no 
protein was detectable; this suggests that the integration-associated linearisation is unlikely to 
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have occurred at a common site within the tandemly repeated viral genomes as all three 
regions were detected.  This suggests that integration is likely to have occurred in different 
regions within the constituent concatemers.  However, the notably reduced band intensity 
present with amplimer C may represent a possible predominance for disruption of E2 within 
the C-terminal region in the tandem repeats contained within both I31 and I61, although in 
some cases this region must remain intact.  Cleavage is therefore also likely to have occurred 
in alternative locations either within the E2 ORF or at different points within the HPV 
genome.  The inability to rescue amplimer C expression in the I31 derivative by altering the 
primer location may indicate the presence of more severe C-terminal disruption within this 
cell line.  It is possible the detection of all three E2 amplimers within the type 2 integrated 
cells could represent amplification from intact ORFs.  However, the absence of E2 protein 
expression in these type 2 cells suggests the transcription of an intact E2 ORF is unlikely.  
The templates could also be derived from a pool of integrated genomes disrupted at different 
points within the E2 ORF.  This may account for the E2 expression patterns shown in I31 and 
I61.  It is therefore possible that E2 DNA and mRNA templates in the type 2 integrated W12 
cells could originate from more than one viral concatemer.  However, Van Tine et al (2004) 30 
have suggested that only those viral genomes located at the host junction are transcriptionally 
active with the majority of the remaining viral DNA being silenced.  Therefore, the mRNA 
templates should be derived only from these viral-host junction sequences; however, the 
source of the mRNA templates could no be confirmed during studies.  If only host junction 
sequences are utilised then the host junction genomes of the different concatemers must be 
derived from episomes cleaved in different regions of the E2 ORF in order to allow 
transcription from all three amplimer regions.   
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The successful detection of E7 and E6/E7 transcripts in the appropriately transduced primary 
cells confirmed the presence of these HPV oncogenes, allowing the function of these genes 
alone to be examined.  Both of the E6 and E7 genes have been shown to be transcribed from a 
single promoter and subsequently subjected to post-transcriptional splicing producing three 
distinctive products E6/E7, E6*I and E6*II as discussed in section 1.1.7.  The RT-PCR 
analysis performed during these studies confirmed that all three splice variants were 
expressed in the W12 derivatives.  An unequal distribution of the splice transcripts was 
identified in the W12s,  although as previously reported the E6*I variant formed the dominant 
PCR product 106,109.  The function of this dominant product is unclear.  It has been proposed to 
encode the E7 protein, to decrease E6 protein levels, or to inhibit the interaction of E6 and E6-
AP 103.  When the E6/E7 RT-PCR data are compared to the published E7 protein levels of the 
W12 derivatives it appears that lower levels of the full length E6/E7 transcript may be 
associated with higher levels of E7 expression in the I22 (1.1AU), I61 (1.3AU) and CaSki 
(1AU) 119, suggesting that splicing of the full length E6/E7 transcript may be required for the 
translation of the E7 protein 103.  Although no evidence for increased E6*I expression between 
the cell lines could be established during this study, possible raised E7 protein expression may 
still be obtained via translation of this spliced transcript 420.   
The E6/E7 transduced PHKs expressed all three splice variants, although the proportions of 
each differed from those seen in the naturally infected W12 and cancer cell lines, with the 
proportion of full length E6/E7 much higher in the transduced cells.  This suggests that the 
splicing of the E6/E7 transcript is innate to the mRNA sequence, with the cellular machinery 
utilised to cleave the transcript at encoded splice sites.  However, the difference in the splicing 
pattern between the naturally infected and transduced cells suggests that other viral 
components, absent from the transduced PHKs, may play a role in the fine tuning of the 
splicing process.  Splicing is undertaken within the spliceosome, this complex is composed of 
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a number of small nuclear ribonucleoprotein particles (snRNPs), with recruitment of these 
splicing factors controlled by the serine/arginine (SR) protein family 421 including SF2/ASF 
(Splicing Factor 2/Alternative Splicing Factor) 422.  Differential phosphorylation of these SR 
proteins has been shown to facilitate the alternative splicing of mRNA transcripts (reviewed 
by 423).  McPhillips et al (2004) 421 have suggested that the alternative splicing of the late viral 
transcripts is achieved by regulation of the splicing factor SF2/ASF, and that this is at least in 
part due to the action of HPV E2 421.  However, as the integrated cell lines lack HPV E2 
protein expression, the variable splicing of the E6/E7 transcript displayed by these lines must 
be regulated by alternative viral proteins expressed by both episomal and integrated HPV.     
 
These studies suggest that the W12 derivatives provide a good model for cells containing both 
episomal and integrated HPV 16.  The presence of E2 within the episomal derivatives should 
allow these cells to maintain tight transcriptional regulation of E6 and E7, minimising viral 
interference with cellular factors such as p53 and pRb.  The loss of E2 in the integrated lines 
is likely to be associated with an increase in E6 and E7 expression within the cells as 
suggested in the previously published proteins levels 119,403.  The greater influence of E6 and 
E7 in the integrated cells is likely to increase their exposure to the potentially harmful 
activities of these oncoproteins, particularly via their interactions with cellular p53 and pRb.  
The apoptotic response in these integrated cells is reduced by two separate integration related 
effects; firstly a rise in E6/E7 leads to increased anti-apoptotic and decreased pro-apoptotic 
signalling, preventing cell-directed apoptosis.  In addition, an anti-apoptotic effect may also 
be achieved directly via the loss of E2-mediated induction of apoptosis, which is known to 
occur in the upper suprabasal layers of the epithelium (section 1.6.5.2).  The effects of 
differential E2, E6 and E7 expression in the W12 derivatives in the context of the whole viral 
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genome may alter the manner in which these cells respond to treatment with pro-apoptotic 
agents such as LMB. 
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Chapter 4: Alterations in Morphology and Colony 
Survival in Response to Leptomycin B 
 136 
4.1. Introduction 
Leptomycin B has previously been shown in our laboratory to induce apoptosis in primary 
human keratinocytes transduced with HPV 16 E6, E7 and E6/E7, but not normal wild type 
PHK cells 374.  The most pronounced apoptotic affect was seen in the presence of the E7 gene 
alone, with the inclusion of E6 appearing to attenuate the LMB response.  The aim of the 
studies presented here were to test the hypothesis that the presence of the entire HPV 16 
genome affects the sensitivity of a cell to LMB and that any integration of the normally 
episomal HPV genome will further influence this response.  The treatment of episomal, type 1 
(single copy) and type 2 (tandem repeat) integrated cells allowed the effect of genome status 
on LMB sensitivity to be assessed in cells that reflect the early pre-malignant changes that are 
thought to occur during the development of cervical neoplasia.  In order to test this hypothesis 
the W12 derivatives were monitored for changes in morphology and colony forming 
behaviour in response to LMB, allowing the immediate and the post-treatment effects to be 
assessed in the context of HPV-associated cell lines.  As HPV gene expression is known to 
alter during the progression of cells through the epithelium (section 1.1.2), organotypic raft 
culture was used to assess the effects of differential viral gene expression and cell 
differentiation on LMB sensitivity.   
4.2. Methods 
Cultured cells were treated with LMB as summarised in section 2.3.  The morphological 
effects of LMB were investigated in both monolayer (section 2.5) and rafted (section 2.6) 
cells.  The effect of treatment on colony forming ability was also investigated as described in 
section 2.11. 
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4.3. Results 
4.3.1. Morphological Effects of LMB on W12 Derivatives in Monolayer 
When cultured in monolayer the W12 derivatives demonstrated the typical keratinocyte 
morphology and tightly packed cell clusters (upper panel figure 4.1). 
 
 
Figure 4.1:  Phase contrast images (x200 magnification) of the W12 derivatives treated with 2nM 
LMB (40h) (lower panel) and time matched controls (upper panel) displaying the morphological 
changes associated with LMB treatment. 
 
After incubation with 2nM LMB (40h), treated cultures and time matched controls were 
examined by phase contrast microscopy (x200 magnification).  Analysis indicated that a 
notable loss of cells had been induced by LMB in all the cell lines, most likely due to the 
induction of apoptosis (lower panel figure 4.1).  After treatment all cultures appeared to 
display typical apoptotic morphology in combination with a large increase in the numbers of 
detached cells and cellular debris. 
4.3.2. Morphological Effects of LMB on W12 Organotypic Raft Culture  
Organotypic raft culture provides an in vitro model that closely resembles the structure of 
human skin, allowing an assessment of the effect of LMB treatment on HPV 16 infected cells 
within a differentiating epithelium-like structure.  This technique has previously been 
undertaken using PHKs transduced with HPV 16 E7, E6, and E6/E7 treated with 50nM LMB 
over 72h 374.  This treatment regime was sufficient to induce apoptosis in raft cultures 
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expressing E7 and E6/E7 374.  In the current study the W12 derivatives E63 and I22 were 
treated with 50nM LMB (72h) to assess the effects on rafted cells containing the complete 
episomal or integrated HPV 16 genome.   
 
 
 
Figure 4.2:  E63 and I22 organotypic raft cultures treated with 50nM LMB for 72h (lower panel) and 
time matched controls (upper panel), stained with haematoxylin and eosin (x200 magnification).   
 
In the absence of LMB the W12 derivatives displayed distinct differences in their raft 
structure, as can be seen in figure 4.2 (upper panel).  The episomal line produced a thick raft 
with a disorganised structure containing a low number of vacuoles throughout the suprabasal 
layers.  The E63 raft also showed signs of differentiation indicated by the presence of 
keratinised cells within the upper layers of the raft.  The type 1 integrated I22 derivative 
produced a raft that was notably thinner and displayed an overall more organised stratified 
structure with an ordered basal layer, a notably reduced number of vacuoles, and the presence 
of keratinised cells.   
 
The addition of 50nM LMB (72h) to the media beneath the rafts led to structural and cellular 
changes in both the E63 and I22 epithelia, as shown in figure 4.2 (lower panel).  The E63 rafts 
treated with LMB showed a decrease in overall thickness and in places an almost total 
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absence of an epithelial structure, with only apparently keratinised cells remaining in some 
regions.  Treatment led to an almost total loss of cells in the lowest layers of the raft, 
representing the basal and immediately suprabasal regions.  LMB-associated disruption was 
also present in the mid and upper regions of the E63 epithelium, with the vacuolated areas 
noted in the untreated raft increasing in size and number after treatment.  In response to LMB 
the I22 derivatives also showed a notable loss of cells, although they did not show the same 
magnitude of cell loss, particularly in the middle and upper regions of the epithelium.  
Nevertheless, the integrated derivative did display the formation of vacuoles and an increased 
loss of the lowest cell layers leading to a thinning of the raft structure.  The extent of these 
changes in the I22 raft was considerably lower when compared with the LMB treated E63 
derivative.  
4.3.3. LMB Affects the Colony Formation of Cells Containing HPV 16  
The ability of cells to form colonies after increasing doses of LMB was assessed using a 
colony survival assay.  In order to gain a broader view of the effectiveness of LMB in a range 
of HPV related lines, survival was assessed in both the E63 and I22 cell lines, PHK transduced 
with HPV 16 E7 and the integrated HPV 16 containing cancer cells lines CaSki and SiHa.     
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Figure 4.3:  The colony forming ability of E63, I22, PHKs transduced with HPV 16 E7 (PHK E7), 
CaSki and SiHa cell lines after treatment with 2nM, 20nM, 50nM or 100nM LMB (40h). Results are 
displayed as the percentage of colonies formed after treatment with LMB, normalised against colonies 
formed from untreated cells (0h).   
 
In all the cell lines, the levels of post-treatment survival decreased in response to increasing 
doses of LMB (40h), as shown in figure 4.3.  However, the extent of this response varied 
considerably between the cell lines.  The E7-transduced PHKs showed the highest survival of 
any cell line after 2nM treatment, but no colony formation was apparent at greater LMB 
concentrations.  Both episomal and integrated W12 derivatives displayed reduced colony-
forming ability in response to LMB treatment, with greater recovery seen with I22 cells than 
with E63 at a concentration of 2nM, suggesting a greater sensitivity of the episomal line to 
LMB.  At concentrations of LMB greater than 2nM neither W12 derivative was found to form 
colonies.  These patterns confirmed initial colony survival experiments with the E63 and I22 
derivatives.   
 
The HPV 16 infected cancer cell lines displayed differences in their colony formation at 2nM, 
with the level of survival in the type 2 integrated CaSki line only exceeded by the E7 
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transduced primary cells (figure 4.3).  The type 1 integrated SiHa line displayed the lowest 
overall colony formation of any of the experimental cell lines at 2nM LMB.  Only the cancer 
cell lines successfully formed colonies at LMB concentrations greater than 2nM, displaying a 
gradual decrease in colony formation with increasing doses of LMB.  As shown in figure 4.3, 
the decrease in colony formation of the CaSki cell line in response to increasing LMB was 
more dramatic than that displayed by SiHa, although colony formation by CaSki cells 
remained higher than that with SiHa cells. 
4.3.3.1. The Effect of LMB on Colony Size 
Treatment of the cells with increasing doses of LMB caused a decrease in colony number.  
However, high levels of colony formation by the E7 transduced lines and the integrated 
derivative were unexpected due to the elevated LMB induced apoptosis previously seen in the 
E7 expressing cells 374 and the predicted sensitivity of the integrated W12 derivative.  
Therefore the colony size of the post-treatment colonies was also investigated to assess for 
any alternative long-term effects of LMB treatment. 
 
The size of colonies in the untreated cell lines varied considerably.  The smallest colonies 
were found with the episomal W12 derivative which formed colonies approximately 50% 
smaller than the type 1 integrated I22 and SiHa cells.  The type 2 integrated CaSki cancer cell 
line and the E7 transduced PHKs formed notably larger colonies than the other cell lines 
(figure 4.4).   
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Figure 4.4:  The variations in the size of colonies formed by E63, I22, PHKs transduced with HPV E7 
(PHK E7), CaSki and SiHa cell lines after treatment with 2nM, 20nM, 50nM or 100nM LMB (40h). 
Results are displayed as the mean colony size in mm2.   
 
 
Treatment with 2nM LMB had little effect on colony size in most of the experimental cell 
lines, with the exception of E7-expressing PHKs where treatment led to a substantial increase 
in colony size (figure 4.4).  In the cancer cell lines the colonies formed by SiHa were smaller 
than those of CaSki cultures, with SiHa colonies displaying little change in size with 
increased LMB dose.  The CaSki colonies did show a gradual decrease in size with increasing 
dose although, with the exception of 100nM LMB, the CaSki colonies remained larger than 
those produced by the SiHa (figure 4.4). 
4.4. Discussion 
Previous data have shown that LMB induces apoptosis in primary human keratinocytes 
expressing HPV 16 E7 or E6/E7 genes, but not in normal keratinocytes 374.  However, the 
presence of the complete episomal or integrated viral genome may have a significant impact 
on the cells response.  Treatment with LMB led to distinct morphological changes in both 
monolayer and rafted W12 cultures, in addition to alternations in their colony forming 
behaviour.  This suggests that cells containing the whole HPV genome in either episomal or 
integrated form are sensitive to LMB treatment.  The LMB-induced loss of cells witnessed in 
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both monolayer and rafted cultures is likely to have occurred via the activation of apoptotic 
pathways, as has previously been reported in the HPV transduced PHKs 374. 
 
When rafted, the epithelium formed by the episomal and integrated W12 derivatives showed 
distinct variations in structure.  Those formed by E63 appeared to show a more substantial yet 
disorganised structure, whilst I22 displayed a thinner yet more normal epithelium.  A similar 
presence of a more organised basal layer and stratification within the integrated W12 raft has 
previously been observed in I61 derivatives grown in raft culture by Aasen et al (2003) 
51.  As 
I61 contains type 2 instead of the type 1 integration found in I22, these features may reflect 
general effects of HPV integration, rather than an influence of specific type 1 or 2 integration.   
 
Within the episomal rafts the LMB-associated damage displayed a greater propensity to 
migrate up the epithelium than was present with the integrated derivative.  These differences 
in the pattern of LMB response may reflect the changes in behaviour associated with HPV 
integration or the clonal nature of the W12 derivatives.  Those cells containing the HPV 
genome in its normal episomal form should maintain typical differentiation-dependent 
expression of the viral genes (section 1.1.2).  As keratinocytes move up the epithelium and 
begin to differentiate an increasing amount of viral interference is required to maintain a 
replication competent environment for the virus.  Integration of HPV is associated with loss of 
this tight relationship through alterations in viral behaviour and loss of viral genes, 
particularly E1/E2.  It is therefore likely that the effects exerted by the virus as the cells move 
up the epithelium will vary between the E63 and I22 rafts; potentially altering the response of 
these cells to LMB.  In particular the episomal raft should maintain the virally derived pro-
apoptotic mechanisms controlled partly by E2 and E4 (section 1.5.5.2) 332,342.  These systems 
function as part of the normal viral life cycle, but the viral pro-apoptotic pathways may also 
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assist the induction of apoptosis within the episomal rafts in response to LMB, particularly in 
the upper layers of the epithelium where virally induced apoptosis is thought to normally aid 
virion release.  
 
The most notable loss of cells from the rafted cultures occurred within the lower regions of 
the structure, which represent the basal layer of the epithelium.  As these cells form the most 
actively dividing layer of the epithelium, the interruption of nuclear export may lead to a 
greater amount of cellular disruption in this particular location than in other regions of the 
epithelium.  Previous research on rafted PHKs containing the empty LXSN vector showed 
that LMB had little effect on this basal layer in normal cells 374, with the addition of E7 and 
E6/E7 to the PHKs leading to the initiation of apoptosis.  These results combined with the 
current data from rafted W12 derivatives suggest that this preferential loss of cells from the 
basal epithelium is not solely due to an innate property of this region, but additional factors 
such as the presence of HPV are required to initiate cell loss.  Also as this basal layer effect 
was present with both episomal and integrated genomes, it appears that this aspect of the 
response may be independent of genome status.   
 
The formation of colonies after LMB treatment was found to decrease in all the cell lines 
studied, illustrating that LMB has long term effects on the survival of HPV-associated cells.  
The effect of treatment appeared to be more dramatic in the episomal E63 derivative which 
displayed lower colony formation than the type 1 integrated I22 suggesting a possible role for 
integration in colony survival.  The levels of E6 and E7 may influence the colony survival 
response to LMB.  The reportedly greater E6 protein expression in the I22 derivative compared 
with E63 
403 may act to sufficiently attenuate the p53 response allowing cells to escape LMB-
induced apoptosis.  The expression of E7 has been associated with greater LMB-induced 
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apoptosis in previous studies 374, but despite the elevated E7 protein expression within the 
transduced cells and the majority of the integrated derivatives 119 the levels of LMB-
associated colony survival remained greater in I22 than E63.  The decrease in survival in the 
W12 derivatives compared with the E7 transduced PHKs may be due to the presence of the 
remaining components of the HPV genome particularly the E6 protein.  This may support the 
view that in the presence of LMB the influence of E7 is attenuated by the apparently 
dominant E6 leading to increased survival.  
 
Although CaSki and SiHa cells both contain integrated HPV 16 their malignant backgrounds 
are likely to have contributed to their greater survival at the higher concentrations of LMB.  
Those cells surviving at high doses may originate from a pre-existing sub-population of cells 
whose formation may have been assisted by the presence of integrated HPV and/or other 
additional cellular mutations.  The differences in the level of colony formation and colony 
size between CaSki and SiHa may relate to the different type of HPV integration present in 
each (SiHa type 1 and CaSki type 2) or may be a function of the additional mutations they 
contain.  The less dramatic changes in both number and size of SiHa colonies in response to 
LMB suggest that these cells contain notably different modifications to those contained in the 
CaSki cell line causing enhanced post-treatment survival.  When compared with behaviour of 
the integrated W12 derivative (I22) it appears that the presence of type 1 integrated HPV alone 
is insufficient to overcome the effects of LMB, and the additional cellular changes present in 
the cancer cell lines facilitate an increase in the resistance to LMB treatment.   
 
During malignant conversion of HPV infected cells it has been proposed that E6 and E7 exert 
their strongest effects during different phases of the process.  E7 primarily functions during 
the initial stages causing the formation of benign lesions, whilst E6 acts more prominently 
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during the conversion to malignancy 28 (section 1.1.8).  A similar pattern of differential E6 
and E7 behaviour may play a role in the response of HPV infected cells to treatment with 
LMB.  Previous data have suggested that E7 transduction sensitises cells to LMB induced 
apoptosis, with the effect attenuated by the presence of E6 possibly via its interaction with 
p53 and absent from wild type cells 374.  The colony survival data presented here appears to 
suggest that the presence of E7 within the transduced cells may aid the cell’s recovery post 
LMB treatment.  Both E6 and E7 are present within the W12s at lower levels than in the 
transduced PHKs, therefore the decreased colony survival in these cells could be attributed to 
either a decrease in any recovery effect due to lower E7 levels or alternatively an attenuation 
of the E7 effect by the presence of E6.  It is possible that E6 may act to protect cells from 
LMB induced apoptosis, while E7 may assist the recovery of cells after treatment. 
 
These data suggest that W12 derivatives, which provide a model for early HPV associated 
neoplasia, are sensitive to the effects of the nuclear export inhibitor LMB.  This response 
appears to be influenced not only by the presence of the complete HPV genome and its 
integration, but also by the differentiation state of the host cells.  The normal lifecycle of the 
virus and any changes due to integration are likely to play an important role in the response of 
these cells to LMB.   
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Chapter 5: Leptomycin B Induces Apoptosis in Cells 
Containing the Whole HPV 16 Genome 
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5.1 Introduction  
The LMB-induced effects previously reported in PHKs transduced with HPV 16 E7, E6 and 
E6/E7 have been shown to be due to the induction of apoptosis 374.  The data presented in this 
chapter aims to confirm that the morphological changes and reduction in colony formation in 
response to LMB in both monolayer and rafted W12 derivatives (chapter 4) can also be 
attributed to the induction of apoptosis.   
 
Apoptotic cell death is associated with the activation or inhibition of numerous cellular 
pathways as discussed in section 1.4.  The induction of this form of cell death can therefore be 
assessed in a number of ways, including the detection of apoptotic enzyme activation (e.g. 
activated caspase-3) and cytoskeletal breakdown (e.g. M30).  As described in section 1.4, act-
casp-3 acts as an executioner caspase, functioning late in the apoptotic initiation cascade to 
actively break down the cellular infrastructure.  As act-casp-3 is one of a group of executioner 
caspases acting at this point in the pathway and because it is likely to be transiently expressed 
due to its enzymatic function, a second marker of apoptosis was also used to provide a more 
accurate measure of LMB-induced apoptotic cell death.  The M30 antibody binds a 
neoepitope of CK18 formed by cleavage of the cytoskeletal protein at amino acids 387-396 
424.  This breakdown is achieved by a range of activated executioner caspases, including 
caspase-3, 6 and 7 425 during the early stages of apoptosis 426.  Initial CK18 cleavage generates 
a 40kDa fragment with further processing later in apoptosis producing an additional smaller 
24kDa protein 426.  The assessment of both act-casp-3 and M30 expression permitted the 
induction of apoptosis by LMB to be verified, while also allowing any differences in the 
response due to alterations in genome status to be assessed in both monolayer and raft culture.  
 149 
5.2. Methods 
Cells were cultured and treated with LMB as summarised in sections 2.2 and 2.3.  The 
induction of apoptosis was assessed by immunocytochemistry (section 2.10) and western 
blotting (section 2.12.1-6 and 2.12.7.2.) by the detection of M30 and activated caspase-3 
antibodies. 
5.3. Results 
5.3.1. Confirmation of Cytokeratin 18 Expression in the W12 Derivatives 
The M30 antibody provides a useful method for the detection of early apoptosis in epithelial 
cells.  However, in order to utilise this method the expression of CK18 within the W12 
derivatives required confirmation utilising the antibody LE65 which stains for CK18 present 
within epithelial cells as described by Lane et al (1992) 427.   
 
 
 
Figure 5.1: The expression of cytokeratin 18 (CK18) in the W12 derivatives and the β-Actin loading 
control. 
 
 
Western analysis established the presence of CK18 expression in all the W12 derivatives, 
with no notable differences in the level of protein present (figure 5.1). 
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5.3.2. The Induction of Apoptosis by LMB in Monolayer Cultures Assessed 
by Immunocytochemistry  
Initially LMB-induced apoptosis was assessed in adherent cells grown on chamber slides and 
subjected to immunocytochemistry for act-casp-3 and M30.  The expression of the apoptotic 
markers was assessed at 500x magnification with the number of cells counted determined by 
the running mean method.  This is achieved by calculating the total accumulated positivity as 
a percentage of the total accumulated cell count (positive and negative).  When graphed the 
formation of a plateau indicates a reliable count (for example see appendix C1).  This method 
ensures that statistically valid numbers of cells are counted from each slide and required cell 
counts ranging from 2,732 (E50 +LMB M30) to 49,087 (I22 –LMB M30).   
 
The W12 derivatives showed low level baseline expression of act-casp-3 in the absence of 
LMB treatment, with levels varying between the derivatives (figure 5.2a).  Treatment with 
2nM LMB (38h) initiated a marked increase in caspase-3 activation in all the W12 cell lines 
(figure 5.2a), with considerably elevated act-casp-3 expression occurring in the episomal E50 
cells.  The induction of act-casp-3 was similar between E63, I31 and I61, but the type 1 
integrated cells I02 and I22 displayed reduced levels, with I02 showing the lowest overall 
expression.   
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Figure 5.2:  The expression of act-casp-3 (a) and M30 (b) detected by immunocytochemistry after 
treatment with 2nM LMB (38h).  Both treated (+) and untreated controls (-) for each W12 derivative 
are shown, with N representing the number of counted cells and the error bars representing ±2x 
standard error of the proportion (SEP). 
   
 
Immunocytochemistry for the M30 neoepitope also revealed a low baseline level of 
expression; although much less variability was apparent between the derivatives (figures 5.2).  
In response to 2nM LMB (38h) a considerable induction of CK18 cleavage occurred in all the 
cell lines, indicated by the rise in M30 positivity (figure 5.2b).   
 
The expression of M30 and act-casp-3 indicated that although not strong there may be an 
association between the episomal, integrated type 1 (single copy) or integrated type 2 
(a) 
(b) 
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(concatemers) status of the viral genome and the sensitivity of these cells to LMB (figure 
5.2b). 
5.3.3. LMB Induces Apoptosis in W12 Derivatives Grown in Raft Culture  
As previously discussed, the LMB induced changes in H&E stained organotypic rafts were 
suggestive of apoptosis (section 4.3.2).  This apoptotic response was verified by examining 
the expression of act-casp-3 and M30 in raft sections by immunocytochemistry. 
 
 
 
Figure 5.3:  The induction of apoptosis in E63 and I22 rafted derivatives in the presence (+) and absence 
(-) of 50nM LMB (72h).  Staining for both act-casp-3 (upper panel) and M30 (lower panel) are shown.  
Arrows indicate exemplar keratinised cells. 
 
In the absence of LMB rafted E63 and I22 cells exhibited low amounts of act-casp-3 and M30 
expression throughout the epithelium; although staining was particularly located in the mid-
upper layers of both rafts (figure 5.3).  The integrated derivative I22 demonstrated staining for 
both act-casp-3 and M30 that was somewhat lower in quantity than the episomal line and 
restricted to a region higher in the epithelium.  Particularly within the episomal rafts, the 
staining for M30 was largely restricted to locations closer to the surface of the epithelium; a 
more widespread pattern of positivity was found with act-casp-3 where staining extended 
further into the mid-level of the raft.  In both cell lines the largest concentrations of positivity 
in the absence of LMB were located in areas of vacuolation and abnormal structure, with 
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expression notably absent from the keratinised cells in both the episomal and integrated rafts.  
Treatment with 50nM LMB (72h) led to an increase in the amount and intensity of act-casp-3 
and M30 staining throughout the E63 and I22 rafts (figure 5.3), with a continued association of 
positivity with areas of vacuolation.  The rise in expression was particularly apparent within 
and immediately above the lost basal layers of the raft especially with act-casp-3, confirming 
the absence of this region.   
 
Immunocytochemistry of monolayer and rafted cells appeared to show variations in the 
appearance of the M30 staining similar to that previously described by Duan et al (2003) 428 
and Grassi et al (2004) 429.  These differences are likely to represent the M30 protein in 
distinct morphological settings, reflecting different stages of the apoptotic process.  Early 
apoptosis is represented by weak/intermediate staining of relatively normal cells, while later 
stages of apoptosis are indicated by darker staining of cells often with either a highly 
compacted or granular appearance (figure 5.4).  The variations in M30 staining provide a 
more detailed picture of apoptotic behaviour allowing a more accurate assessment of any pro- 
or anti-apoptotic effects.  
 
 
 
Figure 5.4:  The changes in cell morphology and M30 expression in rafted W12 cells representing the 
progression of apoptosis from normal (upper left) to late apoptosis (lower left). 
 
These changes in the appearance of M30 staining were apparent both episomal and integrated 
rafts as illustrated in figure 5.4.  The untreated E63 rafts displayed a greater proportion of 
darker staining forms of M30, especially within the lower regions of the epithelium; while the 
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untreated I22 raft showed predominantly paler M30 staining.  LMB treatment was associated 
with an increase in the intensity of M30 staining in both the episomal and integrated rafts.  In 
particular the LMB treated episomal raft showed a rise in both the pale and dark forms of 
M30, although the increase in the darker form was greater, especially in cells displaying a 
notably granular appearance.  
5.3.4. Induction of Apoptosis Assessed by Analysis of Protein Expression  
The immunocytochemistry data for both act-casp-3 and M30 suggest that LMB induces 
apoptosis in all of the W12 derivatives.  However, from the immunocytochemical data it 
remained unclear whether any variations in the response were present between these cell 
lines.  In addition, immunocytochemistry can only assess antigen expression in residual cells 
that remain adherent to the slide.  In order to consider the maximum population response and 
the time-dependence of the LMB effect, a 48h time course, assessed by western blotting, was 
undertaken in the W12 derivatives and PHKs transduced with E7 or E6/E7. 
5.3.4.1. The Temporal Expression of Activated Caspase-3   
Over the 48h time course very little or no act-casp-3 expression was detected in the absence 
of LMB in the E63, I02, and I22 derivatives or the transduced PHKs.  E50, I31 and I61 showed 
some low background expression which tended to increase slightly over time, indicating the 
presence of some innate apoptosis (figure 5.5).   
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  (a) 
 
 
 
Figure 5.5:  The expression of act-casp-3 detected by western blot after 2nM LMB (0-48h).  Both 
untreated control (-) and LMB treated samples (+) are shown at each time point for the E7 or E6/E7 
transduced PHKs and the W12 derivatives.  (a) The upper panel shows act-casp-3 expression with the 
β-actin loading control.  (b) The data were analysed and integrated density quantification undertaken 
using Image J with measurements expressed in arbitrary units.  All values were normalised against β-
actin. 
 
In response to 2nM LMB, act-cap-3 production increased considerably in the W12 derivatives 
and transduced PHKs, with the response varying as illustrated in figure 5.5.  The pattern of 
act-casp-3 expression was notably different between the two transduced PHK cell lines, with 
the maximum act-casp-3 expression achieved in the E6/E7 cells considerably lower than that 
of the E7 expressing cells.  The E7 transduced PHKs attained maximal caspase-3 activation 
by 24h followed by a gradual decrease in expression, whereas activation in the cells 
  (b) 
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expressing E6/E7 did not peak until 12h later at the 36h time point.  A different expression 
pattern was present within the episomal cells which showed a gradual rise in act-casp-3 up to 
and perhaps exceeding 48h of treatment (figure 5.5).  A more rapid activation of caspase-3 
was apparent in the cells containing integrated HPV than in those containing episomal viral 
genomes.  Expression was markedly lower in the type 1 integrated cells, in particular I02.  The 
type 1 integrated HPV cell lines also demonstrated differences in their pattern of act-casp-3 
expression.  The I02 derivative exhibited a gradual rise in act-casp-3 over the entire time 
period, whereas a sharp increase in activation was present in the I22 line at 36h followed by a 
further gradual increase at 48h.  The type 2 integrated derivatives attained levels of act-casp-3 
expression similar to those seen in their episomal counterparts.  However, I31 displayed 
considerably greater activation at 12h of treatment than any other W12 or transduced cell line, 
with this initial rapid induction followed by a further gradual increase in levels up to 
maximum production at 36h.  The I61 derivative displayed a delayed rise in expression until 
24h after the start of treatment, at which point levels rose rapidly and maintained this 
expression at subsequent time points.  
5.3.4.2. Temporal Expression of the M30 Neoepitope 
Analysis of M30 expression over the 48h time course allowed the identification of both the 
early (40kDa) and late (24kDa) CK18 cleavage products by western blot (figure 5.6a).  In the 
absence of LMB the early 40kDa neoepitope, but not the later 24kDa product, could be 
identified in the W12 derivatives and transduced PHKs, although expression levels were very 
low, at less than 1 AU (figure 5.6).   
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(a) 
 
 
 
 
Figure 5.6:  The expression of the total M30 expression by western blot after 2nM LMB (0-48h).  Both 
untreated (-) and treated (+) samples of the transduced PHK and W12 cell lines are shown.  (a)  The 
upper panel shows M30 expression, where filled arrows indicate the position of the early 40kDa form 
of M30 and empty arrows denote the later 24kDa product.  The β-actin loading control is shown in the 
lower panel. (b) The data was analysed and integrated density quantification undertaken using Image J 
with measurements expressed in arbitrary units.  All values are shown as total M30 (both early and 
late forms) and normalised against β-actin. 
 
 
(b) 
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In response to 2nM LMB, the cells displayed increased M30 production (figure 5.6) as 
previously reported by immunocytochemistry (figure 5.2).  The E7 and E6/E7 transduced 
PHKs reacted differently to LMB treatment as reflected in the levels and patterns of M30 
positivity.  Throughout the time course, M30 expression in the E7 expressing cells exceeded 
that of the E6/E7 transduced cells, although notable decreases in E7 expression were present 
as the treatment progressed.  The peak production of M30 in the E7 transduced cells occurred 
at 24h with subsequent expression gradually decreasing, whereas cells transduced with E6/E7 
displayed a slower increase in M30 expression over the entire time course, with levels 
throughout notably lower than the other cell lines.  The W12 derivatives also responded to 
LMB treatment with a rise in CK18 cleavage leading to increased levels of total M30.  
However, in these derivatives the peak levels of M30 were not reached until at least 12h after 
the E7 transduced cells at 36-48h (figure 5.6).  The episomal cell lines displayed a pattern of 
M30 similar to that seen in the E6/E7 transduced PHKs, but with notably more M30 present.  
From 12-36hs of treatment the pattern of M30 expression remained similar between the two 
episomal cell lines; however, in the final 12h the E63 derivative maintained a slow increase in 
M30 levels, whilst a more rapid rise occurred in E50 consequently reaching a higher peak level 
of M30 than E63.  The integrated derivatives, with the exception of I61, displayed levels of 
M30 similar to the episomal derivatives at the 24h and 48h time points.  However, a rapid 
pulse of CK18 cleavage was apparent at 36h where M30 levels were notably greater than in 
either the transduced PHKs or episomal W12s.  The I61 derivative exhibited lower expression 
of M30 with levels between that of the E7 and E6/E7 expressing PHKs.   
 
Both the early and late forms of M30 were expressed in response to LMB treatment in the 
W12 derivatives and transduced lines (figure 5.6a).  Throughout the time course the 40kDa 
early protein was found to be the dominant form, with the later 24kDa neoepitope occurring at 
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considerably lower levels.  The expression of the later 24kDa form was particularly low in the 
E6/E7 expressing PHKs, even after 48h of treatment (figure 5.6a).  Some overlap in the 
expression of the early and late neoepitopes was present over the 48h time course, although in 
most cases a lag period was present between the initiation of early and late protein production.  
However, in the E7 transduced PHKs and the type 2 integrated I22 there appeared to be 
concurrent expression of both forms of the M30 protein.  
5.3.4.3. LMB Induces the Expression of Both Activated Caspase-3 and M30 
The 48h time course data described above (sections 5.3.4.1/2) was also analysed to assess the 
cumulative expression of both act-casp-3 and M30 over the entire treatment period as 
illustrated in figure 5.7.   
 
 
 
Figure 5.7:  The cumulative expression of act-casp-3 (Casp) and M30 in response to 2nM LMB over 
the 48h time course.  The expression of both markers of apoptosis within the E7 or E6/E7 transduced 
PHK lines and the W12 derivatives are shown in the absence (-) or presence (+) of 2nM LMB. 
 
 
The majority of the W12 derivatives showed greater expression of M30 than act-casp-3.  
However, the level of expression and the discrepancy between the markers did appear to 
correlate with HPV genome status in the episomal and type 1 integrated derivatives.  The 
episomal lines E50 and E63 displayed similar expression patterns of both apoptotic markers 
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with the expression of M30 only slightly higher than act-casp-3, although levels of both 
markers were slightly higher in E50.  The cells containing type 1 integrated genomes displayed 
a lower level of act-casp-3 than M30, with the least overall expression of act-casp-3 found 
within the I02 derivative.  The discrepancy in the expression of the two markers was notably 
greater in I02 and I22 than in the episomal lines (figure 5.7).  The type 2 integrants I31 and I61 
exhibited different expression patterns, with the I31 derivative displaying high levels of both 
apoptotic markers with a divergence in expression similar to the episomal lines.  The I61 
derivative and the E7 and E6/E7 transduced PHKs displayed higher expression of act-casp-3 
than M30, unlike the other cell lines, which displayed higher expression of M30 than act-
casp-3.  In cells containing E7 alone the level of act-casp-3 was markedly greater than the 
level of M30, in the presence of both E6 and E7 the expression levels of both markers 
dramatically decreased as did the difference between their expressions.  The expression of 
act-casp-3 and M30 by the I61 derivative, were slightly higher than the E6/E7 transduced line 
as shown in figure 5.7.  
5.3.4.4. Contribution of the W12 Feeder Layer to the Apoptotic Response 
As the W12 derivatives were cultured on a feeder layer of mitomycin C treated J2 3T3 
fibroblasts, the effect of LMB on these cells, including any possible contribution to the 
apoptosis reported above (sections 5.3.4.1-3), was assessed in these cells.  Treatment was 
undertaken on a comparable numbers of J2 3T3 feeder cells in W12 culture conditions over a 
48h time course, with E7-transduced PHKs used as a positive control for the effects of LMB.   
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Figure 5.8:  The effect of 2nM LMB on J2 3T3 grown under W12 culture conditions.  The expression 
of act-casp-3 (a) and M30 (b) was assessed in J2 cells with (+) and without (-) LMB (upper panels) 
and E7 expressing cells treated with LMB (lower panels), with the loading assessed by detection of β-
actin (c).   
 
As shown in figure 5.8, when seeded at the same density used in the W12 experiments, no 
expression of either M30 or act-casp-3 could be detected in mitomycin C treated J2 3T3 cells 
in response to 2nM LMB over the 48h time course.  However, the despite levels of both 
markers in the E7 transduced PHKs being comparable to the previous data (sections 5.3.4.1-
3).  This suggests that these cells are unlikely to contribute appreciably to the apoptosis 
reported in the time course data shown in figures 5.5-7, due to the low numbers of J2 
fibroblasts and/or to a lack of LMB sensitivity. 
5.4. Discussion 
An induction of morphological changes and loss of cells was apparent in both the monolayer 
and rafted W12 cells after treatment with LMB.  Previously in the E7 and E6/E7 transduced 
PHKs 374 these LMB-induced effects have been verified as apoptosis by examination of the 
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apoptotic markers activated caspase-3 (act-casp-3) 217 and the M30 neoepitope of CK18 425,426.  
This chapter provides evidence that LMB also induces a potent increase of the apoptotic 
markers act-casp-3 and M30 in derivatives of the W12 cell line containing predominantly 
episomal or integrated HPV 16 genomes, in both monolayer and rafted environments.     
 
Raft cultures of both episomal and integrated cell lines E63 and I22 displayed notable 
differences in both their structure (section 4.3.2) and apoptotic marker expression (section 
5.3.3) in the presence and absence of LMB.  Although the untreated rafts displayed apoptotic 
marker expression throughout the epithelium, the concentrations of staining associated with 
vacuolation and abnormal structure suggested that these areas within the rafts are produced as 
either a consequence of apoptosis or represent regions more susceptible to apoptosis.  The 
production of M30 is known to be catalyzed by a number of executioner caspases including 
act-casp-3.  Therefore, the spatial differences in location of act-casp-3 and M30 within the raft 
may represent the earlier activation of caspase-3 lower in the epithelium.  The more 
prominent activation of act-casp-3 at a lower level in the episomal derivatives may be due to a 
number of factors, including the cleavage of CK18 by alternative executioner caspases or a 
lower baseline level of apoptosis in the integrated derivative.  As discussed in section 4.4, the 
both the untreated and treated E63 raft displayed higher levels apoptosis including cell loss 
within the mid to upper suprabasal layers.  This could derive from virally induced apoptosis, 
which has been suggested to have a number of possible functions, including limiting the viral 
impact on the host via control of progeny levels and/or facilitating the release of virions by 
disrupting the cytoskeleton 111,332,342 (see section 1.5.5.2).  However, as these functions are 
thought to be highly dependent on the presence of the viral proteins E2 342,343 and E1^E4 332, 
the loss of E2 during HPV integration is likely to contribute to the lower levels of apoptosis 
present within the upper regions of the integrated raft.   
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Treatment with LMB was associated with the upregulation of act-casp-3 and M30 in both E63 
and I22 rafts.  As noted in the morphological studies (chapter 4.3.2), the effects of LMB were 
most pronounced in the basal layers of both rafts, confirming the particular sensitivity of these 
rapidly dividing cells to the apoptotic effects of LMB in the presence of both episomal and 
integrated HPV.  As this LMB-induced effect on the basal epithelium appears absent in rafted 
wild type human keratinocytes 374, this loss of cells within this region is likely to be due to the 
presence of integrated or episomal virus and its interaction with the cell. 
 
Analysis of protein expression in monolayer W12 derivatives in the absence of LMB 
indicated variation in the expression of the apoptotic markers, representing differences in the 
level of innate apoptosis.  These variations may be due to the clonal nature of the cells and/or 
differences in their viral genome status.  The I31 cell line in particular appeared to consistently 
display a high level of background apoptosis indicating that the specific clonal or virally 
induce changes within this particular derivative.  This increased propensity for apoptosis may 
be influenced by increased the cellular pro-apoptotic response via mechanisms such as 
increased p53 signalling and/or a decrease in viral anti-apoptotic signalling, which would lead 
to increased innate apoptosis.   
 
Considerable inter-derivative variation in the levels of LMB-induced apoptosis was apparent 
by both immunocytochemistry and western blot, with the status of the viral genome and the 
clonal nature of the derivatives probably contributing to the variation in LMB sensitivity.   
The episomal cell lines did not share a common level of LMB-induced apoptosis, with E50 
proving to be the more sensitive of the two, suggesting the presence of variation between 
these cell lines, the differences in E7 expression of the two lines reported by Jeon et al (1995) 
119 may contribute to the differences in behaviour.  In additional, Southern analysis of the E63 
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derivative (section 3.3.1) indicated the possible presence of integrated sequences; however, 
Pett et al (2007) 5 have proposed that the presence of E2 derived from episomal HPV inhibits 
gene expression from co-existing integrated sequences.  Indeed data suggests that expansion 
of cells containing integrated HPV does not occur until the episomal viral genomes are lost 
133.  Therefore, it remains unclear what, if any influence the presence of any integrated 
sequences within the E63 derivative would have on their LMB response.   
 
Although the type 2 integrated I31 and I61 line showed similar medium levels of act-casp-3 
induction in response to LMB, the levels were slightly lower in I61.  In addition the expression 
of M30 was found to be notably lower in the I61 derivative after western blot analysis, 
suggesting the presence of prominent differences with this line.  The cumulative time course 
data indicated that I61 appears to behave as an intermediate between PHK E7 and PHK E6/E7 
in terms of both the expression levels of act-casp-3 and M30, and in the discrepancy between 
the two markers.  These data, combined with high levels of both E6 and E7 reported in the 
literature 119,430, suggest that the oncogene expression in this derivative are influencing the 
response of these cells to LMB.  The similarity in act-casp-3 and M30 expression between I22 
and I31 may be a response to clonal differences or an effect of general rather than type specific 
integration.  The I02 derivative showed lower levels of both markers and a larger discrepancy 
in expression between the two apoptotic proteins, with very low levels of act-casp-3 but 
higher levels of M30.  This expression pattern may be a consequence of the clonal selection of 
I02 from a later passage 17 (instead of 14/15) of the parental W12 cell line which has been 
shown to accumulate cellular changes over time increasing the likelihood that further 
alterations in both viral and cellular mechanisms have occurred 117,119,311.   
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Both the early and late forms of the M30 protein were detected in the W12 derivatives and 
transduced PHKs representing cells at difference stages of apoptosis.  Universally the major 
product was the early 40kDa form with variable amounts of further cleavage apparent 
between the different cell lines.  Variations in both the amount and timing of the 24kDa M30 
production were noted, with the delayed expression of the late form in the E6/E7 transduced 
PHKs and the W12 derivatives, suggestive of a more gradual progression of apoptosis.  
However, the concurrent expression of the two forms of M30 in both the E7 transduced PHKs 
and the I22 derivative; suggest that these lines undergo a more rapid onset of secondary M30 
cleavage.  The virus is known to manipulate the host apoptotic mechanisms by interacting 
with the pathways at various points.  This can be achieved by either down regulating pro-
apoptotic proteins such as pro-caspase 8 (E6) 110 or upregulating anti-apoptotic proteins such 
as c-IAP (E6 and E7) 329 (section 1.5.5.1).  In the presence of LMB these pre-existing 
alterations to the apoptotic pathways may influence the progression of apoptosis, particularly 
where the proteins involved undergo CRM1-mediated nuclear export (e.g.  IAP1/2 391 and 
Survivin 394). 
 
The time course data suggest that the presence of selected genes or the whole genome from 
HPV 16 in specific configurations, correlates with temporal expression of the apoptotic 
markers act-casp-3 and M30 (figure 5.8).  The most rapid expression of both apoptotic 
markers was present in the E7 transduced cells after 24h of LMB treatment.  A dramatic 
change in sensitivity, similar to that shown previously in rafted and monolayer cells by Gray 
et al (2007) 374, was provoked by the introduction of the E6 gene, delaying peak apoptosis by 
at least 12h.  Interestingly the presence of E6 also appears to be associated with a temporal 
dissociation of apoptotic markers with act-casp-3 levels peaking 12hs prior to M30.  These 
differences in the induction of apoptosis by LMB in the E7 and E6/E7 transduced PHKs, 
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suggest that the E6 protein may play a role in protecting cells from LMB induced apoptosis, 
possibly in a p53-dependent manner as suggested by Lain et al (1999) 182.  This E6-mediated 
attenuation of LMB-induced apoptosis is thought to be achieved by the continued utilisation 
of nuclear proteasomes during LMB treatment.  The degradation of p53 by E6 utilises cellular 
components such as proteasomes and E6-AP, which although primarily cytoplasmic are also 
located within the nucleus 179,263,431.  It has been illustrated in HPV 18 E6 transfected cells that 
treatment with LMB does not lead to a total loss of p53 degradation, indicating that E6 can 
mediate p53 degradation via both nuclear and cytoplasmic proteasomes 179. 
 
 
 
Figure 5.9:  LMB-induced expression of the apoptotic markers act-casp-3 and M30 varies amongst the 
transduced PHKs and the W12 derivatives and correlates with the genome status of the cells. The 
dotted lines represent the act-casp-3 levels with the shaded areas indicating M30 expression after 
treatment with 2nM LMB over a 48h time course.   
 
 
As illustrated in figure 5.9, the integration status of the viral genome in the W12 cell lines 
correlated with the temporal expression pattern of act-casp-3 and M30.  The delay in 
apoptosis exhibited by the W12 derivatives in comparison to the E7 cells is reminiscent of the 
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change seen in response to the presence of E6 in the E6/E7 transduced PHKs.  The episomal 
lines E50 and E63 demonstrated the most prolonged delay in reaching peak act-casp-3 and 
M30, with levels rising up to and possibly beyond the 48h time point, at least 24h after the E7 
expressing cells.  HPV integration in the W12 derivatives is associated with more rapid 
induction of maximum apoptotic marker expression than present in the episomal lines.  This 
implies that integration has an important role in increasing the rate of the apoptotic response 
of these cells to LMB; this may be a consequence of the presence of greater E6/E7 expression, 
a lack of E2, or some other integration-related mechanism.  The type 1 integrated derivatives 
displayed a dissociation in the expression of the two markers, with M30 peaking at 36h and 
act-casp-3 delayed by at least 12h.  However, the type 2 integrated W12s displayed peak 
levels of both apoptotic markers at 36h; this coincident expression of M30 and act-casp-3 was 
also exhibited by the E7 expressing PHKs.  These differences in expression in the integrated 
cells suggest that, although integration in general appears have some bearing on the response 
to treatment, the type of HPV integration event also has an influence on the response of these 
cells to LMB.   
 
The mechanisms by which LMB-induced apoptosis occurs in the W12 derivatives and 
transduced cells appears to be, at least partially, act-casp-3 dependent 374,399.  Evidence from 
Jang et al (2004) 399 proposes that caspase-9 and caspase-3 play a specific role in the initiation 
of CK18 cleavage, with expression shown to increase in response to LMB treatment of U937 
leukaemic cells.  However, in the time course experiment, the W12 derivatives and in 
particular the type 2 integrated cells showed a lack of correlation between act-casp-3 and M30 
production.  LMB-induced act-casp-3 expression in most of the remaining cell lines was 
either concurrent with or subsequent to M30.  This suggests that executioner caspases other 
than act-casp-3 may play an important role in the induction of apoptosis by LMB in HPV 16 
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infected cells.  Caspase activation, and other factors influencing the apoptotic response to 
LMB are likely to be affected by the context of the HPV genome within these cells, with 
subsequent effects on the level and pattern of LMB induced apoptosis.    
 
LMB has previously been shown to induce apoptosis in cells expressing HPV oncogenes, but 
not in wild type PHKs 374, suggesting that the presence or absence of viral genes influences 
the manner in which keratinocytes respond to LMB.  The data presented above demonstrate 
that LMB also induces apoptosis in keratinocytes containing the whole viral genome in both 
episomal and integrated states, and thus provides a mechanism for the changes in morphology 
and colony survival described in chapter 4.  Furthermore, the viral genome status of the three 
W12 types appears to influence the pattern of LMB-induced apoptosis in both monolayer and 
raft culture.     
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Chapter 6: The Expression of p53 and p21 in Response to 
LMB Treatment 
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6.1. Introduction 
LMB is able to induce apoptosis in W12 derivatives containing either episomal or integrated 
genomes (chapter 5).  In addition to this induction of apoptosis, LMB treatment has 
previously been associated with increased expression of the cell cycle regulator p53 in a range 
of cell types including HPV infected cancer cell lines 182,203, HPV transduced primary cells 
374, primary human fibroblasts 203 and prostate epithelial cells 375.  Therefore, increased 
expression of p53 may also play a role in the LMB-induced response of the W12 derivatives 
shown in chapters 4 and 5, particularly in those cells expressing integrated HPV.   
 
The cell cycle regulator p21 may also play a role in mediating LMB-induced effects.  p21 is 
known to be expressed in both a p53-dependent and independent manner and may therefore 
play a role in any LMB-induced p53 response.  In addition, LMB is known to induce a rise in 
p21 in a number of cell types 385,432, while also inducing a possibly p21-dependent temporary 
cell cycle arrest in wild type primary human keratinocytes 374.  In this study, the LMB-
dependent and independent expression of p53 and p21 was assessed by immunocytochemistry 
of W12 raft cultures and western blot of the time course samples.  
6.2. Methods 
Rafted W12 cells were cultured as described in section 2.6 prior to treatment with 50nM 
LMB.  Treated rafts were then stained for p53 and p21 by immunocytochemistry (section 
2.10.2).  The effects of LMB on the expression of p53 and p21 in monolayer was assessed by 
western analysis, this allowed the time dependence of any response to be assessed and in 
addition, prevented any variations in results due to the loss of cell adherence noted in section 
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5.3.4.  The 48h time course was undertaken as described in section 2.12 and 2.12.7.2 with the 
expression of both markers assessed by western analysis.  Further investigation of the p21 
doublet was performed by phosphatase treatment (section 2.12.7.5) and the use of an 
alternative p21 antibody (2.12.7.2). 
6.3. Results 
6.3.1. The Expression of p53 and p21 in W12 Rafts 
In the absence of LMB the rafted E63 and I22 cells displayed focal staining for p53 throughout 
the suprabasal region of the epithelium, with expression slightly greater within the I22 cells 
(figure 6.1, upper panel).  Rafted E63 cells displayed the strongest and most prolific staining 
within the lower suprabasal region, while the rafts containing integrated HPV demonstrated 
expression that appeared more evenly distributed throughout the epithelium.  In both cases 
staining was low or absent in abnormal or vacuolated areas of the raft.  In the presence of 
50nM LMB (72h) the E63 raft displayed a small increase in the amount and intensity of p53 
staining throughout the epithelium, particularly within the mid to upper regions (figure 6.1, 
upper panel).  The integrated I22 rafts appeared to show little change in the amount or 
distribution of p53 in response to LMB (figure 6.1, upper panel) and in some cases expression 
actually appeared to decrease, although this may be due to the cells of the basal region having 
already been lost via apoptosis as described in chapters 4 and 5.  Both LMB treated rafts 
exhibited little evidence of staining within the lost basal layers positive for the apoptotic 
markers act-casp-3 and M30 (section 5.3.3).  
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Figure 6.1:  The expression of p53 and p21 in rafted W12 derivatives E63 and I22 grown in the presence 
(+) or absence (-) of 50nM LMB (72h). 
 
High background levels of p21 were present in the majority of the epithelium of both the E63 
and I22 rafts (figure 6.1, lower panel).  However, expression was notably reduced within the 
basal and immediately suprabasal regions of the rafts, particularly in the E63 derivative.  50nM 
LMB (72h) led to a decrease in p21 in both raft types, although the effect was more 
pronounced in E63.  A large proportion of this decrease in staining is probably due to the loss 
of cells in the basal and lower suprabasal layers of the rafts (figure 6.1, lower panel). 
6.3.2. LMB Induces Changes in p53 Expression in the W12 Derivatives 
Over a 48h Time Course  
Background levels of p53 expression were present in the majority of the cell lines in 
monolayer time course (figure 6.2), as was previously seen in the raft model (figure 6.1).  
This background expression tended to increase over the time course, as shown in figure 6.2.  
The highest basal levels were displayed by the E7 transduced PHKs where levels continued to 
rise up to the 36h time point.  Conversely, the E6/E7 transduced PHKs displayed very little 
background expression until late in the time course (36h) with levels remaining low.  The p53 
expression of the untreated W12 cells varied between the individual derivatives, with the 
initial increase in baseline expression followed by a plateau or a gradual decrease in most of 
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the cells.  The exception was I61 where background expression continued to rise throughout 
the time course reaching a high level by 48h. 
 
 
 
 
 
 
Figure 6.2:  The expression of p53 protein detected by western blot after 2nM LMB (0-48h).  Both 
untreated (-) and LMB treated samples (+) are shown for E7 or E6/E7 transduced PHKs and W12 
derivatives at each time point. (a) The upper panel shows p53 expression with the β-actin loading 
control in the lower panel, (b) the data was analysed and integrated density quantification undertaken 
using Image J with measurements expressed in arbitrary units.  All values were normalised against β-
actin. 
 
In response to 2nM LMB the expression of p53 increased in both the transduced and W12 cell 
lines (figure 6.2).  The E7 transduced PHKs had the greatest levels of p53 in response to 
LMB, reaching a maximum expression considerably greater than the remaining lines 12-24h 
after treatment commenced.  The E6/E7 expressing cells displayed very little induction of p53 
(a) 
(b) 
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in response to LMB, with notable increased expression only present at 36h.  The W12 
derivatives, with the exception of E63 and I22, demonstrated a rapid induction of peak p53 
expression 12h after LMB treatment.  The remaining two derivatives had a delay in attaining 
maximum p53 response with I22 reaching peak expression by 24h and the E63 derivative 
displaying levels that continued to rise up to at least 48h (figure 6.2).   
6.3.3. LMB Induces Increased Expression of p21 in the W12 Derivatives 
p21 expression in the absence of LMB was present in the W12 derivatives and the E7 
transduced PHKs, with levels varying considerably between the cell lines over time (figure 
6.3).  The increased p21 expression over time seen in many of the cell lines in the absence of 
LMB is likely to be great influenced by the confluence of the cell cultures.  The untreated p21 
response was especially high in the type 2 integrated derivatives I31 and I61 particularly at the 
48h time point (figure 6.3).  However, background expression of p21 was absent from the 
E6/E7 transduced PHKs over the entire time course.  In the case of the E63 derivative which 
expressed p21 as a doublet, the sum of the upper and lower bands was used for analysis of the 
p21 response.  By the 48h time point, cultures grown in the absence of LMB would have 
reached an increase level of confluence with a likely decrease in nutrient availability, this may 
have subsequently contributed to the high levels of p21 displayed by the majority of the cell 
lines.   
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(a) 
(b) 
 
 
 
 
 
 
Figure 6.3:  The expression of p21 protein detected by western blot after 2nM LMB (0-48h).  Both 
untreated (-) and LMB treated samples (+) are shown for E7 or E6/E7 transduced PHKs and W12 
derivatives at each time point.  (a) The upper panel shows p21 expression with the β-actin loading 
control in the lower panel, (b) the data was analysed and integrated density quantification undertaken 
using Image J with measurements expressed in arbitrary units.  All values were normalised against β-
actin. 
 
After 2nM LMB a p21 response was elicited in the W12 derivatives and transduced PHKs 
(figure 6.3).  The p21 response varied between the derivatives, although the differences were 
less dramatic than those between the two transduced lines.  The E7 transduced PHKs 
contained the highest induced levels of p21 while the expression in E6/E7 transduced PHKs 
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remained markedly lower than the other cells.  The majority of cell lines studied showed a 
rapid response to LMB with p21 expression peaking after only 12h of treatment (figure 6.3).  
However, a more prolonged rise in p21 expression was apparent in certain cell lines; E6/E7 
transduced PHK cells not expressing p21 until 36h after treatment, and the W12 derivatives 
E63 and I61 both peaking after 24h.  With the exception of E63, maximum p21 induction was 
followed by a rapid decrease in expression over the following hours.  E63 showed a less 
dramatic decrease in p21 levels, with its peak expression at 24h followed by a gradual 
decrease, then plateau as shown in figure 6.3. 
6.3.4. The Expression of p21 as a Doublet in the E63 Derivative 
During western analysis, the W12 derivative E63 was consistently found to express p21 in the 
form of a doublet, where the lower band represented both a novel and a dominant signal 1.2-
2.5kDa smaller than the native form.  The time course data (figure 6.4) indicated the majority 
of the p21 induction appears to originate in the upper band of this doublet, particularly during 
the cellular response to LMB treatment.  The lower band of the doublet was found to be 
strongly expressed throughout the time course, with very little variation associated with 
changes in the time point or treatment status.  Only where peak expression of the upper band 
was apparent at 24h was there a notable increase in the intensity of the lower band (figure 
6.4). 
 
Figure 6.4:  The expression of the doublet form of p21 in the E63 derivative in the presence (+) or 
absence (-) of LMB treatment over a 48h time course. 
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The mechanism for the formation of the doublet within this single W12 derivative alone was 
unclear.  Evidence from the literature 433 suggested that similarly sized p21 doublets have 
reportedly been formed by changes in the phosphorylation status of the p21 protein.  
Phosphatase digestion of protein derived from W12 cells was therefore undertaken to 
ascertain if dephosphorylation of the E63 p21 protein had led to the formation of the lower 
novel band.   
 
 
Figure 6.5:  The effect of phosphatase digestion on the expression of p21 in the W12 derivatives.  
Western analysis was undertaken for p21 on undigested (-) or phosphatase digested (+) protein lysates.  
 
 
Phosphatase treatment (figure 6.5) appeared to have no effect on the doublet formation in the 
E63 line, suggesting that dephosphorylation of p21 is unlikely to have led to the formation of 
the novel doublet signal.  Alternatively the p21 doublet may have been formed by cleavage of 
the native p21 leading to the formation of the smaller band.  This was investigated by the use 
of antibodies with two distinct epitope locations (figure 6.6a); the previously used C-terminal 
antibody (SX118) and an alternative internally located antibody (EA10).   
 178 
 
 
 
 
Figure 6.6:  Differences in the pattern of p21 expression using antibodies against C-terminal and 
internally located epitopes. (a) A schematic showing the positions of the internal (a-a 58-77) and C-
terminal (a-a 146-164) p21 antibody epitopes.  The a-a positions of the E2 protein are shown above the 
line with the antibody positions below.  (b) Western blot analysis of p21 expression by C-terminal 
(SX118) and internal (EA10) antibodies in the E50, E63, I02 and I31.  Equal loading is shown in the 
lower panel by β-Actin (Actin). 
 
 
As found during the time course experiment, a doublet p21 was detected by the C-terminal 
antibody in the E63 derivative, but was absent in the other W12 representatives (E50, I02 and 
I31).  The presence of a doublet with the C-terminal antibody suggests that this portion of the 
p21 protein is present in both the native and novel bands of the doublet.  Western analysis 
using the internal p21 antibody did not detect a doublet in the E63 sample, suggesting that this 
region of p21 protein may be partially or totally absent from the novel p21 protein.   
6.4. Discussion 
LMB has been shown to cause changes in morphology, colony survival and the induction of 
apoptosis not only in the W12 derivatives (chapters 4 and 5) but also in other HPV associated 
cells during previous studies 182,374.  The mechanisms by which LMB induces apoptosis 
remain unclear.  HPV infection appears to sensitise the cells to LMB-induced cell death; 
(a) 
(b) 
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however, other factors such as the BCR-ABL mutation 400 or the changes associated with 
leukaemic 399 or prostate cancers 375 have also been shown to effect the susceptibility of cells 
to LMB as discussed in section 1.6.2.  A number of studies have shown an association 
between LMB treatment and increased p53 expression 182,203,374,375, providing a possible 
mechanism for the apoptotic effects of LMB.  In addition, wild type PHKs are reported to 
undergo quiescence in response to LMB 374; this may be caused by the cell cycle regulator 
p21 therefore the possible role of p21 was also investigated.   
 
The data presented in this chapter show that increased levels of p53 and p21 protein in 
response to treatment with LMB were present in monolayer W12 derivatives and PHKs 
transduced with E7 and E6/E7 over a 48h time course.  The rafted W12 derivatives displayed 
some increase in expression of p53 in response to LMB, but no such p21 response could be 
detected. 
6.4.1. The Expression of p53 and p21 within Rafted W12 Cells 
When untreated, both the level and pattern of p53 and p21 expressed in the rafted W12 cells 
varied between the episomal E63 and integrated I22 derivatives.  Low expression of p53 and 
p21 was present within the basal region of the epithelium in both rafts, as was previously 
observed in episomal rafts by Flores et al (2000) 27.  This epithelial region contains rapidly 
dividing cells, and should require less viral interference than other regions as the replication 
machinery required by the virus is already present.  Therefore, this lower level of viral 
interference the requirement for expression of the cellular regulators p53 and p21 is likely to 
have contributed to their decreased expression. 
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In the absence of LMB, both p53 staining and the greatest levels of apoptosis (section 5.3.3) 
were located within the mid-upper epithelium in both the episomal and integrated W12s; in 
addition, this correlation between p53 and innate apoptosis has previously been observed in 
rafted E63 cells by Flores et al (2000) 
27.  The notably greater expression of p53 in the 
suprabasal region of the untreated episomal raft is likely to reflect the consequences of HPV 
16 infection, particularly differences in oncogene expression.  Cells containing episomal 
genomes maintain transcriptional control of E6/E7 activity throughout the epithelium and 
subsequently cells are more likely to retain a greater ability to respond to viral interference 
allowing the expression of larger amounts of p53.  It is possible that the p53 detected during 
these studies may represent non-active E7-bound protein.  HPV 16 E7 is known to cause the 
stabilisation and subsequent inactivation of p53 without altering the wild type conformation 
or directly inhibiting the proteasome 27,138,266,434 providing a mechanism for the accumulation 
of non-active p53.  The stabilisation of p53 by E7 is likely to be particularly prevalent in cells 
containing integrated sequences, where higher levels of E6 and E7 are likely to increase 
cellular disturbance and consequently raise p53 expression, whilst also providing additional 
E6 for p53 degradation and E7 for p53 stabilisation.   
 
Treatment with 2nM LMB (72h) led to a small increase in p53 expression within the episomal 
E63 raft, but little change in the I22 raft.  The interaction of p53 with HPV 16 E6 is likely to 
play an important role in p53 regulation in the presence of LMB.  The E6-mediated 
degradation of p53 by nuclear proteasomes 179,263,431 leaves p53 vulnerable to E6-mediated 
degradation in the presence of LMB (section 5.4).  However, free p53 accumulating in the 
nucleus in response to LMB may be in the inactive monomeric or active tetrameric form 
(section 1.3.1).  Although the inactive form may be degraded by the nuclear proteasomes, 
activated p53 has been shown to display reduced binding to Mdm2 due to post-activation 
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modifications 171, leading to a reduction in Mdm2-associated proteasomal degradation 
(section 1.3.1).  If this activated p53 also remains non-degraded by E6-mediated pathways, 
then it potentially provides a pool of transcriptionally active p53 to facilitate the induction of 
apoptosis.  As predicted by their viral genome status, the I22 derivative has been shown to 
express increased levels of E6 compared with the E63 cells 
403.  Therefore, the lower levels of 
p53 detected in the integrated raft after LMB treatment are likely influenced by the greater 
nuclear E6-mediated degradation of p53.  
 
In the absence of LMB both rafts exhibited large amounts of p21 staining suggesting the 
presence of a substantial innate p21 response in the W12 derivatives, confirming the pattern 
previously reported in the same cells by Shai et al (2007) 403.  The presence of viral infection 
with its abnormal DNA synthesis within the suprabasal region is likely to activate the cellular 
p21 response.  Both HPV E6 and E7 are known to inhibit p21 function, with E7 linked with 
increased expression p21 in previous raft models 27.  Some of the p21 detected may represent 
stabilised, non-active forms through short or long term interaction with the viral proteins as 
occurs with E7-stabilised p53 203,239.  Although the virus must counteract the cell cycle 
regulatory role of p21, it has been suggested that during the productive phase of the viral life-
cycle E7 may actually utilises the p21 protein to act as a scaffold to facilitating the assembly 
of cyclin–cyclin-dependent kinase complexes.  This causes the cells of the mid to upper layers 
to remain replication competent aiding the viral life-cycle 27.  Therefore, it is possible that 
some of the staining located in the upper regions of the raft may also represent virally 
sanctioned presence of p21.  A proportion of the p21 staining detected within the E63 raft may 
represent the novel p21 form highlighted during the western analysis (section 6.3.4 and 6.4.3) 
and therefore its functionality is uncertain. 
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Treatment with 50nM LMB led to a decrease in levels of p21 in both the rafts, suggesting an 
LMB induced effect.  Although treatment with LMB was associated with a decrease in p21 
expression, the induction of apoptosis within these rafts (section 5.3.3) and the early p21 
response during the time course, suggest that this p21 staining may reflect the progression of 
these cells to a post-p21 stage of the pro-apoptotic pathway. 
6.4.2. Time Course Expression of p53 and p21 in the W12 Derivatives in 
Response to LMB  
Over the 48h time course both p53 and p21 were found to be expressed in the untreated W12 
derivatives and E7 transduced cells; however, p21 could not be detected in the untreated 
E6/E7 transduced PHKs.   
 
As discussed above (section 6.4.1) background expression of p53 is likely to be highly 
influenced by the presence of HPV 16, in particular by the levels of oncogenic E6 and E7 
which are known to interact with p53 (section 1.5.1).  The high expression of p53 by the E7 
transduced PHKs indicates that greater levels of E7 may be associated with increased p53; 
however, most of this protein is likely to be bound by E7 therefore stabilised and 
transcriptionally inactive 138,266.  The presence of particularly high background p53 in the I61 
derivative over time suggests that these cells may contain particularly high levels of the E7 
protein, leading to the accumulation of bound p53.  PHKs transduced with E6 and E7 
displayed much lower baseline p53 expression reflecting efficient E6-mediated degradation.   
 
The untreated type 2 integrated W12 derivatives I31 and I61, by 48hs, displayed substantially 
greater levels of p21 than the remaining cell lines.  This expression appears to be related to 
the viral genome status and is likely to reflect differences in E6 and E7 expression.  In the 
presence of LMB this high expression of p21 was lost, although the increased levels of 
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apoptosis presented in section 5.3.4 suggest this decrease probably reflects a loss of cells 
rather than a decrease in expression.  
 
The W12 derivatives and transduced PHKs showed increased expression of p53 after 
treatment with 2nM LMB, although in most cases the response was low level and short lived.   
As in the untreated samples, the response to LMB is likely to have been substantially 
influenced by variable expression of E6 and E7 between the different cell lines.  The high 
levels of E7 in the transduced PHKs would lead to the accumulation of substantially greater 
levels of p53 when nuclear export was inhibited.  As E7-bound p53 is reportedly capable of 
nuclear export 138, the trapped p53 is likely to represent a mixed population of both free and 
E7-bound protein.  Although degradation of p53 is not effected by E7 binding 138, it is unclear 
whether transcriptional activity is effected, with Eichen et al (2002) 138 showing a notable 
decrease in p53 transcriptional activity.  Therefore, during LMB-induced nuclear 
accumulation E7-bound p53 has a reduced ability to activate p53-response genes including 
those required for the induction of apoptosis.  In high E7 expressing cells, although reduced, 
the cumulative transcriptional potential of the free and E7-associated p53 may provide 
sufficient transcriptional activity to overcome the weaker apoptotic resistance.  Within the E7 
transduced PHKs, this mechanism may have facilitated the re-activation of the act-casp-3 
response as seen in chapter 5, although further investigation is required.   
 
The efficiency of the E6 anti-p53 response has previously been illustrated by the extremely 
low levels of p53 detected in E6-transduced PHKs in the presence or absence of LMB 374.  
This effect is further demonstrated in both the current and previous studies 374 by the 
substantial decrease in the level and duration of p53 response in both the treated and untreated 
E6/E7 transduced PHKs compared with E7 alone.  In the presence of LMB the E6 protein 
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appears to maintain its ability to mediate the degradation of p53 by utilising nuclear 
proteasomes, as indicated by the maintenance of low levels of p53 in the treated E6/E7 cells.  
The minimal p53 response by the E6/E7 transduced cells, particularly at the 48h time point 
may represent a saturation of either the E6, E7 or proteosome components allowing the 
persistence of a small pool of either free or E7-bound p53.  In addition, the lack of a p53 
response of E6/E7 cells also suggests that E6 is able to bypass the stabilisation of p53 
apparent in the E7 transduced cells leading to degradation of the protein.  This is possibly 
achieved via the E6-mediated ubiquitination of p53 even in the presence of the E7 protein, 
leading to degradation of the p53 protein as suggested by Eichten et al (2002) 138.  Any 
interplay between E6 and E7 in controlling cellular p53 expression is likely to aid viral 
survival.  During a natural infection E7 may bind p53 preventing possible stress related 
activity until the E6-mediated degradation occurs, thus helping to inhibit the initiation of cell 
cycle arrest or apoptosis. 
 
The cell cycle is controlled by numerous cellular proteins including p53, p21 and pRb, which 
act together to block the unwanted progression of cells through cycle checkpoints.  
Manipulation of the cell cycle by HPV is primarily controlled by the E7 protein, with the 
presence of E6 increasing this cell cycle control particularly at the G2/M checkpoint 
171,267.  
Although both p21 and pRb are targeted by the virus, the main effect appears to be aimed at 
the pRb stage of the pathway downstream of p21, as shown in figure 1.9.  Any viral 
regulation of the cell cycle involving p21 appears to be supplementary to the main viral 
mechanisms involving the manipulation of proteins such as pRb.  In addition to any cell cycle 
effects, the interaction of E7 with p21 is also likely to have other pro-viral functions such as 
blocking the interaction of p21 with proteins such as PCNA which decreases DNA replication 
27,209 (section 1.5.2), thus helping to maintain the replication competent environment.  The 
potency of E6 in the E6/E7 transduced PHKs appears to be sufficient to produce upstream 
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interference that in the absence of LMB is able to totally block p21 expression.  The lack of 
p21 expression could reflect E6 directly targeting p21 and/or the consequence of efficient 
upstream degradation of p53 leading to attenuated p53-dependent p21 transcription.  Due to 
the absence of E6 in E7 only expressing cells such as the transduced PHKs, a greater 
checkpoint function is reported to be retained which may contribute to the limited life span of 
E7 transduced cells in culture 268. 
 
The initial rise in p21 expression by the cells in response to LMB is possibly due to the 
prevention of p21 degradation by nuclear accumulation or maintained p21 activation, causing 
an effect on nuclear exported of various proteins in a HPV dependent or independent manner.  
Although p21 acts as an early event in the p53 pathway it can also be activated in a p53-
independent manner 213.  Therefore, some of the p21 response within these cells may 
represent p53-independent induction of p21.  Indeed the p53-dependency of the response may 
differ in the presence or absence of LMB.  However, the p53-dependence of the p21 response 
detected during theses studies cannot be determined from this data partly because of the 
interaction of HPV with both the p53 and p21 pathways.  The pattern of p53 and p21 detected 
during these time studies is likely also to have been highly influenced by the level of 
apoptosis.  From 24h onwards in the E7 transduced PHKs and 36h in the remaining cell lines, 
the expression of both proteins would naturally decrease as increasing numbers of cells 
become apoptotic.   
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Figure 6.7:  The LMB-induced expression of the cell regulators p53 and p21 varies amongst the 
transduced PHKs and the W12 derivatives. The dotted lines represent the p21 levels with the shaded 
areas indicating p53 expression after 2nM LMB over a 48h time course.   
 
 
Unlike the apoptotic markers (figure 5.8, chapter 5), the expression patterns of p53 and p21 
over the 48h time course do not appear to correlate with the genome status of the cells (figure 
6.7).  This suggests that the p53 and p21 expression patterns within the W12 derivatives and 
transduced lines appear to be influenced by differences other than integration type alone; this 
may include the clonal nature of the cells and direct or indirect consequences of viral 
infection.    
 
Most of the cell lines appeared to show a pulse of both p53 and p21 after 12h of LMB 
treatment.  However, as shown in figure 6.7 some deviation from this pattern was apparent 
with p53 expression delayed in I22 and E63, and p21 expression delayed in E63, I61, and E6/E7.  
The presence of both the E6/E7 and the whole viral genome is likely to influence the p53 and 
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p21 responses to LMB.  This is likely to be primarily achieved by direct interaction of E6 and 
E7 with these regulatory proteins.  However, variations in the direct interaction of other viral 
proteins and the differences in the cellular responses may also influence the expression of p53 
and p21 (see section 1.5).  For example, higher E6 expression by a cell line may cause greater 
inhibition of the DNA repair protein XRCC1 316, leading to the increased cellular stress 
signalling including p53 and p21. 
 
The extreme delay in p53 expression by the E63 derivative may be a consequence of the late 
induction of apoptosis reported in these cells in chapter 5, allowing the accumulation of 
greater amounts of p53 in these cells than in those where cells are destroyed more rapidly 
(integrated and transduced cell lines) or where levels of apoptosis appear greater (E50).  
However, other factors such as possible integrated sequences and the presence of the p21 
doublet may also heavily influence this response.   
 
Although the E7 and E6/E7 transduced PHKs provide a useful model for the influence of the 
E6 and E7 oncogenes on the pattern of p53 and p21, the expression within the W12 
derivatives is influenced by a more complex viral environment, where E6 and E7 are 
expressed in the presence of the whole HPV 16 genome in a regulated (episomal) and 
unregulated (integrated) manner; however, some contributions of E6 and E7 can be clearly 
identified.  The E7 transduced PHKs expressed high levels of p53 as did the untreated W12 
derivative I61, which has previously been reported to express high levels of E7 
119.  In I61 
derivative, the presence of a maintained rise in untreated p53 levels appears to mirror the 
expression in the E6/E7 transduced PHKs, supporting the previously reported presence of 
high levels of both oncoproteins within this W12 derivative 119,403.  A possible role for E7 in 
the p53 response is also suggested by the early and largely maintained expression of p53 in 
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both the E7 and E6/E7 transduced lines, a similar pattern to that present in some of the W12 
derivatives particularly I61.  Also a delay was apparent in the p21 response of the E6/E7 
transduced PHKs which was absent in the E7 transduced line, suggesting that high E6 
expression may delay the p21 response.  A similar pattern of p21 expression is also apparent 
in the E63 and I61 derivatives; however, the doublet p21 in the E63 line may be responsible for 
the effect present in this episomal line.  The results for the type 2 integrated derivative I61 
clearly suggest that both E6 and E7 play important roles in both untreated and LMB treated 
cells, probably due to increased expression as a consequence of integration.   
6.4.3. p21 Doublet Formation in W12E63 
Both p21 and p53 expression in the E63 derivative proved different from the remaining cell 
lines.  The most striking difference was the expression of a doublet form of p21 apparent 
during western blotting.  The use of both C-terminal and internal p21 antibodies suggests that 
the novel band may be formed by the alteration or more likely splicing of the p21 sequence in 
the N-terminal portion of the protein with alteration in the epitope of the internally located 
antibody preventing association.  This event has produced a novel band estimated to be 
between 1.2-2.5kDa smaller than the native form.  The size of the band shift between the 
native and novel forms suggests that it is unlikely that all 77 amino acids located from the 
internal antibody epitope to the N-terminus have been lost, as a larger band shift of 
approximately 8.7kDa would be present if the whole of this region was absent (see appendix 
C2 for N-terminal sequence details).  The expression of the smaller novel protein was 
accompanied by the wild type 21kDa protein suggesting there may be variations in the RNA 
sequence/splicing or possible post-translational protein modifications.  It remains unclear if 
the lower band retains function; the majority of the LMB-dependent or independent induction 
of p21 in E63 appears to have occurred in the upper p21 band, suggesting that some functional 
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differences may be present between the two forms.  The amino terminal domain of p21 is 
known to be required for inhibition of the cell cycle control cyclin/cdk complex 204.  It is 
therefore possible that the loss of relatively few amino acids from this region of the protein 
may be sufficient to prevent or attenuate this function leading to abnormal cell cycle 
progression.  The presence of the doublet form of p21 within E63 may influence the behaviour 
of these cells in the presence or absence of LMB, including the expression of p53 and the 
apoptotic markers act-casp-3 and M30 (chapter 5). 
 
The data presented indicates that there is no clear association between delayed apoptosis and 
increased expression of p21, suggesting that prolonged induction of p21 is unlikely to be the 
cause of the delay in apoptosis displayed in chapter 5.  It also remains unclear if the short 
induction of p53 presented in these studies would be sufficient to cause the induction of 
apoptosis presented in chapters 4 and 5, with the data indicating no direct correlation between 
the cell lines displaying higher or more rapid p53 expression and those shown to undergo a 
more rapid or greater apoptotic response.  It is possible that the early induction of p53 may 
still contribute to the apoptotic effect, with the response delayed by alterations in the 
downstream transmission of the proapoptotic signal.   
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Chapter 7: The Contribution of p53 to LMB-Induced 
Apoptosis 
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7.1. Introduction 
LMB-induced apoptosis of the W12 derivatives has been shown to be associated with 
increased levels of both p53 and p21 (chapters 5 and 6).  However, the role of p53 in LMB-
induced apoptosis of the W12 derivatives remains unclear.  The large range of possible 
cargoes utilising the REV type nuclear export pore, means that p53 is just one of a huge range 
of proteins affected by the LMB-induced inhibition of CRM1 mediated export (section 1.7.1).  
Therefore, the induction of apoptosis could be induced by disrupting of one or more of these 
proteins, which may or may not include p53.  In the presence of a HPV infection the activities 
of the virus itself may also influence the mechanisms by which LMB induces apoptosis.  The 
actions of both HPV 16 E6 and E7 mean that the functionality of nuclear accumulated p53 
and its potential role in the induction of apoptosis is difficult to discern.  These studies aimed 
to clarify the role of p53 in LMB-induced apoptosis by assessing the effect of a dominant 
negative p53 on LMB-induced apoptosis.   
7.2. Methods 
Retroviral packaging cells were transfected with the dominant negative (Dnp53) expression 
construct (53R248W) or empty pBabe-puro (section 2.7.3).  This puromycin resistant 
construct was utilised due the existing neomycin resistance of the pLXSN vector within the 
E7 and E6/E7 transduced PHKs.  The retroviral supernatants from the Dnp53 transfected 
packaging cells were used to transduce E7 and E6/E7 expressing PHK lines, W12 derivatives 
E50, I22 and I31, and the osteosarcoma cell line U2OS, as described in section 2.8.  The 
successful transfer of the Dnp53 construct to all the relevant transduced cell lines was 
confirmed by PCR analysis, as described in section 2.16.4.  The ability of the dominant 
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negative construct to reduce p53 DNA binding was assessed by luciferase reporter assay of 
U2OS cells (section 2.19), with the LMB sensitivity also assessed by western analysis 
(section 2.12.7.6).  The sensitivity of the Dnp53 transduced W12 and PHK cells lines to LMB 
treatment was assessed by western blotting, as described in section 2.12.7.7.   
7.3. Results 
The dominant negative p53 R248W (Dnp53R248W, Dnp53) 412 contains a point mutation at 
codon 248, where the arginine is replaced by tryptophan 435.  In the wild type p53 protein this 
region is associated with DNA binding, and is required for the interaction of the positively 
charged side chain of arginine 248 with the negatively charged components of the DNA 
backbone 435.  Therefore, although the overall structure of the protein remains unaffected 435, 
the dominant negative protein is unable to bind DNA and subsequently cannot undertake p53-
dependent transcriptional activity 412.  Some p53 transcriptional activity may be retained due 
to the continued presence of normal p53 protein which may form wild type tetramers (section 
1.3.1).  However, the R248W mutant p53 and any tetramers containing it, will be unable to 
bind DNA and therefore transcription of p53 responsive genes is restricted 435.   
7.3.1. Confirmation of the Presence of the Dnp53R248W Construct  
The Dnp53R248W dominant negative construct was transduced into the E7 and E6/E7 
transduced PHKs, W12 derivatives E50, I22 and I31, and the wild type p53 osteosarcoma cell 
line U2OS 409,410.  Although puromycin selection was applied to select for successfully 
transduced cells, the presence of the Dnp53 construct in the selected cells was also confirmed 
by PCR analysis using a forward primer located in the vector backbone (pLXSN2S) and the 
reverse primer located in the p53 sequence (p53A). 
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(a) 
 
 
      
 
Figure 7.1:  The presence of the Dnp53R248W plasmid within the transduced cells was confirmed by 
PCR.  Amplification was undertaken on (a) PHK lines containing E7 and E6/7, W12 derivatives E50, 
I22 and I31 and (b) the U2OS cell line.  For each cell line DNA from non-Dnp53 transduced (wt), vector 
only (vp) and dominant negative (Dn) cell were analysed in combination with DNA from Dnp53 
transfected PT67 packaging cell (PT) and a no template control (0). 
 
 
The PCR analysis confirmed amplification of an appropriate 467bp band from all the Dnp53 
transduced cell lines, which was absent in the wild type/pLXSN and vector only cell lines, as 
shown in figure 7.1.  This represents the expression of similar amounts of integrated 
construct. 
7.3.2. Decrease in p53 Dependent Transcriptional Activity in Cells 
Transduced with Dominant Negative p53 
 
The ability of Dnp53R248W to reduce p53 transcriptional activity was assessed using a p53 
reporter assay utilising the pSynp53 luciferase reporter construct.  Initial optimisation of the 
assay using W12 derivatives and the E7 and E6/E7 transduced PHKs failed to detect any p53 
transcriptional activity.  Therefore, the osteosarcoma cell line U2OS was used as these cells 
are known to express wild type p53 409,410 and grow robustly in culture.  They therefore 
provide a good model to test the effectiveness of the p53 luciferase reporter assay.  
Optimisation was also undertaken on E7 expressing PHK cells to test the effectiveness of 
(b) 
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HPV E7 anti-p53 activities as a possible mechanism for the lack of signal previously 
encountered in the W12 derivatives and HPV transduced PHKs.  As described in section 
1.3.1, p53 is normally maintained in the cell at low levels due to proteasomal degradation.  
However, increased expression and stabilisation of p53 occurs in response to a number of 
stress stimuli such as nucleotide depletion and DNA damage.  Therefore, the p53 dependent 
transcriptional activity of these cells was assessed in the presence of minimal cellular stress 
(no LMB) and after the induction of a cellular stress response via the addition of 2nM LMB 
(12h).   
 
 
 
Figure 7.2:  The detection of p53 dependent transcriptional activity in U2OS and E7 transduced PHKs 
(PHKE7).  The luciferase expression of U2OS and E7 transduced cells transfected with pSynp53 and 
luciferase control pRL-CMV was assessed with (+) and without (-) 2nM LMB (12h). 
 
 
In the absence of cellular stress the U2OS cells were shown to exhibit notable levels of p53 
dependent transcriptional activity (figure 7.2), with LMB treatment (2nM, 12h) causing a 
notable upregulation of p53 activity with transcription increasing approximately 2-fold.  
However, the p53 expressed by the E7 transduced PHKs failed to show any notable p53 
dependent transcriptional activity even in the presence of increased cellular stress (figure 7.2).   
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Previous experiments with E2 expressing U2OS and vector only controls are shown below in 
figure 7.3.  They indicate that no induction of apoptosis could be detected in the E2 
expressing or pCMV vector only U2OS cell lines following LMB treatment (figure 7.3), 
despite a substantial apoptotic response in the W12 derivatives similar to that previously 
noted in chapter 5.   
 
 
 
Figure 7.3:  U2OS cells (U2) in the presence (U2 E2) or absence (U2 vec) of HPV 16 E2 in 
combination with the W12 derivatives were treated with 2nM LMB (38h).  In the presence (+) or 
absence (-) of 2nM LMB (38h) alterations in act-casp-3 (Casp) or M30 were assessed by western 
blotting with β-actin utilised as a loading control. 
 
The experiments shown above suggested that the U2OS cells would provide a suitable model 
in which to confirm the effectiveness of the dominant negative p53 in decreasing p53–
dependent transcriptional activity.  Therefore, the luciferase reporter assay was undertaken 
with wild type (wt), pBabe vector only (vp) and Dnp53 (Dn) transduced U2OS cell lines. 
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Figure 7.4:  The assessment of p53 dependent transcriptional activity in Dnp53 transduced cells.  Wild 
type (wt), vector only (vp) or Dnp53 transduced U2OS cells were transiently transfected with the p53 
luciferase reporter pSynp53 and control pRL-CMV.  The luciferase activity was then assessed with (+) 
and without (-) 2nM LMB (38h). 
 
 
In the absence of LMB both the wild type and vector only U2OS cells expressed notable 
levels of p53 dependent transcriptional activity (figure 7.4).  The presence of dominant 
negative p53 led to a sizeable decrease in p53 dependent transcriptional activity, reducing 
activity by an average at least 6 fold.  Under LMB-induced stress conditions the p53 
dependent transcriptional activity of the wild type and vector only U2OS cells increased 
substantially, representing an almost 3 fold increase in activity.  However, even in the 
presence of LMB-induced cellular stress the cells containing the dominant negative p53 
displayed only minimal increases in their p53 dependent transcriptional activity 10 fold lower 
than in the wild type and vector only cells (figure 7.4). 
7.3.3. Effect of Dominant Negative p53 on LMB-Induced Apoptosis in HPV 
16 Infected Cells 
The role of p53 in LMB-induced apoptosis was assessed in the wild type, vector only and 
dominant negative transduced lines in the presence or absence of 2nM LMB (38h), by 
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examining changes in the apoptotic markers act-casp-3 and M30, as previously described in 
chapter 5. 
 
 
Figure 7.5:  The effect of dominant negative p53 expression on LMB-induced apoptosis.  The 
expression of act-casp-3 (Casp) and M30 in the non-Dnp53 (wt), vector only transduced (vp) and 
Dnp53 transduced cell lines (Dn), was assessed in the presence (+) or absence (-) of 2nM LMB (38h).  
The 40kDa M40 band is indicated by the filled arrow and where present the 24kDa form indicated by 
an empty arrow. 
 
In the absence of LMB no notable induction of apoptosis was detected in any of the wild type, 
vector only or Dnp53 cells with the exception of E50, where small increases in the basal 
activity of both act-casp-3 and M30 were detected (figure 7.5).  As previously shown (chapter 
5), the treatment of both W12 derivatives and transduced PHKS in the absence of Dnp53 
caused a notable upregulation of both act-casp-3 and M30 (figure 7.5), with the presence of 
the pBabe-puro vector alone having little effect on this response.  The presence of the 
dominant negative p53 also had little effect on the expression of either act-casp-3 or M30 in 
the presence of 2nM LMB (38h), indicating that no notable change in the induction of 
apoptosis occurred despite abrogation of the p53 response.  Both the early 40kDa and late 
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24kDa forms of M30 were apparent in E7 and E6/E7 transduced PHKs; however, the later 
24kDa form was absent in the W12 derivatives.  Although LMB treatment of the Dnp53 
transduced cells did not induce changes in the total M30 expression, some alteration in the 
pattern of early and late M30 was apparent within the E7 and E6/E7 transduced PHKs.  The 
E7 expressing PHKs transduced with Dnp53 showed an increase in the later 24kDa form with 
a corresponding decrease in the 40kDa early protein in the presence of LMB (figure 7.5).  The 
E6/E7 transduced PHKs containing Dnp53 displayed an increase in the late 24kDa form of 
M30 in both the presence and absence of LMB; although expression levels were particularly 
low as previously described (chapter 5) no detectable corresponding decrease in the 40kDa 
form could be detected.  
7.4. Discussion 
The data presented in chapters 5 and 6, combined with previous research from our own 
laboratory 374 and others 182,203,375, suggest that LMB-induced effects may be facilitated by the 
cellular regulator p53, with LMB treatment previously shown to induce increased levels in 
p53.  In wild type PHKs 374 and normal human fibroblasts 398, LMB treatment is associated 
with the induction of cellular quiescence, whilst in HPV-associated cell lines LMB causes the 
induction of apoptosis (chapter 6) 182,203,374.  However, whether this accumulated p53 plays a 
role in the induction of apoptosis by LMB remains unclear.  Previous results from this 
laboratory 374 and the data reported in chapters 5 and 6 show that, although an increase in p53 
is present in response to LMB, this rise is temporally distinct from the induction of apoptosis.  
Therefore, the proposed induction of apoptosis by the direct perturbation of p53 nuclear 
export is brought into question.  In addition, the general nature of CRM1-mediated nuclear 
export provides many possible alternative mechanisms by which LMB-induced apoptosis 
could be initiated within these cells.   
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The normal p53 dependent transcriptional activity of the U2OS cell lines was confirmed by 
luciferase reporter assay, suggesting a wild type p53 conformation was present as proposed by 
both Soni et al (2001)410 and Li et al (2002)409.  The p53 dependent transcriptional activity 
suggests that the p53 transcriptional response is likely to have remained intact despite the 
malignant status of these cells.   
 
The unstressed U2OS cells showed clear evidence of p53 transcriptional activity in the 
absence of LMB.  This activation may be slightly greater than would normally be present in 
an unstressed state due to the malignant nature of the cell lines and/or the possible induction 
of low levels of cellular stress during transfection of the p53 luciferase reporter.  Treatment of 
the U2OS cells with 2nM LMB indicated the presence of a LMB-induced p53-dependent 
transcriptional response, but a failure to induce apoptosis.  This suggests that the U2OS cells 
do not innately contain factors that would sensitise them to LMB-induced apoptosis.  In 
addition, the presence of HPV 16 E2 alone appears insufficient to induce apoptosis in 
response to LMB under conditions previously shown to induce apoptosis in PHKs transduced 
with E7 and E6/E7 374.  However, the failure of the E7 transduced PHKs to exhibit a 
significant p53 dependent transcriptional activity during the luciferase assay implies that this 
response in these cells is severely impaired.  This is probably due to the interaction of HPV 
E7 with the p53 protein, causing the formation of a transcriptionally inactive complex.  
Therefore, any contribution of p53 to LMB-induced apoptosis is likely to be independent of 
its transcriptional activity in this setting. 
 
As previously reported by Shamanin and Androphy (2004) 412, even in the presence of a 
dominant negative p53 mutant the protein does retain some p53 dependent transcriptional 
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activity, although at greatly reduced level.  This diminished response is likely to be a 
consequence of the native p53 whose expression remains unaffected by the dominant negative 
protein.  In the presence of this mixed population of native and mutant p53, some native 
tetramers are likely to form facilitating limited p53-dependent transcriptional activity.  LMB 
treatment of the Dnp53 U2OS cells was associated with a slight increase in p53 dependent 
transcriptional activity likely to represent an increase in native p53 tetramer formation.  This 
may be due to either an increase in p53 expression or an increase propensity for tetramer 
formation in response to LMB. 
 
LMB-induced upregulation of p53 dependent transcriptional activity in the wild type and 
vector only transduced U2OS cells is likely to represent the cumulative effects of a number of 
p53 activation pathways (section 1.3.1).  When exposed to cellular stress the cells not only 
raise the levels of de novo protein by upregulation of p53 transcription 176, but also alter the 
status of existing protein leading to the stabilisation and nuclear accumulation of p53.  Upon 
activation existing p53 is actively imported into the nucleus 179,195, and forms into tetramers 
further aiding nuclear accumulation by masking the p53 nuclear export signal.  In addition, 
p53 degradation is reduced by relocation of the p53 agonist Mdm2 to an alternative nuclear 
region 171 (section 1.3.1) and the inhibition of Mdm2 mediated degradation by N-terminal 
phosphorylation of the accumulated p53 138,171.   
 
The presence of Dnp53 had no effect on LMB-induced expression of either act-casp-3 or M30 
in the W12 derivatives; this suggests that the apoptotic response of these cells is not mediated 
by p53-dependent transcription.  Interestingly, the presence of the dominant negative p53 in 
the LMB treated E7 transduced PHKs and the treated and untreated E6/E7 expressing cells 
led to an altered pattern of M30 expression.  In both cases an increase in the later 24kDa 
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CK18 cleavage product was seen, representing a more rapid progression of apoptosis.  This 
suggests that in the absence of the complete HPV 16 viral genome in either episomal or 
integrated form, the interaction of E6 and E7 with the native p53 slows the progression of 
apoptosis.  However, any effect on the rate of apoptosis in the transduced lines does not 
appear to alter the overall induction of apoptosis, as shown by the unchanged expression of 
act-casp-3 and total M30. 
 
Even in the absence of p53-dependent transcription, the p53 protein may still play a role in the 
initiation of apoptosis by LMB.  Indeed in normal cells it is likely that the transcription-
dependent and independent p53 pathways work together to respond to cellular stress 222.  The 
transcription independent mechanisms of p53 include the release of pro-apoptotic 
mitochondrial products 170 by the inhibition of mitochondrial anti-apoptotic proteins Bcl-XL 
and Bcl-2, and activation of the pro-apoptotic protein BAK by a truncated form of the 
activated p53 protein 251.   
 
These data suggest that the induction of apoptosis may be occurring via p53-independent 
mechanisms.  A possible candidate for this role is the p53 family member p73 387 which like 
p53, plays a role in the regulation of both the cell cycle and apoptosis 436.  p73 has been 
shown to be over expressed in human tumours including cervical neoplasia 437, but is rarely 
found to be mutated unlike its family member p53 438-440 (reviewed in ref 169).  The p53 
family, including the additional member p63, share a highly conserved amino acid sequence 
and are all able to activate p53 response elements 387,441,442 leading to the transcription of 
genes normally associated with p53 443,444.  Indeed studies have suggested that both p63 and 
p73 may be required for p53-dependent apoptosis 445.  Although evidence suggests that 
degradation of p73 can be mediated by ubiquitin-dependent or independent mechanisms, in an 
LMB-dependent manner (table 1.2), the pathways employed appear distinct from those used 
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by p53 169,446,447.  However, the apoptotic stimuli to which p73 responds appears to be distinct 
from those of p53 169,448.  
 
In human neuroblastoma cells and normal human fibroblasts treatment with LMB has been 
associated with a p53-dependent cytotoxicity, which displays a minimal p73 response 398.  
However, the data presented in this chapter suggests that in the W12 derivatives and PHKs 
containing HPV E7 or E6/E7, LMB-induced apoptosis is not dependent on p53 and, therefore, 
in this context p73 may provide an alternative mechanism for the mediation of apoptosis.  In 
HPV 16 infected cells, significant upregulation of BAX and p73 in the absence of notable p53 
expression has been shown to induce apoptosis in response to hydrogen peroxide 436.  The 
subsequent induction of apoptosis mediated by the mitochondrial pathway was shown to be 
associated with increased expression of the initiator caspase-9 and the executioner caspase-3 
436, this act-casp-3 association is reminiscent of that present in response to LMB during the 
current studies (chapter 5).  The occurrence of a p73 response in the absence of p53 induction 
suggests that p73 is able to evade the virally derived mechanisms used to control the 
expression of p53, although it remains unclear if direct viral regulation of p73 occurs in HPV 
infected cells.  Studies on squamous cell carcinomas of the oesophagus have suggested that a 
complex interaction is present between the virus, p53 and p73 indicating that anti-p73 virus 
mechanisms may exist.  This alternative mechanism for the mediation of apoptosis provides a 
possible explanation for the interaction of the virus at several different of stages of the 
relevant regulatory and apoptotic pathways, and could be interpreted as an attempt by the 
virus to close loopholes by which the cell may induce cell cycle arrest or apoptosis. 
 
It remains unclear if the initiation of apoptosis could be achieved by the disruption of p73 
alone.  Although p73 is known to utilise the REV type nuclear pore (section 1.6.1-2 and table 
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1.2), treatment with LMB also affects numerous other proteins which are directly or indirectly 
dependent on CRM1-mediated export.  The data presented in these studies (chapter 5) 
combined with previous studies from this laboratory 374 suggests that the presence of HPV 16 
E7 alone is sufficient to induce the pro-apoptotic effects of LMB.  Sensitisation to LMB is 
therefore likely to be a response to the disruption of an E7 susceptible process, with the effect 
decreased in the presence of both E6 and E7 by either E6-mediated attenuation or a reduction 
in the levels of E7 protein.  p73 appears resistant to the effects of E7 449 and although unable 
to degrade the protein it is uncertain whether E6 can inhibit the transcriptional activity of p73 
450.  Therefore, it seems unlikely that direct disruption of p73 trafficking is initiating LMB-
induced apoptosis.  The apoptotic trigger is likely to originate from the disruption of one or 
more of the alternative E7-sensitive CRM1-exportable proteins, subsequently leading to the 
activation of the p73 regulated apoptotic pathway. 
 
The data presented in this chapter suggest that the LMB-induced apoptosis in W12 
derivatives, and E7 or E6/E7 transduced PHKs is unlikely to be a p53-dependent process.  
The rise in p53 levels in LMB treated cells does not appear to contribute to the induction of 
apoptosis via p53-dependent transcriptional mechanisms, although p53 may contribute to the 
effect in a transcription-independent manner.  However, it appears likely that LMB-induced 
apoptosis in these cells is mediated primarily by an alternative cell regulator such as the p73 
in response to an E7-sensitive trigger.    
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Chapter 8: Conclusions and Further Studies 
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8.1. Conclusions 
The nuclear export inhibitor leptomycin B (LMB) has previously been shown to induce 
apoptosis in HPV-infected cancer cell lines 182,203 and HPV 16 E6, E7 and E6/E7 transduced 
primary human keratinocytes 374.  This LMB-induced effect has been associated with an 
increase in the detectable levels of p53, providing a possible mechanism for the induction of 
cell death.  However, increased levels of apoptosis in response to LMB have also been 
demonstrated in other cells such as human leukaemia cell line U937 399, prostate epithelial cell 
line LNCaP, 375 and cells expressing the abnormal BCR-ABL fusion protein 400.  In these 
cases, the primary cause of the sensitivity to LMB is not viral infection, but carcinogenic 
transformation or the presence of abnormal gene translocations.  The common link between 
these cases of increased LMB sensitivity is the existence of considerable alterations in vital 
cell regulatory systems, which appear to be sufficient to alter the behaviour of the cells in 
response to LMB-induced inhibition of nuclear export.  
 
The overall aim of this project was to assess the effects of LMB on cells containing the whole 
HPV 16 genome in either episomal or integrated forms, with particular interest in the 
induction of apoptosis by LMB and the impact of HPV 16 infection on this process.  The 
episomal and integrated derivatives of the W12 cell line provided a useful model for the 
further study of HPV-associated disease, allowing investigation of the effects of HPV 
integration on the LMB response. 
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Chapter 3: The Status of HPV 16 in W12 Cells Containing Episomal and 
Integrated Viral Genomes 
1) The genome status of the episomal W12 episomal derivatives was confirmed, in 
combination with viral genomic differences associated with type 1 and 2 integrated 
genomes.   
2) As predicted by their integrated status, W12 cells containing both types of HPV 
integration failed to produce a detectable E2 protein, despite the apparent amplification 
and transcription of the complete E2 ORF from the type 2 integrants.   
3) The transcription and subsequent splicing of the HPV 16 E6/E7 transcript was detected in 
all the W12 derivatives, with E6*I dominant throughout.  The pattern of splicing present 
in PHKs transduced with E6/E7 suggests that, although the ability to splice the full length 
mRNA may be innate to the transcript, but the presence of the whole viral genome 
appears to regulate the pattern of splicing activity. 
4) The viral genome status of the W12 derivatives described in these studies is likely to have 
consequences for the interaction of the virus with the host cell systems and the sensitivity 
of the cells to LMB.   
Chapter 4: Alterations in Morphology and Colony Survival in Response to 
Leptomycin B 
1) When grown in raft culture the W12 derivatives showed variation in epithelial structure 
between those containing episomal and integrated HPV.  Episomal rafts appeared thicker, 
with greater amounts of abnormal structure and vacuolation, while rafts formed by cells 
containing integrated HPV formed a more organised structure.  
2) Treatment with LMB induced morphological changes in the W12 derivatives grown in 
both monolayer and raft culture.  In both models, the LMB response was characterised by 
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a loss of cells in combination with apparently apoptotic morphology.  Although levels of 
LMB-induced damage appeared greater in the episomal raft, no definitive differences 
between episomal and integrated lines could be established in monolayer culture. 
3) W12 derivatives and E7 transduced PHKs displayed no colony forming ability at 
concentrations greater than 2nM LMB (40h).  However, the HPV-associated cancer cell 
lines successfully formed colonies after treatment with up to 100nM LMB (40h).  The 
W12 derivatives containing integrated HPV displayed greater colony survival than their 
episomal counterparts, although the greatest colony formation was present in the primary 
keratinocytes expressing only HPV E7.  This suggests that, although the presence of E7 
has previously been shown to sensitise cells to LMB-induced apoptosis in the current and 
previous studies 374, its presence may in fact be beneficial to the post-treatment survival of 
HPV infected cells. 
Chapter 5: Leptomycin B Induces Apoptosis in Cells Containing the Whole 
HPV 16 Genome 
1) In the absence of LMB, both monolayer and rafted W12 derivatives displayed greater 
levels of innate apoptosis than previously reported for E7 or E6/E7 transduced PHKs 374.  
These high levels of innate apoptosis are likely to be at least in part due to the induction of 
virally mediated pro-apoptotic mechanisms which may sensitise cells to undergo 
apoptosis in response to LMB.  In the raft model this pro-apoptotic response appeared 
particularly strong in those cells containing episomal HPV; this may be a response to the 
expression of E2 which is known to have pro-apoptotic function. 
2) LMB treatment was associated with upregulation of the apoptotic markers activated 
caspase-3 and M30 in both monolayer and rafted cells.  Variations in expression between 
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the different HPV-associated cell lines were apparent and are likely to reflect the impact 
of the viral genome and the clonal nature of the derivatives. 
3) The viral genome status of the cells appears to influence both the temporal and the 
cumulative pattern of act-casp-3 and M30 expression, but not necessarily the levels of 
these markers.  E7 alone is associated with a more rapid induction of peak apoptosis and a 
greater discrepancy between the two markers.  However, the presence of E6 causes a 
delay in reaching peak apoptosis and a temporal separation between the two markers.  
Episomal HPV was associated with a slow induction of apoptosis with little difference 
between the markers; viral integration induced more rapid apoptosis with integration type 
affecting the expression pattern of markers.  Cells containing type 2 integrants displayed 
concurrent expression both markers, whilst cells containing type 1 integrants showed a 
delay in reaching peak levels of act-casp-3.    
4) High levels of E7 protein in the transduced PHKs and I61 derivative appeared to be 
associated with greater expression of act-casp-3 as apposed to M30 in the remainder of the 
cell lines.  This is suggestive of a possible relationship between E7, act-casp-3 and LMB 
in the induction of apoptosis. 
Chapter 6: The Expression of p53 and p21 in Response to LMB Treatment 
1) High innate expression of both p53 and p21 was present in the raft cultures of the cells 
containing episomal and integrated HPV.  The pattern of expression of these regulatory 
proteins varied over the raft suggesting alterations in behaviour throughout the raft 
structure.  In response to LMB the levels of p53 showed little alteration, whilst p21 
appeared to decrease. 
2) In monolayer W12 cultures both p53 and p21 were expressed in the absence of LMB and 
displayed particularly high levels of innate p53.  This innate response is likely to be 
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greatly influence by the interplay between E6 and E7, with stabilisation of p53 by E7 
balanced by E6-mediated degradation, as illustrated in the differences between E7 and 
E6/E7 transduced PHKs.   
3) A novel p21 band forming a doublet with the native form was detected in the E63 
derivative.  This smaller protein is likely to be produced by splicing within the central/ N-
terminal region of the protein.  It remains unclear if the novel protein retains any 
functional properties, although the reduced responsiveness to LMB treatment and the 
probable disruption of the cyclin/cdk inhibitory function may indicate some loss of 
function is likely to have occurred.  
4) An increase in p53 and p21 expression in response to LMB treatment was induced in both 
the transduced PHKs and W12 derivatives.  In the majority of cells, both p21 and p53 
were expressed rapidly after only 12h of treatment.   
5) It remains unclear if the rise in p53 levels at the 12h time point would be sufficient to 
elicit the apoptotic response shown in chapters 4 and 5.  The similarity of the p53 response 
suggests that if the p53 is in any way associated with induction of apoptosis, then other 
clonal or virally related factors must also influence the response, leading to the variations 
in apoptosis shown during these studies.   
Chapter 7: The Contribution of p53 to LMB-Induced Apoptosis 
1) Notable levels of transcriptionally active p53 could not be detected in E7 transduced 
PHKs, even in the presence of LMB-induced stress.  This suggests that in these cells the 
majority of the p53 is bound to E7 in a transcriptionally inactive state. 
2) Despite its malignant nature, the U2OS cell line expressed protein capable of p53 
dependent transcriptional activity, whose potential transcriptional activity is increased in 
response to LMB.  The presence of the dominant negative p53 caused a substantial 
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decrease in luciferase production confirming the ability of the Dnp53 construct to inhibit 
p53 dependent transcription from a synthetic reporter. 
3) The induction of apoptosis by LMB did not decrease in response to the dominant negative 
p53 in the W12 derivatives and E7 or E6/E7 transduced PHKs.  However, the transduced 
cells did display an alteration in the rate of apoptosis in the presence of the dominant 
negative protein with increasing levels of the later form of the M30 neoepitope. 
4) The induction of apoptosis by LMB does not appear to be dependent on the presence of 
transcriptionally active p53.  It is therefore likely that the effects of LMB are mediated 
and/or induced via alternative pathways.   
5) The p53 family member p73 is a possible candidate for the mediation of LMB-induced 
apoptosis. However, due to the promiscuous nature of CRM1-mediated export, the actual 
induction of apoptotic signalling may be a reaction to the direct or indirect disruption of 
numerous different proteins.  The apoptotic response of the E7 transduced PHKs suggests 
that the effects of LMB are likely to be induced by disruption of an E7 sensitive protein. 
Clinical Relevance 
LMB has been proposed as a potential therapeutic for the treatment of HPV-associated 
cervical neoplasia.  The W12 model of episomal and integrated cells, in combination with the 
oncogene-transduced PHKs, provides a model of the effects of LMB and should therefore 
contribute to the future therapeutic use of LMB.  These studies show that the status of the 
viral genome, with its subsequent impact on oncogene expression, will influence the way in 
which HPV infected lesions respond to LMB.  Therefore in order to attain a successful 
clinical outcome, variations in treatment schedule will be required.   
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Cells containing episomal HPV 16 appeared to undergo less rapid induction of LMB-induced 
apoptosis compared with their integrated counterparts.  Therefore, early pre-integration 
lesions will likely require more prolonged or higher dosage treatment with LMB to attain the 
same clinical outcome.  It appears that lesions expressing high levels of E6 may be associated 
with decreased effectiveness of LMB.  Conversely increased levels of E7 apparently 
sensitised cells to LMB; therefore, the expression of E6 and E7 are likely to prove important 
in influencing the LMB response of infected lesions.  Interestingly, a greater resilience to 
higher LMB doses was seen in the HPV cancer cell lines, suggesting that malignant lesions 
are likely to prove more resistant to treatment.   
 
These and previous studies have suggested that LMB is a potential therapeutic for both early 
and late stage lesions containing episomal or integrated HPV 16 infections.  By understanding 
the variations in LMB-induced response during malignant progression and the mechanisms 
driving these effects, LMB could be utilised as an additional treatment for patients with HPV-
associated anogenital lesions particularly in the presence of integrated HPV. 
8.2. Further studies 
Chapter 3: The Status of HPV 16 in Cells Expressing Episomal and 
Integrated Viral Genomes 
1) The use of 2-dimensional electrophoresis would allow further investigation of the possible 
integrated sequences detected in the E63 derivative during the Southern analysis. 
2) The effect of integration-associated loss of E2 and its effect on LMB sensitivity could be 
examined further by undertaking E2 siRNA in the episomal derivatives.   
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3) Examination of E6/E7 protein expression was not undertaken during these studies due to 
the low quality of available antibodies.  In future studies the investigation of possible new 
antibodies and the optimisation of staining would prove very useful. 
Chapter 4: Alterations in Morphology and Colony Survival in Response to 
Leptomycin B 
1) The rafting of the remaining W12 derivatives with subsequent immunocytochemistry 
would allow the role of clonal differences and integration type in the presence or absence 
of LMB to be investigated. 
2) The LMB treatment of the W12 rafts could also be undertaken over a time course.  This 
would allow a greater understanding of the pattern of morphological and apoptotic 
changes throughout a differentiated epithelium, and the role of the cell regulatory response 
in these effects. 
3) Repeating the colony survival assay on all the W12 derivatives would allow the role of 
integration on post-treatment survival to be assessed.  The addition of wild type, E6 and 
E6/E7 transduced PHKs in combination with other HPV negative and positive cell lines 
would allow further assessment of the role of HPV in post-LMB survival. 
Chapter 5: Leptomycin B Induces Apoptosis in Cells Containing the Whole 
HPV 16 Genome 
1) An extension of the time course experiment past 48h would allow greater resolution of the 
response to LMB, particularly for the episomal derivatives where both apoptotic markers 
continued to rise up to the 48h time point.   
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2) The examination of alternative members of the executioner caspase family would allow 
the possible role of other caspases in the induction of apoptosis in the W12 derivatives and 
transduced PHK cells to be assessed in the presence or absence of LMB.   
3) The analysis of the current apoptosis data could be combined with that from other 
alternative methods such as the TUNEL assay or FACS analysis to provide a more 
accurate measure of the induction of cell death in response to LMB.  In addition, the use 
of a number of different methods would allow examination of any variation in the LMB-
induced response during different phases of the apoptotic pathway.   
Chapter 6: The Expression of p53 and p21 in Response to LMB Treatment 
1) A more detailed time course experiment focusing on the response to LMB at 0-24h with 
subsequent analysis of p53, p21 and other potential regulatory proteins would allow a 
more detailed examination of the role of these proteins in both untreated and LMB treated 
cells. 
2) The nature of the p21 doublet in the E63 derivative requires further examination.  This 
could be undertaken by PCR mapping and/or protein sequencing to establish the origin 
and size of the novel band.  The functionality of this form of p21 could be assessed using 
a p21-luciferase reporter construct similar to that undertaken for the dominant negative 
p53. 
Chapter 7: The Contribution of p53 to LMB-Induced Apoptosis 
1) The use of alternative dominant negative p53 constructs, containing a range of mutations 
and/or truncations, would confirm the absence of p53-dependence in the induction of 
LMB-induced apoptosis.  
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2) To assess if p53 may play a transcription-independent role in the LMB response, siRNA 
against p53 could be used in the W12 derivatives and transduced lines.   
3) Western analysis for p73 within the W12 derivatives and transduced PHKs will allow an 
assessment of the normal expression in the presence or absence of HPV and the effect of 
LMB.  If increased p73 was present a dominant negative p73 could be used to assess its 
role in the induction of apoptosis.  
4) As p53 does not appear to be initiating LMB-induced apoptosis and alterations in p73 
appear an unlikely stimulatory signal, a proteomic screen of E7 and LMB sensitive 
proteins could be undertaken. 
5) The mechanisms by which HPV derived proteins are exported from the nucleus is unclear.  
Western analysis of LMB treated nuclear and cytoplasmic fractions using HPV specific 
antibodies, would allow CRM1 exported viral proteins to be identified. 
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Appendix A: Suppliers 
 ADDgene: Cambridge, UK. 
 Ambion: Texas, USA. 
 Amresco: Ohio, USA. 
 ATCC/ LGC Promochem: London, UK. 
 BDH/VWR: Pennsylvania, USA. 
 Beckman Coulter: California, USA. 
 Becton and Dickinson: New Jersey, USA. 
 Bioline: London, UK. 
 Biometra: Goettingen, Germany. 
 BMG LABTECH: Offenburg, Germany. 
 Calbiochem/Merck Biosciences: Darmstadt, Germany.  
 Cell Signaling: Massachusetts, USA. 
 Clontech: California, USA. 
 DakoCytomation: Glostrup, Denmark. 
 Fisher Scientific/ Thermo Fisher Scientific: New York, USA. 
 GE Healthcare: New Jersey, USA. 
 Globepharm: Surrey, UK. 
 Hoefer: California, USA. 
 Hybaid/ Thermo Fisher Scientific: Massachusetts, USA. 
 Invitrogen (Gibco/Invitrogen): California, USA. 
 Johnson Screens: Minnesota, USA. 
 Launch Diagnostics: Kent, UK. 
 List Biological Laboratories: California, USA. 
 Melford: Suffolk, UK. 
 Millipore: Massachusetts, USA. 
 Nalgene/ Thermo Fisher Scientific: New York, USA.  
 New England Biolabs: Massachusetts, USA. 
 Novartis: Basel, Switzerland. 
 NUNC/Thermo Fisher Scientific: Massachusetts, USA. 
 Oxiod/ Thermo Fisher Scientific: Massachusetts, USA. 
 Packard Instruments: Illinois, USA. 
 PerkinElmer: Massachusetts, USA. 
 Pharmacia Biotech: Uppsala, Sweden. 
 Pierce: Illinois, USA. 
 Promega: Wisconsin, USA. 
 PromoCell: Heidelberg, Germany. 
 Roche Applied Science: Basel, Switzerland. 
 SCIE-PLAS: Warwickshire, UK 
 Sigma-Aldrich: Missouri, USA. 
 Stratagene: California, USA. 
 Syngene: Maryland, USA. 
 Thermo Electron/ Thermo Fisher Scientific: Massachusetts, USA. 
 Thistle Scientific: Glasgow, UK. 
 ULTRA TEC: California, USA. 
 Upstate/Millipore: Massachusetts, USA. 
 Vector labs: California, USA. 
 VWR: Pennsylvania, USA. 
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Appendix B – Protocol Details  
B1. Solutions and Buffers 
B1.1. Complete DMEM 
ITEM Volume Proportion Source 
DMEM 500ml  Gibco/Invitrogen 
Fetal calf serum (FCS) 50ml 10% (v/v) Globepharm 
Penicillin-streptomycin-glutamine 5ml 1% (v/v) Gibco/Invitrogen 
B1.2. Incomplete F-Medium (400ml) 
ITEM Volume Stock 
solution 
Final 
concentration 
Source 
Hams F12 nutrient 
mix 
300ml  3/4 Gibco/Invitrogen 
Complete DMEM 100ml  1/4 As above 
Hydrocortisone 3.2ml 50µg/ml 400ng/ml Sigma-Aldrich 
Insulin (bovine 
pancreas) 
400µl 5mg/ml 5µg/ml Sigma-Aldrich 
Cholera toxin 4µl 10µM 0.1nM List Biological Laboratories 
Adenine 5ml 2.42mg/ml 30.25µg/ml Sigma-Aldrich 
B1.3. 1x TBS 
Tris  8.8g (10mM) 
NaCl 1.2g( 150mM) 
Water 1L 
pH  7.5 
B1.4. Laemmli Reducing Sample Buffer 
ITEM Volume Stock solution Source 
Sodium dodecyl sulphate (SDS) 1ml 10% BDH 
Glycerol 1ml 20% BDH 
Tris (hydroxymethyl) 
methylamine (Tris) 
600μl 0.5M  (pH6.8) BDH 
Dithiothreitol (DTT) 500μl 1M Melford 
Water 1.9ml   
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B2. Protein Assay Gels and Buffers 
B2.1. Resolving Gel – Mini (10ml) 
Item Stock  Source Volume 
8% gel  10% gel 12% gel 
 
dH2O   4.65ml 3.95ml 3.3ml 
Tris  1.5M 
pH 8.8 
BDH 2.5ml 2.5ml 2.5ml 
Bis acrylamide 30% 
acrylamide 
Thistle 2.65ml 3.35ml 4ml 
SDS 10% BDH 100μl 100μl 100μl 
Ammonium Persulphate (APS)  10% Amresco 100μl 100μl 100μl 
Tetramethylethylenediamine 
(TEMED) 
 Gibco 6μl 4μl 4μl 
B2.2. Resolving Gel – Midi (30ml) 
Item Stock  Source Volume 8% gel 
dH2O   14ml 
Tris  1.5M, pH 8.8 BDH 7.5ml 
Bis acrylamide 30% acrylamide Thistle 7.95ml 
SDS 10% BDH 300μl 
APS 10% Amresco 300μl 
TEMED  Gibco 18μl 
B2.3. Stacking Gel – Mini (3 ml) 
Item Stock  Volume 
dH2O  2.05ml 
Tris  0.5M, pH6.8 375μl 
Acrylamide-bis* 30% acrylamide 500μl 
SDS 10% 30μl 
APS 10% 30μl 
TEMED  3μl 
B2.4. Stacking Gel – Midi (10 ml) 
Item Stock  Volume 
dH2O  6.15ml 
Tris  0.5M, pH6.8 1.1ml 
Acrylamide-bis* 30% acrylamide 1.5ml 
SDS 10% 90μl 
APS 10% 90μl 
TEMED  9μl 
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B2.5. SDS-PAGE Running and Transfer Buffers 
 10x Running Buffer 10x Transfer Buffer 
Tris 30g 30g 
Glycine 144g 144g 
SDS 10g  
Water 1L 1L 
B3. Solutions for Southern Blotting  
B3.1. 5x Random Priming Buffer  
 Final concentration Stock Solution  Ratio Per 5ml 
Tris (pH 8) 250mmM 500mM 1:2 2.5ml 
MgCl2 25mM 1M 1:40 125μl 
NaCl 100mM 5M 1:50 100μl 
HEPES  1M 3M 1:3 1.6ml 
DTT* 10mM 1M 1:100 50ul 
Water    515μl 
*add immediately prior to use from frozen 1M stock  
Taken from Sambrook and Russell (2001) 451 
B3.2. Random Priming Stop/Storage Buffer 
 Final concentration Stock Solution  Ratio Per 5ml 
Tris-HCl (pH 7.5) 50mM 500mM 1:10 500μl 
NaCl 50mM 5M 1:100 50μl 
EDTA (pH 8) 5mM 0.5M 1:100 50μl 
SDS 0.5% (w/v) 10% (w/v) 1:20 250μl 
Water    4.50ml 
Taken from Sambrook and Russell (2001) 451 
 
B3.3. Denhardt’s Solution (50x) 
 Amount Source 
Ficoll 1g Pharmacia biotech 
Polyvinylpyrrolidone 1g Sigma-Aldrich 
Bovine Serum Albumen 1g Sigma-Aldrich 
dH2O 100ml  
Store at 4ºC 
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B3.4 Hybridisation Solution 
 Stock Volume (ml) 
Denhardts Solution 50x 3 
SSC 20x 7.5 
SDS 10% 3 
dH2O  16.5 
 
B4. Antibody Details 
B4.1. Primary Antibody Details 
Antibody Source Clone Raised in  Mono/poly M.W (kDa) 
-Actin Sigma-Aldrich AC-15 Mouse Monoclonal 42 
Caspase-3 Cell Signaling Asp175 Rabbit Polyclonal 17/19 
Cytokeratin-18 
(CK-18) 
E. B. Lane 
(Dundee) 427 
LE65 Mouse Monoclonal 47 
E2-monoclonal I. Morgan 
(Glasgow) 
TGV261 Mouse Monoclonal 42 
M30 Roche M30 Mouse Monoclonal 40 (early) 
24 (late) 
P21 (C-terminal) Dako SX118 Mouse Monoclonal 21 
P21 (internal) Calbiochem mAbl Mouse Monoclonal 21 
P53 S. Lain (Dundee) DO-1 Mouse Monoclonal 53 
B4.2. Secondary Antibody Details 
Antibody Conjugate Source Use 
Rabbit anti-mouse F(ab’)2 fragment Biotin Dako Immuno 
Swine anti-rabbit F(ab’)2 fragment Biotin Dako Immuno 
Goat anti-mouse IgG (H+L)  Horseradish Peroxidase Pierce Western 
Goat anti-rabbit IgG (H+L) Horseradish Peroxidase Pierce Western 
B4.3. Antibody use in Immunocytochemistry 
 
 
* component of ABC elite Vectorstain mouse or universal staining kits 
 
Antibody ICC Dilution  Secondary Dilution 
Monolayer Rafts 
Caspase-3 1:100 1:100 1:300 
CK-18  Neat/1:5  1:200 
M30 1:100 1:20 1:200 
P21 1:25 1:50 1:200* 
P53 1:50 1:50 1:200* 
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B4.4. Antibody use in the Analysis of Protein and Western Blot 
Antibody Gel 
percentage 
Dilution  Primary 
time 
Secondary  
Diluted in 
Detect 
-Actin all 1:5000 1hr PBST* 10-15s 
Caspase-3 12% 1:800 Overnight PBST 1/3/10min 
CK-18  12% 1:500 Overnight mPBST** 3/5/8min 
E2-mono (mini) 10% 1:1000 Overnight mPBST 1h 
E2-mono (midi) 8% 1:1000 Overnight 3% mPBST 10min/1h 
M30 12% 1:500 Overnight PBST 3/5/15min 
p21 12%/15% 1:250 Overnight PBST 45min 
Internal p21 15% 1:100 Overnight PBST 45min /1h  
p53 12% 1:1000 1h 3% mPBST 45min 
PBST = PBS+0.1% Tween-20 (Sigma) **mPBST = PBST+ semi skimmed milk powder 
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Appendix C: Additional Information  
C1. Example of Running Mean Calculation for Immunocytochemistry 
C1.1. Example of raw data from immunocytochemistry 
W12E50 ( 13 ) + LMB 17/5/06 M30 M 
Blue 
(negative) 
Red 
(positive) 
 
Running Red Total 
Running 
Total 
Running % 
positivity 
20 3 3 23 23 13.04348 
22 1 4 23 46 8.695652 
24 2 6 26 72 8.333333 
22 1 7 23 95 7.368421 
18 1 8 19 114 7.017544 
25 1 9 26 140 6.428571 
17 3 12 20 160 7.5 
9 1 13 10 170 7.647059 
39 4 17 43 213 7.981221 
1 0 17 1 214 7.943925 
2 0 17 2 216 7.87037 
33 8 25 41 257 9.727626 
49 6 31 55 312 9.935897 
4 0 31 4 316 9.810127 
20 5 36 25 341 10.55718 
60 12 48 72 413 11.62228 
16 6 54 22 435 12.41379 
11 0 54 11 446 12.10762 
1 0 54 1 447 12.08054 
23 5 59 28 475 12.42105 
16 1 60 17 492 12.19512 
15 2 62 17 509 12.18075 
23 2 64 25 534 11.98502 
7 0 64 7 541 11.82994 
12 2 66 14 555 11.89189 
5 0 66 5 560 11.78571 
11 0 66 11 571 11.55867 
1 0 66 1 572 11.53846 
46 4 70 50 622 11.25402 
10 0 70 10 632 11.07595 
5 0 70 5 637 10.98901 
25 2 72 27 664 10.84337 
8 0 72 8 672 10.71429 
22 4 76 26 698 10.88825 
37 8 84 45 743 11.30552 
29 6 90 35 778 11.56812 
29 1 91 30 808 11.26238 
30 2 93 32 840 11.07143 
6 0 93 6 846 10.99291 
1 0 93 1 847 10.97993 
6 0 93 6 853 10.9027 
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14 1 94 15 868 10.82949 
11 0 94 11 879 10.69397 
8 1 95 9 888 10.6982 
2 0 95 2 890 10.67416 
25 2 97 27 917 10.57797 
11 2 99 13 930 10.64516 
82 9 108 91 1021 10.57786 
31 3 111 34 1055 10.52133 
36 10 121 46 1101 10.99001 
5 0 121 5 1106 10.94033 
27 4 125 31 1137 10.99384 
30 10 135 40 1177 11.46984 
18 1 136 19 1196 11.37124 
1 0 136 1 1197 11.36174 
35 5 141 40 1237 11.39854 
49 9 150 58 1295 11.58301 
15 1 151 16 1311 11.51793 
1 1 152 2 1313 11.57654 
12 1 153 13 1326 11.53846 
56 10 163 66 1392 11.70977 
13 2 165 15 1407 11.72708 
10 0 165 10 1417 11.64432 
31 7 172 38 1455 11.82131 
52 9 181 61 1516 11.93931 
17 0 181 17 1533 11.80691 
63 18 199 81 1614 12.32962 
9 1 200 10 1624 12.31527 
24 1 201 25 1649 12.18921 
8 0 201 8 1657 12.13036 
63 5 206 68 1725 11.94203 
25 1 207 26 1751 11.82182 
28 3 210 31 1782 11.78451 
7 0 210 7 1789 11.7384 
19 1 211 20 1809 11.6639 
20 1 212 21 1830 11.5847 
1 0 212 1 1831 11.57837 
21 2 214 23 1854 11.54261 
1  214 1 1855 11.53639 
20 4 218 24 1879 11.60192 
7 3 221 10 1889 11.69931 
2 0 221 2 1891 11.68694 
34 6 227 40 1931 11.75557 
7 1 228 8 1939 11.75864 
8 2 230 10 1949 11.80092 
9 5 235 14 1963 11.97147 
15 10 245 25 1988 12.32394 
9 3 248 12 2000 12.4 
33 2 250 35 2035 12.28501 
26 3 253 29 2064 12.25775 
32 7 260 39 2103 12.36329 
41 4 264 45 2148 12.2905 
4 0 264 4 2152 12.26766 
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12 5 269 17 2169 12.40203 
26 3 272 29 2198 12.37489 
33 1 273 34 2232 12.23118 
32 3 276 35 2267 12.17468 
32 9 285 41 2308 12.34835 
4 0 285 4 2312 12.32699 
2 0 285 2 2314 12.31634 
5 5 290 10 2324 12.47849 
21 3 293 24 2348 12.47871 
13 2 295 15 2363 12.48413 
16 2 297 18 2381 12.47375 
8 1 298 9 2390 12.46862 
55 5 303 60 2450 12.36735 
21 5 308 26 2476 12.43942 
6 3 311 9 2485 12.51509 
23 6 317 29 2514 12.60939 
2 0 317 2 2516 12.59936 
26 1 318 27 2543 12.50492 
17 3 321 20 2563 12.52439 
3 0 321 3 2566 12.50974 
29 2 323 31 2597 12.43743 
20 2 325 22 2619 12.40932 
42 8 333 50 2669 12.47658 
42 3 336 45 2714 12.38025 
 
C1.2. Example of Rnning Mean Plot from Immunocytochemistry Data 
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 Res 
No. 
Amino Acid MW 
(Da) 
Res 
No. 
Amino Acid MW 
(Da) 
1 M Methionine 131.2 40 G Glycine 57.05 
2 S Serine 87.08 41 C Cystine 103.14 
3 E Glutamic Acid 129.12 42 I Isoleucine 113.16 
4 P Proline 97.12 43 Q Glutamine 128.13 
5 A Alanine 71.08 44 E Glutamic Acid 129.12 
6 G Glycine 57.05 45 A Alanine 71.08 
7 D Aspartic acid 115.09 46 R Arginine 156.19 
8 V Valine 99.13 47 E Glutamic Acid 129.12 
9 R Arginine 156.19 48 R Arginine 156.19 
10 Q Glutamine 128.13 49 W Tryptophan 186.21 
11 N Asparagine 114.1 50 N Asparagine 114.1 
12 P Proline 97.12 51 F Phenylalanine 147.18 
13 C Cystine 103.14 52 D Aspartic acid 115.09 
14 G Glycine 57.05 53 F Phenylalanine 147.18 
15 S Serine 87.08 54 V Valine 99.13 
16 K Lysine 128.17 55 T Threonine 101.11 
17 A Alanine 71.08 56 E Glutamic Acid 129.12 
18 C Cystine 103.14 57 T Threonine 101.11 
19 R Arginine 156.19 58 P Proline 97.12 
20 R Arginine 156.19 59 L Leucine 113.16 
21 L Leucine 113.16 60 E Glutamic Acid 129.12 
22 F Phenylalanine 147.18 61 G Glycine 57.05 
23 G Glycine 57.05 62 D Aspartic acid 115.09 
24 P Proline 97.12 63 F Phenylalanine 147.18 
25 V Valine 99.13 64 A Alanine 71.08 
26 D Aspartic acid 115.09 65 W Tryptophan 186.21 
27 S Serine 87.08 66 E Glutamic Acid 129.12 
28 E Glutamic Acid 129.12 67 R Arginine 156.19 
29 Q Glutamine 128.13 68 V Valine 99.13 
30 L Leucine 113.16 69 R Arginine 156.19 
31 S Serine 87.08 70 G Glycine 57.05 
32 R Arginine 156.19 71 L leucine 113.16 
33 D Aspartic acid 115.09 72 G Glycine 57.05 
34 C Cystine 103.14 73 L Leucine 113.16 
35 D Aspartic acid 115.09 74 P Proline 97.12 
36 A Alanine 71.08 75 K Lysine 128.17 
37 L Leucine 113.16 76 L Leucine 113.16 
38 M Methionine 131.2 77 Y Tyrosine 163.18 
39 A Alanine 71.08     
 
The N-terminal amino acids of the p21 proteins, residues 1-77 (MW 8.7kDa, accession no. 
NCBI AAB29246).  The location of the internal antibody AB-1 (calbiochem) epitope is 
shown in grey (a-a 58-77) with a molecular weight of 2.3kDa.   
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Appendix D – Publications 
D.1. Published Meeting Abstracts 
C. Jolly, S. Talukdar, L. Gray, and C.S. Herrington (2005).  Leptomycin B induces apoptosis 
in keratinocytes containing the whole HPV 16 genome.  3rd Joint Meeting of the British 
Division of the IAP and the Pathological Society of Great Britain and Ireland, Newcastle, UK. 
 
C. Jolly, S. Talukdar, L. Gray, and C.S. Herrington (2006).  Leptomycin B induces apoptosis 
in keratinocytes containing the whole HPV 16 genome.  23rd International Papillomavirus 
Conference, Prague, Czech Republic.  
 
D.2. Review and Research Publications 
Gray, L., Jolly, C. & Herrington, C.S. Human papillomaviruses and their effects on cell cycle 
control and apoptosis. in Molecular Pathogenesis of Virus Infections, Vol. 64 235 - 252 
(SGM symposium, Cambridge University Press, 2005). 
 
Gray, L.J, Bjelogrlic, P., Appleyard, V.C.L., Thompson, A.M., Jolly, C.E., Lain, S., and 
Herrington, C.S. Selective induction of apoptosis by leptomycin B in keratinocytes expressing 
HPV oncogenes. Int J Cancer 120, 2317-24 (2007).  
 
